NO329484B3 - Nye kinuklidinderivater og medisinske sammensetninger inneholdende det samme, samt anvendelse derav for fremstilling av medikamenter - Google Patents
Nye kinuklidinderivater og medisinske sammensetninger inneholdende det samme, samt anvendelse derav for fremstilling av medikamenter Download PDFInfo
- Publication number
- NO329484B3 NO329484B3 NO20020180A NO20020180A NO329484B3 NO 329484 B3 NO329484 B3 NO 329484B3 NO 20020180 A NO20020180 A NO 20020180A NO 20020180 A NO20020180 A NO 20020180A NO 329484 B3 NO329484 B3 NO 329484B3
- Authority
- NO
- Norway
- Prior art keywords
- octane
- azoniabicyclo
- hydroxy
- bromide
- compound according
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 9
- 239000000203 mixture Substances 0.000 title description 56
- 238000004519 manufacturing process Methods 0.000 title description 3
- 150000008584 quinuclidines Chemical class 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 252
- -1 5,6,7,8-tetrahydronaphthalenyl Chemical group 0.000 claims abstract description 94
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 9
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 190
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical group [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 105
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 39
- 238000002360 preparation method Methods 0.000 claims description 37
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims description 12
- 125000005843 halogen group Chemical group 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 9
- 150000001450 anions Chemical class 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 239000011541 reaction mixture Substances 0.000 claims description 7
- 208000023504 respiratory system disease Diseases 0.000 claims description 7
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 208000014001 urinary system disease Diseases 0.000 claims description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 230000000241 respiratory effect Effects 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 claims description 3
- HOSIJIINLUWTDR-ZDUSSCGKSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-2-yl)-2-hydroxyacetate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1OC=CC=1)C1=CC=CO1 HOSIJIINLUWTDR-ZDUSSCGKSA-N 0.000 claims description 3
- NENRZCSTZIWMEU-NSHDSACASA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 2-(furan-2-yl)-2-oxoacetate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(=O)C1=CC=CO1 NENRZCSTZIWMEU-NSHDSACASA-N 0.000 claims description 3
- 239000002168 alkylating agent Substances 0.000 claims description 3
- 229940100198 alkylating agent Drugs 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 206010006451 bronchitis Diseases 0.000 claims description 3
- 229910052799 carbon Inorganic materials 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229910052731 fluorine Inorganic materials 0.000 claims description 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 3
- 125000002883 imidazolyl group Chemical group 0.000 claims description 3
- 238000002414 normal-phase solid-phase extraction Methods 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- RZYBPZPILUXNNH-JTQLQIEISA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 2-oxo-2-thiophen-2-ylacetate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(=O)C1=CC=CS1 RZYBPZPILUXNNH-JTQLQIEISA-N 0.000 claims description 2
- 239000004305 biphenyl Substances 0.000 claims description 2
- 235000010290 biphenyl Nutrition 0.000 claims description 2
- 208000023819 chronic asthma Diseases 0.000 claims description 2
- 201000009151 chronic rhinitis Diseases 0.000 claims description 2
- 239000003246 corticosteroid Substances 0.000 claims description 2
- 208000010643 digestive system disease Diseases 0.000 claims description 2
- 239000011737 fluorine Substances 0.000 claims description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 claims description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 2
- YLSVSNYPDKQJJE-LWCCLMHTSA-M C(C1=CC=CC=C1)OCC[N+]12C[C@@H](C(CC1)CC2)OC(C(C=2SC=CC2)(C=2SC=CC2)O)=O.[Br-] Chemical compound C(C1=CC=CC=C1)OCC[N+]12C[C@@H](C(CC1)CC2)OC(C(C=2SC=CC2)(C=2SC=CC2)O)=O.[Br-] YLSVSNYPDKQJJE-LWCCLMHTSA-M 0.000 claims 1
- 101001117086 Dictyostelium discoideum cAMP/cGMP-dependent 3',5'-cAMP/cGMP phosphodiesterase A Proteins 0.000 claims 1
- AODUMGUMFGRDRE-SJBAUBOLSA-M [(3R)-1-(3-thiophen-2-ylpropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate bromide Chemical compound OC(C(=O)O[C@H]1C[N+]2(CCC1CC2)CCCC=2SC=CC2)(C=2SC=CC2)C=2SC=CC2.[Br-] AODUMGUMFGRDRE-SJBAUBOLSA-M 0.000 claims 1
- PWFARANTDRNLBZ-MSZWFKHVSA-M [O-]C(=O)C(F)(F)F.OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1ccsc1)c1ccsc1 Chemical compound [O-]C(=O)C(F)(F)F.OC(C(=O)O[C@H]1C[N+]2(CCCOc3ccccc3)CCC1CC2)(c1ccsc1)c1ccsc1 PWFARANTDRNLBZ-MSZWFKHVSA-M 0.000 claims 1
- NDYUJGPKQFPCSF-CBTJMOJFSA-M [O-]C(=O)C(F)(F)F.OC(C(=O)O[C@H]1C[N+]2(CCCn3cccc3)CCC1CC2)(c1cccs1)c1cccs1 Chemical compound [O-]C(=O)C(F)(F)F.OC(C(=O)O[C@H]1C[N+]2(CCCn3cccc3)CCC1CC2)(c1cccs1)c1cccs1 NDYUJGPKQFPCSF-CBTJMOJFSA-M 0.000 claims 1
- GRGKPKAOUPDYLO-YDSHNTAWSA-M [O-]C(=O)C(F)(F)F.OC(C(=O)O[C@H]1C[N+]2(CCc3cccs3)CCC1CC2)(c1cccs1)c1cccs1 Chemical compound [O-]C(=O)C(F)(F)F.OC(C(=O)O[C@H]1C[N+]2(CCc3cccs3)CCC1CC2)(c1cccs1)c1cccs1 GRGKPKAOUPDYLO-YDSHNTAWSA-M 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 150000001649 bromium compounds Chemical group 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 abstract description 5
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 abstract description 5
- 125000006267 biphenyl group Chemical group 0.000 abstract 1
- 150000002390 heteroarenes Chemical class 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 314
- 238000005160 1H NMR spectroscopy Methods 0.000 description 181
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 30
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- 239000007787 solid Substances 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 239000002904 solvent Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003921 oil Substances 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- NXFFJDQHYLNEJK-UHFFFAOYSA-N 2-[4-[(4-chlorophenyl)methyl]-7-fluoro-5-methylsulfonyl-2,3-dihydro-1h-cyclopenta[b]indol-3-yl]acetic acid Chemical compound C1=2C(S(=O)(=O)C)=CC(F)=CC=2C=2CCC(CC(O)=O)C=2N1CC1=CC=C(Cl)C=C1 NXFFJDQHYLNEJK-UHFFFAOYSA-N 0.000 description 7
- IVLICPVPXWEGCA-ZETCQYMHSA-N (3r)-1-azabicyclo[2.2.2]octan-3-ol Chemical compound C1CC2[C@@H](O)CN1CC2 IVLICPVPXWEGCA-ZETCQYMHSA-N 0.000 description 6
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 6
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 230000027455 binding Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 150000003891 oxalate salts Chemical class 0.000 description 5
- 238000010561 standard procedure Methods 0.000 description 5
- GIWRVUADKUVEGU-UHFFFAOYSA-N 2-oxo-2-thiophen-2-ylacetic acid Chemical compound OC(=O)C(=O)C1=CC=CS1 GIWRVUADKUVEGU-UHFFFAOYSA-N 0.000 description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- YNQLUTRBYVCPMQ-UHFFFAOYSA-N Ethylbenzene Chemical compound CCC1=CC=CC=C1 YNQLUTRBYVCPMQ-UHFFFAOYSA-N 0.000 description 4
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- 208000009079 Bronchial Spasm Diseases 0.000 description 3
- 208000014181 Bronchial disease Diseases 0.000 description 3
- 206010006482 Bronchospasm Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- WOPPGGGGQFNBFL-FQEVSTJZSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 2,2-diphenylpropanoate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(C)(C=1C=CC=CC=1)C1=CC=CC=C1 WOPPGGGGQFNBFL-FQEVSTJZSA-N 0.000 description 3
- KKEWMOSHVGOQOG-UCFFOFKASA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 2-(furan-2-yl)-2-hydroxy-2-phenylacetate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1C=CC=CC=1)C1=CC=CO1 KKEWMOSHVGOQOG-UCFFOFKASA-N 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000007941 film coated tablet Substances 0.000 description 3
- 239000012458 free base Substances 0.000 description 3
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical class OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 125000004178 (C1-C4) alkyl group Chemical class 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- RQRSQXFVRUWISR-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-ol Chemical compound C1CN2CCC1(O)CC2 RQRSQXFVRUWISR-UHFFFAOYSA-N 0.000 description 2
- VIKSKCIJBNEIKG-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-yl 2-oxo-2-thiophen-2-ylacetate Chemical compound C1CN(CC2)CCC12OC(=O)C(=O)C1=CC=CS1 VIKSKCIJBNEIKG-UHFFFAOYSA-N 0.000 description 2
- WRDWRFQPCQESHV-UHFFFAOYSA-N 2-(furan-2-yl)-2-hydroxy-2-phenylacetic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CO1 WRDWRFQPCQESHV-UHFFFAOYSA-N 0.000 description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000017925 CHRM3 Human genes 0.000 description 2
- 101150060249 CHRM3 gene Proteins 0.000 description 2
- 206010063057 Cystitis noninfective Diseases 0.000 description 2
- 206010020853 Hypertonic bladder Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 description 2
- 206010029279 Neurogenic bladder Diseases 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- 206010036018 Pollakiuria Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 2
- NETKUYSZWVBUQE-ZVOVCPRUSA-N [(3r)-1-(2-phenylmethoxyethyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCOCC1=CC=CC=C1 NETKUYSZWVBUQE-ZVOVCPRUSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000005605 benzo group Chemical group 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 239000000812 cholinergic antagonist Substances 0.000 description 2
- 201000003139 chronic cystitis Diseases 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000007784 diverticulitis Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 2
- 208000002551 irritable bowel syndrome Diseases 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 150000004702 methyl esters Chemical class 0.000 description 2
- 239000010413 mother solution Substances 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 230000001148 spastic effect Effects 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- OZFAFGSSMRRTDW-UHFFFAOYSA-N (2,4-dichlorophenyl) benzenesulfonate Chemical compound ClC1=CC(Cl)=CC=C1OS(=O)(=O)C1=CC=CC=C1 OZFAFGSSMRRTDW-UHFFFAOYSA-N 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- CFDXNDOROWMXIV-UHFFFAOYSA-N 1-(3-chloropropoxy)naphthalene Chemical compound C1=CC=C2C(OCCCCl)=CC=CC2=C1 CFDXNDOROWMXIV-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- DSNGLKATJGBVIX-UHFFFAOYSA-N 1-azabicyclo[2.2.1]heptan-4-ol Chemical compound C1CN2CCC1(O)C2 DSNGLKATJGBVIX-UHFFFAOYSA-N 0.000 description 1
- YYXNXGQEMYTJDE-UHFFFAOYSA-N 1-azabicyclo[2.2.2]octan-4-yl 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound C1CN(CC2)CCC12OC(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 YYXNXGQEMYTJDE-UHFFFAOYSA-N 0.000 description 1
- IXVPCJUAKDVYKX-UHFFFAOYSA-N 2-(furan-2-yl)-2-oxoacetic acid Chemical compound OC(=O)C(=O)C1=CC=CO1 IXVPCJUAKDVYKX-UHFFFAOYSA-N 0.000 description 1
- TUCRZHGAIRVWTI-UHFFFAOYSA-N 2-bromothiophene Chemical compound BrC1=CC=CS1 TUCRZHGAIRVWTI-UHFFFAOYSA-N 0.000 description 1
- FVEJUHUCFCAYRP-UHFFFAOYSA-N 2-hydroxy-2,2-dithiophen-2-ylacetic acid Chemical compound C=1C=CSC=1C(O)(C(=O)O)C1=CC=CS1 FVEJUHUCFCAYRP-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- NMGODFWGUBLTTA-UHFFFAOYSA-N 3-amino-1h-quinazoline-2,4-dione Chemical compound C1=CC=C2C(=O)N(N)C(=O)NC2=C1 NMGODFWGUBLTTA-UHFFFAOYSA-N 0.000 description 1
- NIDWUZTTXGJFNN-UHFFFAOYSA-N 3-bromopropoxybenzene Chemical compound BrCCCOC1=CC=CC=C1 NIDWUZTTXGJFNN-UHFFFAOYSA-N 0.000 description 1
- IVLICPVPXWEGCA-UHFFFAOYSA-N 3-quinuclidinol Chemical class C1C[C@@H]2C(O)C[N@]1CC2 IVLICPVPXWEGCA-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- HAMMHSUBQYOIFQ-UHFFFAOYSA-N 9,10-dihydroanthracene-9-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)C3=CC=CC=C3CC2=C1 HAMMHSUBQYOIFQ-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 229930003347 Atropine Natural products 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 206010066091 Bronchial Hyperreactivity Diseases 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000012591 Dulbecco’s Phosphate Buffered Saline Substances 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 1
- 206010040741 Sinus bradycardia Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000012931 Urologic disease Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- UAUSTCLJJODBIH-VITNCHFBSA-N [(3r)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-bis(furan-2-yl)-2-hydroxyacetate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3OC=CC=3)C=3OC=CC=3)[N+]21CCCOC1=CC=CC=C1 UAUSTCLJJODBIH-VITNCHFBSA-N 0.000 description 1
- ZPUIFOBXUIMYGP-YMVPHMABSA-N [(3r)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2,2-dithiophen-2-ylpropanoate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(C)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 ZPUIFOBXUIMYGP-YMVPHMABSA-N 0.000 description 1
- IYWRNILAOARDKA-WDVLHWPLSA-N [(3r)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 2-(furan-2-yl)-2-hydroxy-2-thiophen-2-ylacetate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3OC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1 IYWRNILAOARDKA-WDVLHWPLSA-N 0.000 description 1
- WZXRPTLWADRYET-GYNTZMJKSA-N [(3r)-1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-3-yl] 6,11-dihydro-5h-dibenzo[1,2-a:1',2'-e][7]annulene-11-carboxylate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C3C4=CC=CC=C4CCC4=CC=CC=C43)[N+]21CCCOC1=CC=CC=C1 WZXRPTLWADRYET-GYNTZMJKSA-N 0.000 description 1
- QEXWJULWOZTIGD-WJUMYPGWSA-N [(3r)-1-[3-(2,4-difluorophenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=C(F)C=C1F QEXWJULWOZTIGD-WJUMYPGWSA-N 0.000 description 1
- VUBTVAJZRQUMAG-JZETWELJSA-N [(3r)-1-[3-(2,4-difluorophenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-methylfluorene-9-carboxylate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C3(C)C4=CC=CC=C4C4=CC=CC=C43)[N+]21CCCOC1=CC=C(F)C=C1F VUBTVAJZRQUMAG-JZETWELJSA-N 0.000 description 1
- RHVNLHKKXWNLHB-LGCWNYSLSA-O [(3r)-1-[3-(2-carbamoylphenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound NC(=O)C1=CC=CC=C1OCCC[N+]1(C[C@@H]2OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)CCC2CC1 RHVNLHKKXWNLHB-LGCWNYSLSA-O 0.000 description 1
- MBYLOEWSZFYCBU-JKLGZZSBSA-N [(3r)-1-[3-(2-chlorophenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC=C1Cl MBYLOEWSZFYCBU-JKLGZZSBSA-N 0.000 description 1
- HVUYZXPDGVAYIH-ICFHYRHXSA-N [(3r)-1-[3-(3-cyanophenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC1=CC=CC(C#N)=C1 HVUYZXPDGVAYIH-ICFHYRHXSA-N 0.000 description 1
- GOQZLTZVGNWQNP-QIJSRAMZSA-N [(3r)-1-[3-(4-fluorophenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 9-hydroxyxanthene-9-carboxylate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C3(O)C4=CC=CC=C4OC4=CC=CC=C43)[N+]21CCCOC1=CC=C(F)C=C1 GOQZLTZVGNWQNP-QIJSRAMZSA-N 0.000 description 1
- IESXEBRBMNIIIB-WTTUPNFKSA-N [(3r)-1-[3-(4-phenylphenoxy)propyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound C([C@@H](C(CC1)CC2)OC(=O)C(O)(C=3SC=CC=3)C=3SC=CC=3)[N+]21CCCOC(C=C1)=CC=C1C1=CC=CC=C1 IESXEBRBMNIIIB-WTTUPNFKSA-N 0.000 description 1
- LIBPBHTXCSZAHE-SLRLHWDHSA-N [(3r)-1-[3-[3-(dimethylamino)phenoxy]propyl]-1-azoniabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound CN(C)C1=CC=CC(OCCC[N+]23CCC(CC2)[C@H](C3)OC(=O)C(O)(C=2SC=CC=2)C=2SC=CC=2)=C1 LIBPBHTXCSZAHE-SLRLHWDHSA-N 0.000 description 1
- YQPNKRDRENWYPM-CWQZNGJJSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 2-(furan-2-yl)-2-hydroxy-2-thiophen-2-ylacetate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1SC=CC=1)C1=CC=CO1 YQPNKRDRENWYPM-CWQZNGJJSA-N 0.000 description 1
- GYDFTKNRHZMENP-ZDUSSCGKSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 GYDFTKNRHZMENP-ZDUSSCGKSA-N 0.000 description 1
- MYLRUMTYZFICQR-UCFFOFKASA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 2-hydroxy-2-phenyl-2-thiophen-2-ylacetate Chemical compound O([C@@H]1C2CCN(CC2)C1)C(=O)C(O)(C=1C=CC=CC=1)C1=CC=CS1 MYLRUMTYZFICQR-UCFFOFKASA-N 0.000 description 1
- DCVFVRXNLHLACD-FQEVSTJZSA-N [(3r)-1-azabicyclo[2.2.2]octan-3-yl] 9,10-dihydroanthracene-9-carboxylate Chemical compound C12=CC=CC=C2CC2=CC=CC=C2C1C(=O)O[C@@H]1C(CC2)CCN2C1 DCVFVRXNLHLACD-FQEVSTJZSA-N 0.000 description 1
- CGXUXXWCFRCLCU-UHFFFAOYSA-N [1-(1-phenylethyl)-1-azoniabicyclo[2.2.2]octan-4-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound C1CC(OC(=O)C(O)(C=2SC=CC=2)C=2SC=CC=2)(CC2)CC[N+]12C(C)C1=CC=CC=C1 CGXUXXWCFRCLCU-UHFFFAOYSA-N 0.000 description 1
- MTYDMUSNAYECGU-UHFFFAOYSA-N [1-(3-phenoxypropyl)-1-azoniabicyclo[2.2.2]octan-4-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate Chemical compound C=1C=CSC=1C(C=1SC=CC=1)(O)C(=O)OC(CC1)(CC2)CC[N+]21CCCOC1=CC=CC=C1 MTYDMUSNAYECGU-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000001022 anti-muscarinic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 229940124575 antispasmodic agent Drugs 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 230000036427 bronchial hyperreactivity Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 150000001793 charged compounds Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- BIHFCPRVAAVAPP-UHFFFAOYSA-N hydroxy(phenyl)2-thienylacetic acid Chemical compound C=1C=CC=CC=1C(O)(C(=O)O)C1=CC=CS1 BIHFCPRVAAVAPP-UHFFFAOYSA-N 0.000 description 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- KCTBOHUTRYYLJA-UHFFFAOYSA-N lithium;2h-furan-2-ide Chemical compound [Li+].C=1C=[C-]OC=1 KCTBOHUTRYYLJA-UHFFFAOYSA-N 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- HTJPDOPKPWUNBX-UHFFFAOYSA-M magnesium;2h-thiophen-2-ide;bromide Chemical compound [Mg+2].[Br-].C=1C=[C-]SC=1 HTJPDOPKPWUNBX-UHFFFAOYSA-M 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- RMOZPQBMCDJIHD-UHFFFAOYSA-N methyl 2-(furan-2-yl)-2-hydroxy-2-phenylacetate Chemical compound C=1C=CC=CC=1C(O)(C(=O)OC)C1=CC=CO1 RMOZPQBMCDJIHD-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- UANSQQFYKHHDJM-KRWDZBQOSA-N n-[(3r)-1-azabicyclo[2.2.2]octan-3-yl]naphthalene-1-carboxamide Chemical compound C1=CC=C2C(C(N[C@@H]3C4CCN(CC4)C3)=O)=CC=CC2=C1 UANSQQFYKHHDJM-KRWDZBQOSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ANRQGKOBLBYXFM-UHFFFAOYSA-M phenylmagnesium bromide Chemical compound Br[Mg]C1=CC=CC=C1 ANRQGKOBLBYXFM-UHFFFAOYSA-M 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000075 poly(4-vinylpyridine) Polymers 0.000 description 1
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
Abstract
En forbindelse i henhold til formel (I):. hvori: © er en fenylring, en C4 til C9 heteroaromatisk forbindelse inneholdende ett eller flere heteroatomer, eller en naftalenyl-, 5,6,7,8-tetrahydronaftalenyl- eller bifenylgruppe; som viser høy affinitet for muskarin-M3-reseptorer (Hm3).
Description
Foreliggende oppfinnelse vedrører nye terapeutisk nyttige kinuklidinderivater som angitt i krav 1, fremgangsmåter ved deres fremstilling som angitt i krav 24, farma-søytiske sammensetninger inneholdende dem som angitt i krav 30 samt anvendelse derav for fremstilling av medikamenter som angitt i krav 35 og 36.
De nye strukturer i henhold til oppfinnelsen er antimuskarinmidler med en potent og langvarig effekt. Spesielt viser disse forbindelser høy affinitet for muskarin-M3-reseptorer (Hm3).
I overensstemmelse med deres natur som M3-antagonister er de nye forbindelser egnet for behandling av de følgende sykdommer: respiratoriske forstyrrelser slik som kronisk obstruktiv lungesykdom (COPD), kronisk bronkitt, bronkial hyperreak-tivitet, astma og rhinitt; urologiske forstyrrelser slik som urininkontinens, pollakisuri i neuripenia pollakisuri, nevrogen eller ustabil blære, cystospasme og kronisk cystitt; og gastrointestinale forstyrrelser slik som irritabelt tarmsyndrom, spastisk kolitt, divertikulitt og peptisk magesår.
De krevede forbindelser er også nyttige for behandlingen av de respiratoriske sykdommer spesifisert over i assosiasjon med p2-agonister, kortikosteroider, eller fos-fodiesterase-IV-inhibitorer.
Forbindelser av den foreliggende oppfinnelse kan også forventes å ha antitussive egenskaper.
Avhengig av deres natur kan de nye forbindelser være egnet for behandling av "va-gally" indusert sinusbradykardi.
Forbindelser med beslektede strukturer har blitt beskrevet som anti-spasmodiske og anti-kolinergiske midler i flere patenter.
For eksempel er det i patent FR 2012964 beskrevet kinuklidinolderivater med formel hvor R er H, OH eller en alkylgruppe med 1 til 4 karbonatomer; Ri er en fenyl- eller tienylgruppe; og R2eren cykloheksyl-, cyklopentyl- eller tienylgruppe, eller, når R er H, danner Ri og R2sammen med karbonatomet til hvilket de er bundet en tricyk-lisk gruppe med formel:
hvor X er -O-, -S- eller -CH2-, eller et syreaddisjons- eller kvaternært ammoniums-alt derav.
EP-418716 beskriver tienylkarboksylatestere med formel
hvori A er en gruppe
m og n = 1 eller 2
Q er en -CH2-CH2-, -CH2-CH2-CH2-, -CH=CH-, gruppe
Q' er en =NR- eller NRR'-gruppe; Ri er en tienyl-, fenyl-, furyl-, cyklopentyl- eller cykloheksylgruppe, eventuelt substituert; R2er H, OH, Ci-C4alkoksy eller Ci-C4alkyl og Ra er H, F, Cl, CH3- eller -NR.
US 5,654,314 beskriver forbindelser med formel:
hvori R er en eventuelt halo- eller hydroksy-substituert C1-4 alkylgruppe; R er en Ci-4alkylgruppe; eller R og R'danner sammen en C4.6alkylengruppe; X" er et anion; og RierH, OH, -CH2OH, Ci.4alkyl eller Ci-4alkoksy.
Den foreliggende oppfinnelse tilveiebringer nye kinuklidinderivater med potent an-tagonistaktivitet ved muskarin-M3-reseptorer som har den kjemiske struktur beskrevet i formel (I):
hvori:
© er en fenyl-, pyrrolyl-, tienyl-, furyl-, bifenyl-, naftalenyl-, 5,6,7,8-tetrahydronaftalenyl-, benzo[l,3]dioksolyl-, imidazolyl- eller benzotiazolylgruppe
R<1>, R2 og R3 hver uavhengig representerer et hydrogenatom eller halogenatom, eller en -OR<4>, -NHCOR<4>, -CN, -N02eller -COOR<4>-gruppe, eller en rett eller forgrenet Ci-C8alkylgruppe som eventuelt kan være substituert med en hydroksygruppe, hvori R<4>representerer et hydrogenatom eller en rett eller forgrenet Ci-C8alkylgruppe;
n er et heltall fra 0 til 4;
A representerer en -CH=CH-, -CH2-, -O-, -S- eller -S(0)-gruppe,
m er et heltall fra 0 til 8; forutsatt at når m = 0, er A ikke -CH2-;
p er et heltall fra 1 til 2 og substitusjonen i den azoniabicyklisk ring kan være i 2-, 3- eller 4-stillingen inklusive alle mulige konfigurasjoner av de asymmetriske karboner;
B representerer en gruppe med formel i) eller ii):
hvori R<10>representerer et hydrogenatom, en hydroksy- eller metylgruppe; og R8 og R<9>representerer hver uavhengig
hvori R<11>representerer et hydrogen- eller halogenatom eller en rett eller forgrenet Ci-C8alkylgruppe og Q representerer en enkeltbinding eller -0-; og
X representerer et farmasøytisk akseptabelt anion av en mono- eller polyvalent syre.
I de kvaternære ammoniumforbindelser av den foreliggende oppfinnelse representert ved formel (I) er en ekvivalent av et anion (X") forbundet med den positive ladning på N-atomet. X" kan være et anion av forskjellige mineralsyrer slik som, for eksempel, klorid, bromid, jodid, sulfat, nitrat, fosfat, og organiske syrer slik som, for eksempel, acetat, maleat, fumarat, citrat, oksalat, succinat, tartrat, malat, mandelat, metansulfonat og p-toluensulfonat. X" er fortrinnsvis et anion valgt fra klorid, bromid, jodid, sulfat, nitrat, acetat, maleat, oksalat eller succinat. Mer foretrukket er X" klorid, bromid eller trifluoracetat.
Forbindelsene av den foreliggende oppfinnelse representert ved formelen (I) beskrevet over, som kan ha ett eller flere asymmetriske karboner, inkluderer alle de mulige stereoisomerer. De enkelte isomerer og blandinger av isomerene faller innenfor rammen av den foreliggende oppfinnelse.
Hvis noen av R<1>til R4 eller R<11>representerer en alkylgruppe, er det foretrukket at alkylgruppen inneholder 1 til 8, fortrinnsvis 1 til 6 og mer foretrukket 1 til 4 karbonatomer. Spesielt er det foretrukket at en hvilken som helst alkylgruppe er representert ved en metyl, etyl, propyl, inklusive i-propyl, butyl inklusive en n-butyl, sek-butyl og tert-butyl.
Foretrukne forbindelser med formel (I) er de hvori © representerer en fenyl-, pyrrolyl-, tienyl-, furyl-, bifenyl-, naftalenyl-, 5,6,7,8-tetrahydronaftalenyl-, ben-zo[l,3]dioksolyl-, imidazolyl- eller benzotiazolylgruppe, spesielt en fenyl-, pyrrolyl-, eller tienylgruppe; R<1>, R<2>og R<3>representerer hver uavhengig et hydrogen- eller halogenatom, eller en hydroksyl, metyl, tert-butyl, -CH2OH, 3-hydroksypropyl, - OMe, -NMe2, -NHCOMe, -CONH2, -CN, -N02, -COOMe eller -CF3-gruppe, spesielt et hydrogenatom, en hydroksygruppe eller et halogenatom, hvori halogenatomet fortrinnsvis er fluor; n = 0 eller 1; m er et heltall fra 1 til 6, spesielt 1, 2 eller 3; A representerer en -CH2-, -CH=CH-, -O- eller -S-gruppe, spesielt en -CH2-, -CH=CH-eller -O-gruppe.
Det er også foretrukket at p = 2 og substituentgruppen -OC(0)B bundet til azoniabicyklo[2.2.2]oktanet er i 3-stillingen, som fortrinnsvis har (R)-konfigurasjon.
Ytterligere foretrukne forbindelser med formel I er de hvori B er en gruppe med formel i) eller ii) som definert over hvori, hvis B er en gruppe med formel (i), representerer R<8>og R<9>hver uavhengig en fenyl-, 2-tienyl, 3-tienyl, 2-furyl- eller 3-furylgruppe, hvori R<11>er hydrogenatom; og, hvis B er en gruppe med formel (ii), representerer Q en enkeltbinding, eller -0-; og i ethvert tilfelle er R<10>et hydrogenatom eller en hydroksy- eller metylgruppe; og når i) eller ii) inneholder et kiralt senter kan de representere enten (R)- eller (S)-konfigurasjonen.
Mest foretrukket er -OC(0)B-gruppen i formel (I) difenylacetoksy, 2-hydroksy-2,2-difenylacetoksy, 2,2-difenyl-propionyloksy,
2-hydroksy-2-fenyl-2-tien-2-ylacetoksy, 2-furan-2-yl-2-hydroksy-2-fenylacetoksy, 2,2-ditien-2-ylacetoksy, 2-hydroksy-2,2-ditien-2-ylacetoksy, 2-hydroksy-2,2-ditien-3-ylacetoksy, 9-hydroksy-9[H]-fluoren-9-karbonyloksy,
9-metyl-9[H]-fluoren-9-karbonyloksy, 9[H]-xanten-9-karbonyloksy, 9-hydroksy-9[H]-xanten-9-karbonyloksy, 9-metyl-9[H]-xanten-9-karbonyloksy, 2,2-bis(4-fluorfenyl)-2-hydroksyacetoksy, 2-hydroksy-2,2-di-p-tolylacetoksy, 2,2-difuran-2-yl-2-hydroksyacetoksy, 2,2-ditien-2-ylpropionyloksy, 9,10-dihydroantra-cen-9-karbonyloksy, 9[H]-tioxanten-9-karbonyloksy eller 5[H]-di-benzo[a,d]cyklohepten-5-karbonyloksy. Spesielt foretrukne forbindelser er de hvori -OC(0)B-gruppen i formel (I) er difenylacetoksy, 2-hydroksy-2,2-difenylacetoksy, 2,2-difenylpropionyloksy, 2-hydroksy-2-fenyl-2-tien-2-ylacetoksy, 2-furan-2-yl-2-hydroksy-2-fenylacetoksy, 2,2-ditien-2-ylacetoksy, 2- hydroksy-2,2-ditien-2-ylacetoksy, 2-hydroksy-2,2-ditien-3-ylacetoksy, 9-hydroksy-9[H]-fluoren-9-karbonyloksy, 9-metyl-9[H]-fluoren-9-karbonyloksy, 9[H]-xanten-9-karbonyloksy, 9-hydroksy-9[H]-xanten-9-karbonyloksy eller 9-metyl-9[H]-xanten-9-karbonyloksy.
De mest foretrukne forbindelser med formel (I) er de hvori azoniabicyklogruppen er substituert på nitrogenatomet med en 3-fenoksypropyl, 2-fenoksyetyl, 3-fenylallyl, fenetyl, 4-fenylbutyl, 3-fenylpropyl, 3-[2-hydroksyfenoksy]propyl, 3-[4-fluor-fenoksy]propyl, 2-benzyloksyetyl, 3-pyrrol-l-ylpropyl, 2-tien-2-yletyl, 3-tien-2-ylpropyl, 3-fenylaminopropyl, 3-(metylfenylamino)propyl, 3-fenylsulfanylpropyl, 3- o-tolyloksypropyl, 3-(2,4,6-trimetylfenoksy)propyl,
3-(2-tert-butyl-6-metylfenoksy)propyl, 3-(bifenyl-4-yloksy)propyl, 3-(5,6,7,8-tetrahydronaftalen-2-yloksy)-propyl, 3-(naftalen-2-yloksy) propyl, 3-(naftalen-l-yloksy)propyl, 3-(2-klorfenoksy)propyl, 3-(2,4-difluorfenoksy)propyl, 3-(3-trifluormetylfenoksy)propyl, 3-(3-cyanofenoksy)propyl, 3-(4-cyanofenoksy)-propyl, 3-(3-metoksyfenoksy)propyl, 3-(4-metoksyfenoksy)propyl, 3-(benzo[l,3]-dioksol-5-yloksy)propyl, 3-(2-karbamoylfenoksy)propyl, 3-(3-dimetylamino-fenoksy)propyl, 3-(4-nitrofenoksy)propyl, 3-(3-nitrofenoksy)propyl, 3-(4-acetylaminofenoksy)propyl, 3-(3-metoksykarbonylfenoksy)propyl, 3-[4-(3-hydroksypropyl)fenoksy]propyl, 3-(2-hydroksymetylfenoksy)propyl, 3-(3-hydroksymetylfenoksy)propyl, 3-(4-hydroksymetylfenoksy)propyl, 3-(2-hydroksyfenoksy)propyl, 3-(4-hydroksyfenoksy)propyl, 3-(3-hydroksyfenoksy)propyl, 4-okso-4-tien-2-ylbutyl,
3-(l-metyl-[lH]-imidazol-2-ylsulfanyl)propyl, 3-(benzotiazol-2-yloksy)propyl, 3-benzyloksypropyl, 6-(4-fenylbutoksy)heksyl, 4-fenoksybutyl eller 2- benzyloksyetylgruppe. Spesielt foretrukne forbindelser er de hvori azoniabicyklogruppen er substituert på nitrogenatomet med en 3-fenoksypropyl, 2-fenoksyetyl, 3- fenylallyl, fenetyl, 4-fenylbutyl, 3-fenylpropyl, 3-[2-hydroksyfenoksy]propyl, 3-[4-fluorfenoksy]propyl, 2-benzyloksyetyl, 3-pyrrol-l-ylpropyl, 2-tien-2-yletyl eller
3-tien-2-ylpropylgruppe.
De følgende forbindelser er ment for å illustrere foreliggende oppfinnelse.
3(R)-Difenylacetoksy-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(2-Hydroksy-2,2-difenylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2,2-Difenylpropionyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2-Hydroksy-2-fenyl-2-tien-2-ylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)-l-(3-fenylallyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)-l-(2-fenoksyetyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2,2-Ditien-2-ylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2-Hydroksy-2,2-di-tien-2-ylacetoksy)-l-fenetyl-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2-Hydroksy-2,2-di-tien-2-ylacetoksy)-l-(4-fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-fenoksypropyl)-l-azonia-bicyklo[2.2.2]oktan; bromid
l-[3-(4-Fluorfenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2-yla-cetoksy)-l-azoniabicyklo[2.2.2]oktan; klorid
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(2-hydroksyfenoksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-pyrrol-l-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(2-tien-2-yletyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
l-(2-Benzyloksyetyl)-3(R)-(2-hydroksy-2,2-ditien-2-ylacetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
3(R)-(2-Hydroksy-2,2-ditien-3-ylacetoksy)-l-(3-fenoksypropyl)-l-
azoniabicyklo[2.2.2]oktan; bromid
l-(3-fenylallyl)-3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-fenetyl-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(9-Hydroksy-9H-fluoren-9-karbonyloksy)-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(9-Metyl-9[H]-fluoren-9-karbonyloksy)-l-(3-fenylallyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(9-Metyl-9[H]-fluoren-9-karbonyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
l-(4-Fenylbutyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; bromid l-(2-Fenoksyetyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo-[2.2.2]oktan; bromid l-(3-Fenoksypropyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo-[2.2.2]oktan; bromid l-Fenetyl-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(9-Hydroksy-9[H]-xanten-9-karbonyloksy)-l-(3-fenoksypropyl)-l- azoniabicyklo[2.2.2]oktan; bromid
3(R)-(9-Hydroksy-9[H]-xanten-9-karbonyloksy)-l-fenetyl-l-azoniabicyklo-[2.2.2]oktan; bromid
3(R)-(9-Hydroksy-9H-xanten-9-karbonyloksy)-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(9-Metyl-9[H]-xanten-9-karbonyloksy)-l-(3-fenoksy-propyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Den foreliggende oppfinnelse tilveiebringer også fremgangsmåter ved fremstilling av forbindelser med formel (I) som angitt i krav 24.
De kvaternære ammoniumderivater med generell formel I, kan fremstilles ved reaksjon av et alkyleringsmiddel med generell formel II med forbindelser med generell formel III. I formel I, II og III er R<1>, R<2>, R3, ©, A, X, B, n, m og p som definert over.
Denne alkyleringsreaksjon kan utføres ved to forskjellige eksperimentelle fremgangsmåter, a) og b), som er beskrevet under. Spesielt fremgangsmåte b) tilveiebringer en ny eksperimentell fremgangsmåte, ved å anvende fast fase ekstrak-sjonsmetodologier, som tillater den parallelle fremstilling av flere forbindelser. Fremgangsmåte a) og b) er beskrevet i den eksperimentell del. Forbindelser med generell formel II som ikke er kommersielt tilgjengelige har blitt fremstilt ved syn-tese i henhold til standardmetoder. For eksempel ble forbindelser hvori n = 0 og A= -O- eller -S-, oppnådd ved reaksjon av det tilsvarende aromatisk derivat eller dets kaliumsalt med et alkyleringsmiddel med generell formel Y-(CH2)m-X, hvori X kan være et halogen og Y kan være et halogen eller en sulfonatester. I andre eksempler ble forbindelser med generell formel II, hvor n> = l syntetisert fra det tilsvarende alkoholderivat med generell formel IV ved kjente metoder.
Forbindelser med generell formel III kan fremstilles ved tre forskjellige fremgangsmåter c, d og e illustrert i det følgende skjema og spesifisert i den eksperimentell del.
Noen forbindelser med generell formel III hvor B er en gruppe med formel i), R8 og R<9>er som beskrevet over og R<10>er en hydroksygruppe, kan også fremstilles fra glyoksalatesterene med generell formel VII ved reaksjon med det tilsvarende or-ganometalliske derivat.
Forbindelser med generell formel VII kan fremstilles fra de tilsvarende glyoksylsy-reer etter standardmetodene c, d og e beskrevet over og spesifiser i den eksperimentell del. Glyoksalatderivatene med formel VII hvor R<8>er en 2-tienyl- eller 2-furylgruppe har ikke blitt beskrevet før.
De følgende forbindelser er eksempler på forbindelser med generell formel III og VII som ikke har blitt beskrevet før: 9-Metyl-9[H]-fluoren-9-karboksylsyre-l-azabicyklo[2.2.2]okt-3(R)-ylester (intermediat I-lc);
9-Metyl-9[H]-xanten-9-karboksylsyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester (inter-
mediat I-ld);
2-Hydroksyditien-2-yl-eddiksyre l-azabicyklo[2.2.2]okt-4-yl-ester (intermediat I-4a).
Oksotien-2-yl-eddiksyre l-azabicyklo[2.2.2]okt-4-yl-ester (intermediat I-4b). Oksotien-2-yl-eddiksyre l-azabicyklo[2.2.2]okt-3(R)-yl-ester (intermediat I-4g). Oksofuran-2-yl-eddiksyre l-azabicyklo[2.2.2]okt-3(R)-yl-ester (intermediat I-4e). 2-Hydroksy-2,2-difuran-2-yl-eddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester (intermediat I-4d).
Forbindelser med formel V kunne være:
4-hydroksy-l-azabicyklo[2.2.1]heptan, beskrevet i WO150080 4-hydroksy-l-azabicyklo[2.2.2]oktan, beskrevet i Grob, CA. et.al. Heiv.Chim.Acta
(1958), 41, 1184-1190
3(R)-hydroksy-l-azabicyklo[2.2.2]oktan eller 3(S)-hydroksy-l-azabicyklo[2.2.2]oktan, beskrevet i Ringdahl, R. Acta Pharm Suec. (1979), 16, 281-283 og kommersielt tilgjengelig fra CU Chemie Uetikon GmbH.
De følgende eksempler er ment å illustrere de eksperimentelle prosedyrer som har blitt beskrevet over.
Strukturene til de fremstilte forbindelser ble bekreftet ved<1>H-NMR og MS. NMR ble tatt opp ved å anvende et Varian 300 MHz instrument og kjemisk skift er uttrykket som deler per million (8) fra den interne referanse tetrametylsilan. Deres renhet ble bestemt ved HPLC, ved å anvende omvendt fase kromatografi på et Waters instrument, hvor verdier større enn 95% ble oppnådd. Molekylioner ble oppnådd ved elektrospray ionisasjon massespektrometri på et Hewlett Packard instrument.
Fremgangsmåte -a-
Eksempel 20- Fremstilling av 3(R)-(2-furan-2-yl-2-hydroksy-2-fenyl-acetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan, bromid.
200 mg (Furan-2-yl)-hydroksy-fenyleddiksyre-l-aza-bicyklo[2.2.2]okt-3(R)-yl-ester (0,6 mmol) ble suspendert i 4 ml CH3CN og 6 ml CHCI3. Til denne suspensjon ble 0,48 ml (3 mmol) 3-fenoksypropylbromid tilsatt. Etter omrøring i 72 timer ved romtemperatur i inert atmosfære, ble løsningsmidler fordampet. Eter ble tilsatt og blandingen omrørt. Det erholdte faste stoff ble filtrert og vasket flere ganger med
eter. Utbyttet var 0,27 g (83%) tittelforbindelse som en blanding av diastereomerer.
<1>H-NMR (DMSO-d6): 8 1,50-2,20 (m, 6H), 2,25 (m, 1H), 3,10 (m, 1H), 3,20-3,60 (m, 6H), 3,95 (m, 1H), 4,05 (m, 2H), 5,00 (m, 1H), 6,25-6,35 (dobbel dd, 1H), 6,45 (m, 1H), 6,95 (m, 4H), 7,30-7,50 (m, 7H), 7,70 (m, 1H); MS [M-Br] + : 462; smp. 166°C.
Fremgangsmåte -b-
Eksempel 51 - Fremstilling av 3(R)-(2-hydroksy-2,2-ditien-2-ylace-toksy)-l-[3-(naftalen-l-yloksy)propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat 60 mg (0,17 mmol) hydroksy-ditien-2-yl-eddiksyre-l-aza-bicyklo[2.2.2]okt-3(R)-yl-ester ble løst i 1 ml DMSO. Til denne løsning ble 188 mg (0,85 mmol) 3-(naftalen-l-yloksy)-propylklorid tilsatt. Etter omrøring natten over ved romtemperatur, ble blandingen renset ved fast fase ekstraksjon med en kationbytter Mega Bond Elut patron, tidligere kondisjonert ved pH = 7,5 med 0,1 M NaH2P04-buffer. Reaksjonsblandingen ble applisert på patronen og vasket først med 2 ml DMSO og deretter tre ganger med 5 ml CH3CN, som renser vekk alle startmaterialer. Ammo-niumderivatet ble eluert med 5 ml 0,03 M TFA-løsning i CH3CN:CHCI3 (2:1). Denne løsning ble nøytralisert med 300 mg poly(4-vinylpyridin), filtrert og fordampet til tørrhet.
Utbyttet var 17 mg (15%) tittelforbindelse.<1>H-NMR (DMSO-d6): 8 1,7 - 2,1 (m, 4H), 2,2-2,4 (m, 3H), 3,2-3,6 (m, 7H), 4,0 (m, 1H), 4,2 (t, 2H), 5,25 (m, 1H), 7,0 (m 3H), 7,2 (m, 2H), 7,4-7,6 (m, 7H), 7,85 (d, 1H), 8,2 (d, 1H); MS [M-CF3COO]<+>: 534.
Fremgangsmåte -c-
Metylesterderivater med generell formel VI ble fremstilt ved standardmetoder for
forestering fra den tilsvarende karboksylsyre eller ved å følge prosedyrene beskrevet i eksempel I-le, I-lf og I-lg eller i henhold til prosedyrer beskrevet i litteratur: FR 2012964; Larsson. L et al. Acta Pharm. Suec. (1974), 11(3), 304-308; Nyberg, K. et.al. Acta Chem.Scand. (1970), 24, 1590-1596; og Cohen, V.I. et.al. J.Pharm.Sciences (1992), 81, 326-329.
Eksempel I-la- Fremstilling av (furan-2-yl)hydroksyfenyleddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
3,24 g (0,014 mol) (Furan-2-yl)-hydroksy-fenyleddiksyremetylester ble løst i 85 ml toluen. Til denne løsning ble 2,08 g (0,016 mol) 3-(R)-hydroksy-l-azabicyklo[2.2.2]oktan og 0,224 g (5,6 mmol) HNa (60% dispersjon i mineralolje) tilsatt. Blandingen ble refluksert med kontinuerlig fjerning av destillat og når nød-vendig utskifting med frisk toluen i 1,5 timer. Den avkjølte blanding ble ekstrahert med 2 N HCI-syre, den vandige fase vasket med etylacetat, gjort basisk med K2C03 og ekstrahert med CHCI3. Den organiske fase ble tørket over Na2S04 og fordampet. Den erholdte olje (3,47 g) krystallisert etter avkjøling ved romtemperatur. Dette faste stoff ble suspendert i heksan og filtrert. Utbyttet var 2,5 g (54%) av en blanding av diasteroisomerer, smp: 140-142°C; GC/MS [M]<+>: 327;
<1>H-NMR (CDCI3): 8 1,20-1,70 (m, 4H), 1,90-2,10 (m, 1H), 2,45-2,80 (m, 5H), 3,10-3,30 (m, 1H), 4,8 (bs, OH), 4,90-5,0 (m, 1H), 6,20 (m, 1H), 6,35 (m, 1H), 7,30-7,50 (m, 4H), 7,60-7,70 (m, 2H).
Etter fire krystallisasjoner av 0,5 g av denne blanding fra kokende acetonitril, ble 0,110 g av en ren diastereomer (1) erholdt.
Fra krystallisasjonens moderløsninger ble den andre diastereomer (2) erholdt.
(<*>:konfigurasjon ikke tilordnet). Diastereomer 1 ble hydrolysert for å gi (+)-2-hydroksy-2-fenyl-2-furan-2-yleddiksyre som en ren enantiomer, [a]<25>D= +5,6 (c=2, EtOH). Diastereomer 2 ble hydrolysert for å gi (-)-2-hydroksy-2-fenyl-2-furan-2-yleddiksyre som en ren enantiomer, [a]<25>D= -5,7 (c=2, EtOH).
Diastereomer 1: 2(<*>)-(Furan-2-yl)hydroksyfenyleddiksyre-l-azabicyklo-[2.2.2]okt-3(R)-yl-ester.<1>H-NMR (CDCI3): 81,20-1,70 (m, 4H), 1,90 (m, 1H), 2,45-2,50 (m, 1H), 2,50-2,80 (m, 4H), 3,10-3,20 (m, 1H), 4,8 (bs, OH), 4,90-5,0 (m, 1H), 6,20 (m, 1H), 6,35 (m, 1H), 7,30-7,50 (m, 4H), 7,60-7,70 (m, 2H).
Diastereomer 2: 2(<*>)-(Furan-2-yl)hydroksyfenyleddiksyre-l-azabicyklo-[2.2.2]okt-3(R)-yl ester.<1>H-NMR (CDCI3): 8 1,20-1,70 (m, 4H), 2,10 (m, 1H), 2,50-2,80 (m, 5H), 3,20-3,30 (m, 1H), 4,8 (bs, OH), 4,90-5,0 (m, 1H), 6,20 (m, 1H), 6,35 (m, 1H), 7,30-7,50 (m, 4H), 7,60-7,70 (m, 2H).
Eksempel I-lb- Fremstilling av furan-2-ylhydroksytien-2-yleddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
Fremstilt som i eksempel I-la. Utbyttet var 3,06 g (64,3%) av en blanding av di-astereoisomerer, smp: 172°C; GC/MS [M]<+>: 333;
<1>H-NMR (DMSO-d6): 81,21-1,27 (m, 1H), 1,41-1,60 (m, 3H), 1,87 (m, 1H), 2,36-2,69 (m, 5H), 3,02-3,14 (m, 1H), 4,75-4,82 (m, 1H), 6,24-6,25 (m, 1H), 6,42-6,45 (m, 1H), 7,01-7,06 (m, 1H), 7,11-7,14 (m, 2H), 7,51-7,54 (m, 1H), 7,66-7,69 (m, 1H).
Eksempel I-lc- Fremstilling av 9-Metyl-9[H]-fluoren-9-karboksylsyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
Fremstilt som i eksempel I-la. Utbyttet var 3,34 g av en olje (80%). Dette produkt ble størknet ved dannelse av oksalatsaltet (1:1), smp: 186°C. MS [M fri base + 1]<+>: 334.
Oksalatsalt,<1>H-NMR (DMSO-d6): 8 1,43-1,55 (m, 2H), 1,68-1,78 (m, 2H), 1,75 (s, 3H), 2,02 (m, 1H), 2,70-2,90 (m, 1H), 2,92-3,15 (m, 4H), 3,50-3,57 (m, 1H), 4,88 (m, 1H), 7,35-7,47 (m, 4H), 7,62-7,70 (m, 2H), 7,89-7,91 (m, 2H).
Eksempel I-ld- Fremstilling av 9-metyl-9[H]-xanten-9-karboksylsyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
Fremstilt som i eksempel I-la. Utbyttet var 1,91 g av en olje (53%). Dette produkt ble størknet ved dannelse av oksalatsaltet (1:1), smp: 152°C. MS [M fri base + 1]<+>: 350.
Oksalatsalt,<1>H-NMR (DMSO-d6): 8 1,20-1,30 (m, 1H), 1,40-1,52 (m, 1H), 1,64-1,81 (m, 2H), 1,90 (s, 3H), 2,0 (m, 1H), 2,53-2,66 (m, 1H), 2,71-2,76 (m, 1H), 2,97-3,10 (m, 3H), 3,44-3,52 (m, 1H), 4,90-4,92 (m, 1H), 7,12-7,18 (m, 4H), 7,32-7,38 (m, 2H), 7,43-7,48 (m, 2H), 8,0-9,8 (bs, 1H, H<+>).
Eksempel I-le- Fremstilling av 9-metyl-9[H]-fluoren-9-karboksylsyre-metylester.
Litiumdiisopropylamid (26,7 ml av en 2 M løsning i heptan/tetrahydro-furan/etylbenzen, 0,053 mol) ble tilsatt til en omrørt løsning av 9[H]-fluoren-9-karboksylsyre (5 g, 0,0237 mol) i THF (70 ml) ved mellom 0 og 5°C i ^-atmosfære. Blandingen ble varmet til romtemperatur og refluksert 1,5 timer. Reaksjonsblandingen ble avkjølt til romtemperatur og en løsning av CH3I (1,85 ml, 0,03 mol) i THF (1,85 ml) ble tilsatt. Blandingen ble omrørt natten over ved romtemperatur og fordampet. Til residuet i MeOH (70 ml) ble det tilsatt konsentrert svovelsyre (3,9 ml) i MeOH (25 ml), blandingen ble refluksert i 2 timer og fordampet. Residuet ble fordelt mellom kloroform og mettet K2C03-løsning. Den vandige fase ble ekstrahert igjen med kloroform og de organiske faser ble kombinert, vasket med vann, tørket over natriumsulfat og fordampet til tørrhet for å erholde 5,73 g av en brun olje. Dette produkt ble renset ved kolonnekromatografi (silikagel, heksan/etylacetat 95:5) for å gi 4,43 g, (78,5%) av et rent produkt, struktur bekreftet ved<1>H-NMR.
<1>H-NMR (CDCI3): 8 1,80 (s, 3H), 3,60 (s, 3H), 7,50-7,65 (m, 4H), 7,75 (m, 2H), 8,0 (m, 2H).
Eksempel I-lf- Fremstilling av 9-metyl-9[H]-xanten-9-karboksylsyre-metylester.
Fremstilt som i eksempel I-le. Utbyttet ble 2,65 g (47,2%).<1>H-NMR (CDCI3): 8 1,90 (s, 3H), 3,6 (s, 3H), 7,05-7,35 (m, 8H).
Eksempel I-lg- Fremstilling av 9-hydroksy-9[H]-xanten-9-karboksylsyre-metylester.
Litiumdiisopropylamid (20,3 ml av en 2 M løsning i heptan/tetrahydro-furan/etylbenzen, 0,041 mol) ble tilsatt til en omrørt løsning av 7 g (0,029 mol) 9[H]-xanten-9-karboksylsyremetylester (fremstilt ved en standardmetode) i THF (70 ml) ved mellom 0 og 5°C i N2-atmosfære. Blandingen ble omrørt 1 time ved denne temperatur og ble deretter tilsatt med N2-trykk til en tørr løsning av oksygen i eter ved 0°C. Etter 30 min ble et like stort volum NaHS03, 40% vandig løsning, tilsatt, og reaksjonsblandingen ble varmet til romtemperatur og omrørt i 30 min. De to faser ble separert og den vandige fase ble ekstrahert to ganger med etylacetat. De organiske faser ble kombinert, behandlet med NaHS03 (40% vandig løs- ning), vasket med vann, tørket over natriumsulfat og fordampet til tørrhet for å erholde 8,89 g av et brunt fast stoff. Denne prosedyre ble gjentatt med 5 g start-materiale som ga 6,04 g av det samme brune faste stoff. Produktene ble kombinert og renset ved kolonnekromatografi (silikagel, heksan/etylacetat 90:10) for å gi 7,60 g (global Rt: 59,4%) av et rent produkt, struktur bekreftet ved<1>H-NMR.<1>H-NMR (DMSO-d6): 8 3,5 (s, 3H), 7,0 (s, 1H, OH), 7,2 (m, 4H), 7,4 (m, 2H), 7,55 (m, 2H).
Fremgangsmåte -d-
Eksempel I-2a- Fremstilling av 10,ll-dihydro-5[H]-dibenzo[a,d]cyklo-heptan-5-karboksylsyre-l-azabicyklo[2.2.2]okt-3-(R)-yl-ester.
2,15 g 10,ll-Dihydro-5[H]-dibenzo[a,d]cykloheptan-5-karboksylsyre (9,0 mmol) ble løst i 40 ml CHCI3 (etanolfri). Løsningen ble avkjølt ved 0°C og 0,86 ml oksalylklorid (9,9 mmol) og en dråpe DMF ble tilsatt. Blandingen ble omrørt og tillatt å varme til romtemperatur. Etter en time ved denne temperatur ble løsningsmidlene fordampet og residuet ble løst i CHCI3 og fordampet igjen. Denne prosedyre ble gjentatt to ganger. Den erholdte olje ble løst i 20 ml toluen og tilsatt til en løsning av 1,26 g (9,9 mmol) 3-(R)-hydroksy-l-azabicyklo[2.2.2]oktan i 40 ml varm toluen. Reaksjonsblandingen ble refluksert i 2 timer. Etter avkjøling ble blandingen ekstrahert med 2 N HCI-syre. Den vandig fase ble gjort basisk med K2C03 og ekstrahert med CHCI3. Den organiske fase ble tørket over Na2S04 og fordampet til tørrhet. Residuet ble renset ved kolonnekromatografi (silikagel, CHCI3:MeOH:NH40H, 95:5:0,5). Utbyttet var 1,5 g (48%); smp: 112-113°C; CG/MS [M]<+>: 347;<1>H-NMR (CDCI3): 8 1,10-1,35 (m, 2H), 1,40-1,52 (m, 1H), 1,52-1,68 (m, 1H), 1,90 (m, 1H), 2,40-2,60 (m, 2H), 2,60-2,77 (m, 3H), 2,83-2,96 (m, 2H), 3,07-3,19 (m, 1H), 3,25-3,40 (m, 2H), 4,80 (m, 2H), 7,10-7,30 (m, 8H). 10,ll-Dihydro-5[H]-dibenzo[a,d]cykloheptan-5-karboksylsyre ble fremstilt som beskrevet i Kumazawa T. et al., J. Med. Chem., (1994), 37, 804-810.
Eksempel I-2b- Fremstilling av 5[H]-dibenzo[a,d]cyklohepten-5-karboksylsyre-l-azabicyklo[2.2.2]okt-3-(R)-yl-ester.
Fremstilt som i eksempel I-2a. Utbyttet var 3,12 g (71%); smp. 129°C; MS [M+l]<+>: 346;<1>H-NMR (DMSO-d6): 8 0,90-1,10 (m, 2H), 1,30-1,50 (m, 2H), 1,58 (m, 1H), 2,21-2,26 (m, 2H), 2,47-2,50 (m, 3H), 2,86-2,94 (m, 1H), 4,48-4,51 (m, 1H), 5,33 (s, 1H), 7,0 (m, 2H), 7,29-7,43 (m, 6H), 7,49-7,51 (m, 2H).
5[H]-Dibenzo[a,d]cyklohepten-5-karboksylsyre ble fremstilt som beskrevet i M.A. Davis et al; J. Med. Chem., (1964), Vol 7, 88-94.
Eksempel I-2c-Fremstilling av 9,10-dihydroantracen-9-karboksylsyre-l-azabicyklo[2.2.2]okt-3-(R)-yl-ester
Fremstilt som i eksempel I-2a. Utbyttet var 0,77 g (62,6%); smp. 139°C; MS [M+l]<+>: 334;<1>H-NMR (DMSO-d6): 8 1,1-1,2 (m, 1H), 1,25-1,40 (m, 2H), 1,40-1,55 (m, 1H), 1,73 (m, 1H), 2,20 (m, 1H), 2,35-2,65 (m, 4H), 2,90-2,98 (m, 1H), 3,93-4,14 (dd, 2H, J = 1,8 Hz, J = 4,3 Hz), 4,56 (m, 1H), 5,14 (s, 1H), 7,25-7,35 (m, 4H), 7,35-7,50 (m, 4H).
9,10-Dihydro-antracen-9-karboksylsyre ble fremstilt som beskrevet i E. L. May og E. Mossettig; J. Am. Chem. Soc, (1948), Vol 70, 1077-9.
Fremgangsmåte -e-
Eksempel 1-3. Fremstilling av 2,2-difenylpropionsyre-l-azabicyklo[2.2.2]-okt-3(R)-yl-ester.
1,1 g (4,8 mmol) 2,2-difenylpropionsyre ble løst i 20 ml THF. Til denne løsning ble 0,87 g (5,3 mmol) l,l'-karbonyldiimidazol tilsatt og blandingen ble refluksert i en time. Reaksjonen ble overvåket med TLC etter dannelsen av imidazolidet. Da reaksjonen var fullført ble en del av løsningsmidlet fordampet og 0,67 g (5,3 mmol) 3-(R)-hydroksy-l-azabicyklo[2.2.2]oktan ble tilsatt. Reaksjonsblandingen ble refluksert i 16 timer, avkjølt, fortynnet med eter og vasket med vann. Den organiske fase ble ekstrahert med HCI 2 N, den sure løsning ble gjort basisk med K2C03 og ekstrahert med CHCI3. Den organiske løsning ble tørket over Na2S04 og fordampet til tørrhet for å gi 1,21 g (75,2%) av en olje som ble identifisert som tittelesteren.
0,64 g (1,9 mmol) 2,2-Difenylpropionsyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester ble løst i 6 ml keton og 0,085 g (0,95 mmol) oksalsyre ble tilsatt. Etter langsom tilsetning av eter ble et hvitt fast stoff dannet. Utbyttet var 0,33 g (45,6%) av oksalatet av 2,2-difenyl-propionsyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester; smp: 146°C; MS [M fri base+l]<+>: 336.
Oksalatsalt,<1>H-NMR (CDCI3): 8 1,40-1,64 (m, 2H), 1,90 (s, 3H),
1,80-2,0 (m, 2H), 2,31 (m,lH), 2,73-2,85 (m, 1H), 3,0-3,10 (m,lH), 3,10-3,32 (m, 3H), 3,53-3,70 (m, 1H), 5,13 (m, 1H), 7,14-7,40 (m, 10H), 9,25 (bredt bånd, 2H, H<+>).
Fremgangsmåte -f-
Eksempel I-4a- Fremstilling av 2-hydroksy-2,2-ditien-2-yleddiksyre-l-azabicyklo[2.2.2]okt-4-yl-ester.
En løsning av 2-tienylmagnesiumbromid ble fremstilt fra 220 mg (9 mmol) magne-sium og 0,86 ml (9 mmol) 2-bromtiofen i 15 ml THF. Denne løsning ble tilsatt til 1,95 g (7 mmol) oksotien-2-yl-eddiksyre-l-azabicyklo[2.2.2]okt-4-yl-ester (intermediat I-4b) løst i 20 ml THF. Blandingen ble omrørt ved romtemperatur i 1 time, refluksert i 1 time, avkjølt, behandlet med en mettet løsning av ammoniumklorid og ekstrahert med eter. Etter fjerning av løsningsmidlet ble det erholdte faste stoff omkrystallisert fra acetonitril for å gi 1,45 g av et hvitt fast stoff (56%),<X>H-NMR (DMSO-d6): 8 1,80-2,0 (m, 6H), 2,80-3,0 (m, 6H), 7,0 (m, 2H), 7,13 (m, 2H), 7,18 (s, 1H), 7,51 (m, 2H); MS [M+l]: 350; smp. 174°C.
Eksempel I-4b-
Fremstilling av oksotien-2-yl-eddiksyre-l-azabicyklo[2.2.2]okt-4-yl-ester. Oksalylklorid (1,5 ml, 0,017 mol) ble tilsatt til en løsning av oksotien-2-yl-eddiksyre (2,24 g, 0,014 mol) og dimetylformamid (en dråpe) i 30 ml kloroform (etanol fri) ved 0°C. Blandingen ble omrørt og tillatt å varme ved romtemperatur. Etter en time ble løsningsmidlet fordampet. Residuet ble løst i kloroform og fordampet igjen. Denne prosedyre ble gjentatt to ganger. Det erholdte produkt ble løst i CHCI3 (30 ml) og tilsatt til en suspensjon av 1,1 g (0,009 mol) 4-hydroksy-l-azabicyklo [2.2.2]oktan, 1,8 ml trietylamin (0,013 mol), 0,6 g (0,9 mmol) N-(metylpolystyren) -4-(metylamino)pyridin ved 70°C. Blandingen ble refluksert i 1 time, avkjølt, filtrert og vasket med vann. Tittelproduktet ble ekstrahert med en løsning av fortynnet HCI, vasket med CHCI3, gjort basisk med K2C03 og ekstrahert igjen med CHCI3. Etter fjerning av løsningsmidlet ble 1,47 g (45%) av et fast stoff erholdt.<1>H-NMR (DMSO): 8 2,0 (m, 6H), 2,9 (m, 6H), 7,35 (m, 1H), 8,05 (m, 1H), 8,3 (m, 1H).
Eksempel I-4c-
Fremstilling av (furan-2-yl)hydroksyfenyleddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
Fenylmagnesiumbromid (0,0057 mol, 5,7 ml av en løsning 1 M i THF) ble tilsatt til en løsning av 1,3 g (0,0052 mol) oksofuran-2-yleddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester (intermediat I-4e) løst i 15 ml THF, ved -70°C i N2-atmosfære. Blandingen ble omrørt ved denne temperatur i 10 minutter og deretter varmet til rom temperatur. Etter 1 time ble reaksjonsblandingen behandlet med en mettet løsning av ammoniumklorid og ekstrahert tre ganger med etylacetat. De organiske faser ble kombinert, vasket med vann og tørket over Na2S04. Etter fjerning av løsnings-midlet ble det erholdte faste stoff behandlet med eter og filtrert for å gi 0,67 g (40%) av et produkt hvis struktur ble bekreftet ved<1>H-NMR. Denne forbindelse ble også fremstilt som beskrevet i eksempel I-la (Fremgangsmåte c). Diastereomerene ble separert ved krystallisasjon fra acetonitril ogkarakterisert ved^-NMR.
Eksempel I-4d-
Fremstilling av 2-hydroksy-2,2-difur-2-yl-eddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
Tittelforbindelsen ble syntetisert som i eksempel I-4c fra intermediat I-4e og 2-furanyllitium som ble fremstilt med furan og butyllitium ved å følge en standardmetode. Utbyttet var 380 mg (8%).<1>H-NMR (CDCI3): 8 1,2-1,4 (m, 1H), 1,4-1,8 (m, 3H), 2,0 (m, 1H), 2,6-2,85 (m, 5H), 3,2 (m, 1H), 5,0 (m, 1H), 6,4 (m, 3H), 7,3 (m, 1H), 7,5 (m, 2H). MS [M+l] + : 318.
Eksempel I-4e-
Fremstilling av oksofuran-2-yl-eddiksyre-l-azabicyklo [2.2.2]okt-3(R)-yl-ester.
Oksalylklorid (9,75 ml, 0,112 mol) ble tilsatt til en løsning av oksofuran-2-yleddiksyre (10 g, 0,071 mol) og dimetylformamid (en dråpe) i 150 ml kloroform (etanol fri) ved 0°C. Blandingen ble omrørt og tillatt å varme ved romtemperatur. Etter fem timer ble løsningsmidlet fordampet. Residuet ble løst i kloroform og fordampet igjen. Denne prosedyre ble gjentatt to ganger. Det erholdte produkt ble løst i CHCI3 (150 ml) og en løsning av 3(R)-kinuklidinol (10,90 g, 0,086 mol) i CHCI3 (150 ml) ble tilsatt til denne ved 0°C. Blandingen ble omrørt og tillatt å varme ved romtemperatur. Etter 15 timer ved r.t. ble blandingen vasket med 10% vandig kaliumkarbonat, deretter med vann, tørket over Na2S04 og fordampet for å gi 9,34 g (52,5%) av tittelforbindelsen som en mørk olje. Estruktur bekreftet ved
NMR.
<1>H-NMR (CDCI3): 8 1,40-1,60 (m, 1H), 1,60-1,80 (m, 2H), 1,80-2,05 (m, 1H), 2,20 (m, 1H), 2,70-3,10 (m, 5H), 3,30-3,45 (m, 1H), 5,10 (m, 1H), 6,7 (m, 1H), 7,7 (m, 1H), 7,8 (m, 1H).
Eksempel I-4f-
Fremstilling av 2-hydroksy-2-fenyl-2-tien-2-yleddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
Tittelforbindelsen ble fremstilt som beskrevet i eksempel I-4c fra intermediat I-4g. Utbyttet ble 3 g (33%) som en blanding av diastereomerer. Etter fem krystallisasjoner av 1,5 g av denne blanding fra kokende isopropanol, ble 0,200 g av en ren diastereomer (1) erholdt. Moderløsningen fra første krystallisasjon ble anriket med den andre diastereomer (2). Diastereomer 1 ble hydrolysert for å gi (+)-2-hydroksy-2-fenyl-2-tien-2-yleddiksyre som en ren enantiomer, [a]<25>D= +25,4 (c=2, EtOH). Denne verdi ble tilordnet til R-konfigurasjonen gitt som i litteraturen (A.I.Meyers et.al. J.Org.Chem.(1980),45(14), 2913) 2(S)-enantiomeren har blitt beskrevet med [a]<25>D= - 20 (c=2, EtOH).
Diastereomer 1: 2(R)-2-Hydroksy-2-fenyl-2-tien-2-yleddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
<1>H-NMR(DMSO-d6): 8 1,1-1,25 (m, 1H), 1,3-1,6 (m, 3H), 1,83 (m, 1H), 2,4-2,7 (m, 5H), 3,1 (m, 1H), 4,8 (m, 1H), 7,0 (m, 2H), 7,05 (m, 1H), 7,3-7,4 (m, 3H), 7,4-7,45 (m, 2H), 7,5 (m, 1H).
Diastereomer 2: 2(S)-2-hydroksy-2-fenyl-2-tien-2-yleddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester
<1>H-NMR (DMSO-d6): 8 1,1-1,25 (m, 1H), 1,4-1,6 (m, 3H), 1,9 (m, 1H), 2,3-2,7 (m, 5H), 3,05 (m, 1H), 4,8 (m, 1H), 7,0 (m, 2H), 7,05 (m, 1H), 7,3-7,4 (m, 3H), 7,4-7,45 (m, 2H), 7,5 (m, 1H).
Eksempel I-4g-
Fremstilling av oksotien-2-yl-eddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
Oksalylklorid (1,34 ml, 0,0154 mol) ble tilsatt til en løsning av oksotien-2-yl-eddiksyre (2 g, 0,0128 mol) og dimetylformamid (en dråpe) i 30 ml kloroform (etanol fri) ved 0°C. Blandingen ble omrørt og tillatt å varme ved romtemperatur. Etter en time ble løsningsmidlet fordampet. Residuet ble løst i kloroform og fordampet igjen. Denne prosedyre ble gjentatt to ganger. Det erholdte produkt ble løst i CHCI3 (30 ml) og en løsning av 3(R)-kinuklidinol (1,95 g, 0,0154 mol) i CHCI3 (30 ml) ble tilsatt til denne ved 0°C. Blandingen ble omrørt og tillatt å varme ved romtemperatur. Etter 1,5 timer ved r.t. ble blandingen vasket med 10% vandig kaliumkarbonat, så med vann, tørket over Na2S04 og fordampet for å gi 3,14 g (92,6%) av tittelforbindelsen som en gul olje.<1>H-NMR (CDCI3): 8 1,40-1,50 (m, 1H), 1,50-1,70 (m, 1H), 1,70-1,80 (m, 1H), 1,90-2,0 (m, 1H), 2,15 (m, 1H), 2,70-3,05 (m, 5H), 3,30-3,40 (m, 1H), 5,05 (m, 1H), 7,20 (m, 1H), 7,85 (m, 1H), 8,10 (m, 1H).
Andre karboksylsyrer med formel B-C(0)OH, hvis fremstilling (eller syntesene av deres derivater metylester, klorid eller imidazolid) ikke har blitt beskrevet i fremgangsmåte c, d, e eller i eksempelene I-le, I-lf og I-lg, og som ikke er kommersielt tilgjengelige, kunne fremstilles som beskrevet i de følgende referanser: FR 2012964
M.A. Davis et al; J. Med. Chem. (1963), 6, 513-516.
T. Kumazawa et al; J.Med. Chem, (1994), 37(6), 804-810.
M.A. Davis et al; J. Med. Chem., (1964), Vol(7), 88-94.
Sestanj, K; Can. J. Chem., (1971), 49, 664-665.
Burtner, R. ; J. Am. Chem. Soc, (1943), 65, 1582-1585
Heacock R.A. et al; Ann. Appl. Biol., (1958), 46(3), 352-365.
Rigaudy J. et.al; Bull. Soc. Chim. France, (1959), 638-43.
Ueda I. et al; Bull. Chem. Soc. Jpn; (1975), 48 (8), 2306-2309.
E.L. kan et.al.; J. Am. Chem. Soc, (1948), 70, 1077-9.
Også inkludert innenfor rammen av den foreliggende oppfinnelse er farmasøytisk sammensetning som omfatter, som den aktive ingrediens, minst ett kinuklidinderi-vat med generell formel (I) sammen med en farmasøytisk akseptabel bærer eller fortynningsmiddel. Fortrinnsvis er sammensetningen laget opp i en form egnet for oral administrasjon.
Den farmasøytisk akseptable bærer eller fortynningsmidler som blandes med den aktive forbindelse eller forbindelser, for å danne sammensetningen av denne oppfinnelse er velkjente perse og de faktisk anvendte eksipienter avhenger inter alia av den tiltenkte administrasjonsmetode til sammensetningen.
Sammensetninger av denne oppfinnelse tilpasses fortrinnsvis for oral administrasjon. I dette tilfelle kan sammensetningen for oral administrasjon ha form av tabletter, filmbelagte tabletter, flytende medikament for inhalasjon, pulvermedikament for inhalasjon og inhalasjonsaerosol; alle inneholdende en eller flere forbindelser av oppfinnelsen; slike fremstillinger kan lages ved fremgangsmåter velkjente i faget.
Fortynningsmidlene som kan anvendes i fremstillingene av sammensetningene inkluderer de flytende og faste fortynningsmidler som er kompatible med den aktive ingrediens, sammen med farge- eller smaksstoffer, om ønsket. Tabletter eller filmbelagte tabletter kan hensiktsmessig inneholde mellom 500 og 1 mg, fortrinnsvis fra 5 til 300 mg aktiv ingrediens. Sammensetningene for inhalasjon kan inneholde mellom 1 jxg og 1.000 |xg, fortrinnsvis fra 10 til 800 |xg aktiv ingrediens. I human terapi avhenger dosen av forbindelsen med generell formel (I) av den ønskede effekt og varighet av behandling; voksene doser er generelt mellom 3 mg og 300 mg per dag som tabletter og 10^g og 800 jxg per dag som sammensetning for inhalasjon.
Farmakologisk virkning
De følgende eksempler demonstrerer de utmerkede farmakologiske aktiviteter til forbindelsene av den foreliggende oppfinnelse. Resultatene på humane muskarinre-septorerbinding og i testen på bronkospasme i marsvin, ble erholdt som beskrevet under.
Humane muskarinreseptorstudier
Bindingen av [<3>H]-NMS til humane muskarinreseptorer ble utført i henhold til Wael-broek et al (1990) (1). Undersøkelser ble utført ved 25°C. Membranpreparater fra stabilt transfekterte kinesiske hamster ovarie-Kl celler (CHO) som uttrykker gene-ne for de humane muskarinreseptorer Hm3 ble anvendt.
For bestemmelse av IC50, ble membranpreparater suspendert i DPBS til en slutt - konsentrasjon på 89 ug/ml for Hm3-subtypen. Membransuspensjon ble inkubert med den tritierte forbindelse i 60 min. Etter inkubasjon ble membranfraksjonen separert ved filtrering og den bundne radioaktivitet bestemt. Ikke-spesifikk binding ble bestemt ved tilsetning av 10"<4>M atropin. Minst seks konsentrasjoner ble testet i duplikat for å generere individuelle fortrengningskurver. (1) M. Waelbro, M. Tastenoy, J. Camus, J Christophe. Binding of selective antago-nists to four muscarinic receptors (Ml to M4) in rat forebrain. Mol. Pharmacol.
(1990) 38: 267-273.
Resultatene viser at forbindelsene av den foreliggende oppfinnelse har affiniteter for M3-reseptorene som er svært lignende referanseforbindelsene.
Forbindelsene av oppfinnelsen har fortrinnsvis høye affiniteter for muskarin-M3-reseptorer (HM3), fortrinnsvis humane muskarinreseptorer. Affinitetsnivåer kan typisk måles ved in vitro tester, for eksempel, som beskrevet over.
Foretrukne forbindelser av oppfinnelsen har en IC50-verdi ( nM) for M3-reseptorer på mindre enn 35, fortrinnsvis mindre enn 25, 20 eller 15, mer foretrukket mindre enn 10, 8 eller 5.
Test på bronkospasme i marsvin
Studiene ble utført i henhold til Konzett og Rossler (2). Vandige løsninger av midle-ne som skulle testes ble nebulisert og inhalert av anesteserte ventilerte hannmar-svin (Dunkin-Hartley). Den bronkiale respons på intravenøs acetylkolinutfordring ble bestemt før og etter legemiddeladministrasjon og den prosentvise endring i pulmonær motstand ved flere tidspunkter.
2. Konzett H., Rossler F. Versuchsanordnung zu Untersuchungen ander bronchial-muskulatur. Arch. Exp. Path. Pharmacol. 195: 71-74 (1940)
Forbindelsene av den foreliggende oppfinnelse hemmet bronkospasmeresponsen på acetylkolin med høy potens og en lang virkningsvarighet.
Fra de over beskrevne resultater kan fagmannen lett forstå at forbindelsene av den foreliggende oppfinnelse har utmerket antimuskarinaktivitet (M3) og således er nyttige for behandlingen av sykdommer hvor muskarin-M3-reseptoren er implisert, inklusive respiratoriske sykdommer slik som kronisk obstruktiv lungesykdom, kronisk bronkitt, astma og rhinitt, urinveissykdommer slik som urininkontinens og pollakisuri i neuripenia pollakisuri, nevrogen blære, nokturnal enurese, ustabil blære, cystospasme og kronisk cystitt og gastrointestinale sykdommer slik som irritabelt tarmsyndrom, spastisk kolitt og divertikulitt.
Den foreliggende oppfinnelse tilveiebringer ytterligere en forbindelse med formel (I) eller en farmasøytisk akseptabel sammensetning omfattende en forbindelse med formel (I) for anvendelse i en fremgangsmåte ved behandling av det humane eller animalske legeme ved terapi, spesielt for behandlingen av respiratoriske, urinveis-eller gastrointestinal sykdom.
Den foreliggende oppfinnelse tilveiebringer videre anvendelsen av en forbindelse med formel (I) eller en farmasøytisk akseptabel sammensetning omfattende en forbindelse med formel (I) ved fremstillingen av et medikament for behandlingen av respiratoriske, urinveis- eller gastrointestinal sykdom.
Videre kan forbindelsene med formel (I) og farmasøytiske sammensetninger omfattende en forbindelse med formel (I) anvendes i en fremgangsmåte for å behandle respiratoriske, urinveis- eller gastrointestinal sykdom, hvilken fremgangsmåte omfatter å administrere til en human eller animalsk pasient som trenger slik behandling en effektiv mengde av en forbindelse med formel (I) eller en farmasøytisk sammensetning omfattende en forbindelse med formel (I).
Den foreliggende oppfinnelse vil bli ytterligere illustrert ved de følgende eksempler.
Eksempel 1
3(R)-Difenylacetoksy-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 500 mg, 81%.<1>H-NMR (CDCI3): 8 1,72-2,18 (m, 6H), 2,35 (m, 1H), 3,0 (m, 1H), 3,23 (m, 1H), 3,59-3,88(m, 5H), 4,0 (m, 2H), 4,30 (m, 1H), 5,1 (s, 1H), 5,25 (m, 1H), 6,8-6,9 (m, 2H), 6,9-7,0 (m, 1H), 7,2-7,4 (m, 12H); MS [M-Br] + : 456; smp. 129°C.
Eksempel 2
3(R)-(2-Hydroksy-2,2-difenylacetoksy)-l-(3-fenoksypropyl)-l-azoniabi-cyclo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 280 mg, 42%.<1>H-NMR (DMSO-d6): 8 1,5-1,7 (m, 2H), 1,9-2,1 (m, 4H), 2,3 (m, 1H), 3,1 (m, 1H), 3,2-3,5 (m, 6H), 3,9-4,1 (m, 3H), 5,25 (m, 1H), 6,8 (bs, OH), 6,95 (m, 3H), 7,2-7,5 (m, 12H); MS [M-Br]<+>: 472; smp. 199°C.
Eksempel 3
3(R)-[2,2-Bis(4-fluorfenyl)-2-hydroksyacetoksy]-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 400 mg, 85%.<1>H-NMR (DMSO-d6): 8 1,5-1,65 (m, 1H), 1,7-1,8 (m, 1H), 1,85-2,0 (m, 2H), 2,05-2,2 (m, 2H), 2,3 (m, 1H), 3,1-3,2 (m, 1H), 3,3-3,5 (m ,6H), 3,95 (m, 1H), 4,05 (m, 2H), 5,25 (m, 1H), 6,9-7,0 (m, 4H), 7,1-7,5 (m, 10H); MS [M-Br]<+>: 508; smp. 253°C.
Eksempel 4
3(R)-[2,2-Bis(4-fluorfenyl)-2-hydroksyacetoksy]-l-fenetyl-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 300 mg, 67%.<1>H-NMR (DMSO-d6): 8 1,5-1,65 (m, 1H), 1,7-1,85 (m, 1H), 1,85-2,1 (m, 2H), 2,3 (m, 1H), 2,9-3,1 (m, 2H), 3,15-3,25 (m, 1H), 3,3-3,6 (m, 6H), 3,95-4,05 (m, 1H), 5,25 (m, 1H), 6,95 (s, OH), 7,1-7,5 (m, 13H); MS [M-Br]<+>: 478; smp. 182°C.
Eksempel 5
3(R)-(2-Hydroksy-2,2-di-p-tolylacetoksy)-l-(3-fenoksypropyl)-l-azoniadi-cyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 500 mg, 54%.<1>H-NMR (DMSO-d6): 8 1,55-1,8 (m, 2H), 1,85-2,0 (m, 2H), 2,05-1,15 (m, 2H), 2,3 (s, 7H), 3,05-3,15 (m, 1H), 3,25-3,5 (m, 6H), 3,95 (m, 1H), 4,05 (t, 2H), 5,2 (m, 1H), 6,8 (s, OH), 6,95 (m, 3H), 7,1-7,2 (m, 4H), 7,2-7,35 (m, 6H); MS [M-Br]<+>:500; smp. 183°C.
Eksempel 6
3(R)-(2-Hydroksy-2,2-di-p-tolylacetoksy)-l-fenetyl-l-azoniabicyklo-[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 650 mg, 74%.<1>H-NMR (DMSO-d6): 8 1,55-1,8 (m, 2H), 1,85-2,05 (m, 2H), 2,25 (s, 7H), 2,9-3,05 (m, 2H), 3,1-3,25 (m, 1H), 3,3-3,55 (m, 6H), 3,95 (m, 1H), 5,25 (m, 1H), 6,8 (s, OH), 7,1-7,2 (m, 4H), 7,2-7,35 (m, 9H); MS [M-Br]<+>:470; smp. 144°C.
Eksempel 7
3(R)-(2,2-Difenylpropionyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo-[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte e og a. Utbyttet i siste trinn var 250 mg, 61%.<1>H-NMR (CDCI3): 8 1,47-1,60 (m, 1H), 1,8-2,0 (m, 1H), 2,0 (s, 3H), 2,0-2,15 (m, 4H), 2,39 (s, 1H), 2,6 (m, 1H), 2,92 (d, 1H), 3,6 (m, 1H), 3,7-3,9 (m, 4H), 4,0 (m, 2H) , 4,3 (m, 1H), 5,25 (m, 1H), 6,85 (m, 2H), 7,0 (m, 1H), 7,3 (m, 12H); MS [M-Br]<+>: 470; smp. 186 °C.
Eksempel 8
3(R)-(2-Hydroksy-2-fenyl-2-tien-2-ylacetoksy)-l-(3-fenoksy-
propyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert som en blanding av diastereomerer i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 520 mg, 62%.<1>H-NMR (DMSO-d6): 8 1,5-1,95 (m, 4H), 2,1 (m, 2H), 2,3 (m, 1H), 3,1 (m, 1H), 3,3-3,5(m, 6H), 3,9 (m, 1H), 4,05 (t, 2H), 5,2 (m, 1H), 7,0 (m, 4H), 7,15 (m, 2H), 7,35 (m, 5H), 7,5 (m, 3H); MS [M-Br]<+>: 478; smp. 220°C.
Eksempel 9
3(R)-[2(R)-(2-Hydroksy-2-fenyl-2-tien-2-ylacetoksy)]-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte f og b fra intermediat I-4f, diastereomer 1. Utbyttet i siste trinn var 10 mg, 23%.<1>H-NMR (DMSO-d6): 8 1.5- 1,6 (m, 1H), 1,65-1,75 (m, 1H), 1,8-2,0 (m, 2H), 2,05-2,1 (m, 2H), 2,3 (m, 1H), 3,05-3,2 (m, 1H), 3,25-3,55 (m, 6H), 3,85-3,95 (m, 1H), 4,0 (t, 2H), 5,2 (m, 1H), 6,95 (m,3H), 7,03 (m, 1H), 7,15 (dd, 1H), 7,2 (s, OH), 7,3-7,5 (m, 5H), 7,45-7,55 (m, 3H); MS [M-CF3COO]<+>: 478.
Eksempel 10
3(R)-[2(S)-(2-Hydroksy-2-fenyl-2-tien-2-ylacetoksy)]-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte f og b fra intermediat I-4f, diastereomer 2. Utbyttet i siste trinn var 3 mg, 11%.<1>H-NMR (DMSO-d6): 8 1.6- 1,75 (m, 2H), 1,8-2,0 (m, 4H), 2,25 (m, 1H), 2,8 (t, 2H), 2,95-3,1 (m, 1H), 3,15-3,5 (m, 6H), 3,8-3,95 (m, 1H), 5,2 (m, 1H), 6,92 (m, 1H), 6,96-7,03 (m, 2H), 7,1 (dd, 1H), 7,18 (s, OH), 7,3-7,4 (m, 4H), 7,43-7,5 (m, 2H), 7,51 (dd, 1H); MS [M-CF3COO] + : 478.
Eksempel 11
3(R)-[2(R)-(2-Hydroksy-2-fenyl-2-tien-2-ylacetoksy)]-l-(3-fenylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte f og b fra intermediat I-4f, diastereomer 1. Utbyttet i siste trinn var 9 mg, 22%.<1>H-NMR (DMSO-d6): 8 1,45-1,55 (m, 1H), 1,65-1,75 (m, 1H), 1,85-2,05 (m, 2H), 2,3 (m, 1H), 2,9-3,l(m, 2H), 3,1-3,25 (m, 1H), 3,25-3,55 (m, 6H), 3,9-4,0 (m, 1H), 5,25 (m, 1H), 7,05 (m, 1H), 7,15 (m, 1H), 7,2 (m, 1H), 7,25-7,4 (m, 8H), 7,45 (m, 2H, 7,55 (m, 1H); MS [M-CF3COO] + : 448.
Eksempel 12
3(R)-[2(R)-(2-Hydroksy-2-fenyl-2-tien-2-ylacetoksy)]-l-(3-fenylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte f og b fra intermediat I-4f, diastereomer 1. Utbyttet i siste trinn var 11 mg, 26%.<1>H-NMR (DMSO-d6): 8 1,45-1,55 (m, 1H), 1,6-1,75 (m, 1H), 1,8-2,0 (m, 4H), 2,25 (m, 1H), 2,55 (t, 2H), 3,0-3,1 (m, 1H), 3,15-3,55 (m, 6H), 3,8-3,9 (m, 1H), 5,2 (m, 1H), 7,0 (m, 1H), 7,1 (m, 1H), 7,15-7,4 (m, 9H), 7,45 (m, 2H), 7,5 (m, 1H); MS [M-CF3COO] + : 462.
Eksempel 13
3(R)-[2(R)-(2-Hydroksy-2-fenyl-2-tien-2-ylacetoksy)]-l-(2-tien-2-yl-etyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte f og b fra intermediat I-4f, diastereomer 1. Utbyttet i siste trinn var 10 mg, 24%.<1>H-NMR (DMSO-d6): 8 1,45-1,55 (m, 1H), 1,65-1,75 (m, 1H), 1,8-2,0 (m, 2H), 2,3 (m, 1H), 3,1-3,6 (m, 9H), 3,9-4,0 (m, 1H), 5,25 (m, 1H), 7,0 (m, 3H), 7,15 (dd, 1H), 7,2 (s, OH), 7,3-7,4 (m, 3H), 7,45-7,55 (m, 4H); MS [M-CF3COO]<+>:454.
Eksempel 14
3(R)-[2(R)-(2-Hydroksy-2-fenyl-2-tien-2-ylacetoksy)]-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte f og b fra intermediat I-4f, diastereomer 1. Utbyttet i siste trinn var 8 mg, 19%.<1>H-NMR (DMSO-d6): 8 1,45-1,6 (m, 1H), 1,65-1,75 (m, 1H), 1,8-2,05 (m, 4H), 2,25 (m, 1H), 2,8 (t, 2H), 3,0-3,15 (m, 1H), 3,2-3,5 (m, 6H), 3,8-3,95 (m, 1H), 5,2 (m, 1H), 6,92 (m,lH), 6,96-7,03 (m,2H), 7,13 (dd, 1H), 7,2 (s, OH), 7,3-7,4 (m, 4H), 7,45-7,5 (m, 2H), 7,52 (dd, 1H); MS [M-CF3COO]<+>: 468.
Eksempel 15
3(R)-[2(S)-(2-Hydroksy-2-fenyl-2-tien-2-ylacetoksy)]-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte f og b fra intermediat I-4f, diastereomer 2. Utbyttet i siste trinn var 7 mg, 26%.<1>H-NMR (DMSO-d6): 8 1,6-1,75 (m, 2H), 1,8-2,0 (m, 4H), 2,25 (m, 1H), 2,8 (t, 2H), 2,95-3,1 (m, 1H), 3,15-3,5 (m, 6H), 3,8-3,95 (m, 1H), 5,2 (m, 1H), 6,92 (m,lH), 6,96-7,03 (m, 2H), 7,1 (dd, 1H), 7,18 (s, OH), 7,3-7,4 (m, 4H), 7,43-7,5 (m, 2H), 7,51 (dd, 1H); MS [M-CF3COO]<+>: 468.
Eksempel 16
3(R)-[2(R)-(2-Hydroksy-2-fenyl-2-tien-2-ylacetoksy)]-l-(2-fenoksyetyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte f og b fra intermediat I-4f, diastereomer 1. Utbyttet i siste trinn var 11 mg, 26%.<1>H-NMR (DMSO-d6): 8 1,5-1,6 (m, 1H), 1,65-1,75 (m, 1H), 1,8-2,0 (m, 2H), 2,25 (m, 1H), 3,15-3,6 (m, 5H), 3,7 (m, 2H), 4,0 (m, 2H), 4,4 (m, 2H), 5,25 (m, 1H), 6,95-7,03 (m, 4H), 7,12 (dd, 1H), 7,2 (s, OH), 7,3-7,4 (m, 5H), 7,4-7,5 (m, 3H); MS [M-CF3COO] + : 464.
Eksempel 17
3(R)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)-l-(3-fenylallyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert som en blanding av diastereomerer i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 240 mg, 77%.<1>H-NMR (DMSO-d6): 8 1,55-2,0 (m, 4H), 2,27 (m, 1H), 3,05-3,55 (m, 5H), 3,88-3,98 (m, 1H), 4,0-4,10 (m, 2H), 5,21 (m, 1H), 6,23-6,31 (doble dd, 1H), 6,36-6,48 (m, 2H), 6,83-6,90 (dd, 1H), 6,95 (d, OH), 7,26-7,66 (m, 11H); MS [M-Br]<+>: 444; smp. 99°C.
Eksempel 18
3(R)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)-l-(2-fenoksyetyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert som en blanding av diastereomerer i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 210 mg, 66%.<1>H-NMR (DMSO-d6): 8 1,50-2,05 (m, 4H), 2,27 (m, 1H), 3,20 (m, 1H), 3,37-3,65 (m, 4H), 3,65-3,75 (m, 2H), 4,04 (m, 1H), 4,40 (m, 2H), 5,21 (m, 1H), 6,23-6,32 (dobbel dd, 1H), 6,44 (m, 1H), 6,94-7,04 (m, 4H), 7,33-7,50 (m, 7H), 7,64 (m, 1H); MS [M-Br]<+>: 448; smp. 163°C.
Eksempel 19
3(R)-[2(<*>)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)]-l-(2-fenoksyetyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b fra intermediat I-la, diastereomer 1. Utbyttet i siste trinn var 11 mg, 23%.<1>H-NMR (DMSO-d6): 8 1,65-1,80 (m, 2H), 1,80-2,10 (m, 2H), 2,27 (m, 1H), 3,15-3,65 (m, 5H), 3,68 (m, 2H), 4,0 (m, 1H), 4,40 (t, 2H), 5,20 (m, 1H), 6,23 (d, 1H), 6,42 (m, 1H), 6,92-7,04 (m, 4H), 7,30-7,38 (m, 5H), 7,44-7,50 (m, 2H), 7,64 (m, 1H); MS [M-CF3COO] + : 448.
Eksempel 20
3(R)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen har blitt beskrevet i fremgangsmåte -a-.
Eksempel 21
3(R)-[2(<*>)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)]-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a fra intermediat I-la, diastereomer 1. Utbyttet i siste trinn var 1,15 g, 99%.<1>H-NMR (DMSO-d6): 8 1,60-2,20 (m, 6H), 2,25 (m, 1H), 3,10 (m, 1H), 3,20-3,60 (m, 6H), 3,95 (m, 1H), 4,05 (m, 2H), 5,20 (m, 1H), 6,25 (dd, 1H), 6,45 (m, 1H), 6,95 (m, 4H), 7,30-7,50 (m, 7H), 7,70 (m, 1H); MS [M-Br]<+>: 462; smp. 156°C.
Eksempel 22
3(R)-[2(<*>)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)]-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b fra intermediat I-la, diastereomer 2. Utbyttet i siste trinn var 10 mg, 20%.<1>H-NMR (DMSO-d6): 8 1,50-2,20 (m, 6H), 2,25 (m, 1H), 3,10 (m, 1H), 3,20-3,60 (m, 6H), 3,95 (m, 1H), 4,05 (m, 2H), 5,20 (m, 1H), 6,35 (dd, 1H), 6,45 (m, 1H), 6,95 (m, 4H), 7,30-7,50 (m, 7H), 7,70 (m, 1H); MS [M-CF3COO] + : 462.
Eksempel 23
3(R)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)-l-fenetyl-l- azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert som en blanding av diastereomerer i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 12 mg, 13%. ^-NMR (DMSO-d6): 8 1,5 (m, 1H), 1,7 (m, 1H), 1,9-2,05 (m, 2H), 2,3 (m, 1H), 2,95 (m, 2H), 3,15 (m, 1H), 3,25-3,55 (m, 6H), 3,95 (m, 1H), 5,25 (m, 1H), 6,3 (d, 1H), 6,45 (m, 1H), 6,95 (d, 1H), 7,25-7,45 (m, 8H), 7,5 (m, 2H), 7,7 (m, 1H); MS [M-CF3COO]<+>: 432.
Eksempel 24
3(R)-[2(<*>)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)]-l-fenetyl-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b fra intermediat I-la, diastereomer 1. Utbyttet i siste trinn var 16 mg, 40%.<1>H-NMR (DMSO-d6): 8 1,65-1,80 (m, 2H), 1,90-2,05 (m, 2H), 2,3 (m, 1H), 2,95 (m, 2H), 3,15 (m, 1H),
3,25-3,55 (m, 6H), 3,95 (m, 1H), 5,25 (m, 1H), 6,26 (dd, 1H), 6,46 (m, 1H), 6,95 (s, 1H, OH), 7,25-7,45 (m, 8H), 7,5 (m, 2H), 7,7 (m, 1H); MS [M-CF3COO]<+>: 432.
Eksempel 25
3(R)-[2(<*>)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)]-l-fenetyl-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b fra intermediat I-la, diastereomer 2. Utbyttet i siste trinn var 14 mg, 35%.<1>H-NMR (DMSO-d6): 8 1,50-1,80 (m, 2H), 1,90-2,05 (m, 2H), 2,3 (m, 1H), 2,95 (m, 2H), 3,15 (m, 1H), 3,25 - 3,55 (m, 6H), 3,95 (m, 1H), 5,25 (m, 1H), 6,32 (dd, 1H), 6,46 (m, 1H), 6,95 (s, 1H, OH), 7,25 - 7,45 (m, 8H), 7,5 (m, 2H), 7,7 (m, 1H); MS [M-CF3COO] + : 432.
Eksempel 26
3(R)-[2(<*>)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)]-l-(3-fenylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b fra intermediat I-la, diastereomer 1. Utbyttet i siste trinn var 10 mg, 21%.<1>H-NMR (DMSO-d6): 8 1,60-1,75 (m, 2H), 1,80-2,0 (m, 4H), 2,25 (m, 1H), 2,50-2,60 (m, 2H), 3,0 (m, 1H), 3,10-3,50 (m, 6H), 3,83 (m, 1H), 5,17 (m, 1H), 6,25 (d, 1H), 6,45 (m, 1H), 6,95 (s, 1H), 7,20-7,40 (m, 8H), 7,46-7,48 (m, 2H), 7,66 (m, 1H); MS [M-CF3COO] + : 446.
Eksempel 27
3(R)-[2(<*>)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)]-l-(2-tien-2-yl-etyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b fra intermediat I-la, diastereomer 1. Utbyttet i siste trinn var 9 mg, 19%.<1>H-NMR (DMSO-d6): 8 1,65-1,80 (m, 2H), 1,85-2,05 (m, 2H), 2,30 (m, 1H), 3,10-3,40 (m, 3H), 3,40-3,60 (m, 6H), 3,95 (m, 1H), 5,24 (m, 1H), 6,27 (d, 1H), 6,47 (m, 1H), 6,96 (s, 1H), 7,0-7,04 (m 2H), 7,36-7,48 (m, 4H), 7,49-7,54 (m, 2H), 7,70 (m, 1H); MS [M-CF3COO] + : 438.
Eksempel 28
3(R)-[2(<*>)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)]-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b fra intermediat I-la, diastereomer 1. Utbyttet i siste trinn var 9 mg, 19%.<1>H-NMR (DMSO-d6): 8 1,60-1,75 (m, 2H), 1,80-2,05 (m, 4H), 2,26 (m, 1H), 2,81 (t, 2H), 3,02 (m, 1H), 3,10-3,45 (m, 6H), 3,85 (m, 1H), 5,18 (m, 1H), 6,25 (d, 1H), 6,45 (m, 1H), 6,90-7,0 (m, 3H), 7,32-7,42 (m, 4H), 7,45-7,51 (m, 2H), 7,66 (m, 1H); MS [M-CF3COO] + : 452.
Eksempel 29
3(R)-(2-Furan-2-yl-2-hydroksy-2-tien-2-ylacetoksy)-l-fenetyl-l- azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert som en blanding av diastereomerer i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 18 mg, 20%.<1>H-NMR (DMSO-d6): 8 1,65-2,05 (m, 4H), 2,3 (m, 1H), 3,0 (m, 2H), 3,15-3,6 (m, 7H), 3,95 (m, 1H), 5,25 (m, 1H), 6,35 (dd, 1H), 6,45 (m, 1H), 7,05 (m, 1H), 7,2 (dd, 1H), 7,25-7,5 (m, 6H), 7,55 (m, 1H), 7,65 (m, 1H); MS [M-CF3COO]<+>: 438.
Eksempel 30
3(R)-(2-Furan-2-yl-2-hydroksy-2-tien-2-ylacetoksy)-l-(2-fenoksyetyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert som en blanding av diastereomerer i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 22 mg, 23%.<1>H-NMR (DMSO-d6): 8 2,65-2,05 (m, 4H), 2,3 (m, 1H), 3,15-3,65 (m, 7H), 4,05 (m, 1H), 4,4 (m, 2H), 5,15 (m, 1H), 6,35 (dd, 1H), 6,45 (m, 1H), 6,95-7,05 (m, 4H), 7,15 (d, 1H), 7,3-7,4 (m, 3H), 7,5 (dd, 1H), 7,65 (d, 1H); MS [M-CF3COO]<+>: 454.
Eksempel 31
3(R)-(2-Furan-2-yl-2-hydroksy-2-tien-2-ylacetoksy)-l-(4-okso-4- fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert som en blanding av diastereomerer i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 15,4 mg, 15%. ^-NMR (DMSO- d6): 8 1,65-2,1 (m, 6H), 7,05-7,55 (m, 9H), 3,95 (m, 1H), 5,1 (m, 1H), 6,35 (dd, 1H), 6,5 (m, 1H), 7,05 (m, 1H), 7,15 (m, 1H), 7,3 (d, 1H), 7,55 (m, 3H), 7,7 (dd, 2H), 8,0 (d, 2H); MS [M-CF3COO]<+>: 480.
Eksempel 32
l-(3-Fenoksypropyl)-3(R)-(2-furan-2-yl-2-hydroksy-2-tien-2-yl- acetok-sy)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert som en blanding av diastereomerer i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 100 mg, 41%.<1>H-NMR (DMSO-d6): 8 1,65-2,05 (m, 4H), 2,1-2,0 (m, 2H), 2,3 (m, 1H), 3,15 (m, 1H), 3,25-3,6 (6H), 3,9-4,1 (m, 3H), 5,1 (m, 1H), 6,35 (d, 1H), 6,45 (s, 1H), 6,95 (m, 3H), 7,05 (m, 1H), 7,2 (d, 1H), 7,3 (m, 3H), 7,55 (d, 1H), 7,7 (s, 1H); MS [M-Br]<+>: 520; smp. 173°C.
Eksempel 33
l-(3-fenoksypropyl)-3(R)-(2,2-difuran-2-yl-2-hydroksyacetoksy)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte fog a. Utbyttet i siste trinn var 200 mg, 60%.<1>H-NMR (DMSO-d6): 8 1,6-2,20 (m, 6H), 2,3 (m, 1H), 2,95-3,65 (m, 7H), 3,80-4,10 (m, 3H), 5,2 (m, 1H), 6,3-6,6 (m, 4H), 6,8-7,0 (m, 3H), 7,1 (s, OH), 7,3 (m, 2H), 7,7 (m, 2H); MS [M-Br] + : 452.
Eksempel 34
3(R)-(2,2-Ditien-2-ylacetoksy)-l-(2-fenoksyetyl)-l-azoniabicyklo-[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 240 mg, 60%.<1>H-NMR (DMSO-d6): 8 1,85-2,10 (m, 4H), 2,30 (s, 1H), 3,40 (m, 1H), 3,44-3,80 (m, 6H), 4,10 (m, 1H), 4,45 (m, 2H), 5,20 (m, 1H), 5,90 (s, 1H), 6,95-7,05 (m, 5H), 7,05-7,15 (m, 2H), 7,30-7,40 (m, 2H), 7,45 (m, 2H); MS [M-Br]<+>: 454; smp. 98°C.
Eksempel 35
3(R)-(2,2-Ditien-2-ylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo-[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 280 mg, 83%.<1>H-NMR (DMSO-d6): 8 1,80-2,06 (m, 4H), 2,06-2,20 (m, 2H), 2,20-2,30 (m, 1H), 3,20-3,65 (m,7H), 3,90-4,10 (m, 3H), 5,20 (m, 1H), 5,90
(s, 1H), 6,95-7,05 (m, 5H), 7,05-7,20 (m,2H), 7,30-7,35 (m, 2H), 7,50 (m, 2H); MS [M-Br]<+>: 468; smp. 148°C.
Eksempel 36
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-fenetyl-l-azoniabicyklo-[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 180 mg, 59%.<1>H-NMR (DMSO-d6): 8 1,65-2,0 (4H, m), 2,35 (m, 1H), 3,0 (m, 2H), 3,2-3,6 (m, 7H), 3,95 (m, 1H), 5,25 (m, 1H), 7,0 (m, 2H), 7,2 (m, 2H), 7,35 (m, 5H), 7,55 (m, 3H); MS [M-Br]<+>: 454; smp. 216°C.
Eksempel 37
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-fenylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 450 mg, 58%.<1>H-NMR (CDCI3): 8 1,8-2,1 (m, 6H), 2,4 (m, 1H), 2,6 (m, 2H), 3,4-3,8 (m, 7H), 4,2 (m, 1H), 5,25 (m, 1H), 6,1 (bs, OH), 6,9 (m, 2H), 7,1-7,3 (m, 9H); MS [M-Br]<+>: 468; smp. 64°C.
Eksempel 38
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-fenylallyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 260 mg, 34%.<1>H-NMR (CDCI3): 8 1,8-2,05 (m, 4H), 2,4 (m, 1H), 3,55-3,95 (m, 5H), 4,15-4,5 (m, 3H), 5,25 (m, 1H), 5,9 (s, OH), 6,15 (m, 1H), 6,85 (t, 1H), 6,9-7,05 (m, 3H), 7,15 (m, 1H), 7,2-7,45 (m, 7 H); MS [M-Br]<+>: 466; smp. 124°C.
Eksempel 39
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(4-fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 320 mg, 40%.<1>H-NMR (CDCI3): 8 1,6-2,0 (m, 8H), 2,4 (m, 1H), 2,6 (m, 2H), 3,4-3,8 (m, 7H), 4,2 (m, 1H), 5,25 (m, 1H), 6,05 (bs, OH), 6,95 (m, 2H), 7,1-7,3 (m, 9H); MS [M-Br]<+>: 482; smp. 64°C.
Eksempel 40
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(4-okso-4-fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 16 mg, 15%.<1>H-NMR (DMSO-d6): 8 1,7-2,0 (m, 6H), 2,15 (m, 1H), 3,1 (t, 2H), 3,15-3,55 (m, 7H), 3,95(m, 1H), 5,25 (m, 1H), 7,0 (d, 2H), 7,15 (d, 2H), 7,55 (m, 5H), 7,65 (t, 1H), 8,0 (d, 2H); MS [M-CF3COO]<+>: 496.
Eksempel 41
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-fenylaminopropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 14 mg, 14%.<1>H-NMR (DMSO-d6): 8 1,7-2,0 (m, 5H), 2,3 (m, 1H), 3,0-3,5 (m, 9H), 3,9 (m, 1H), 5,25 (m, 1H), 5,65 (t, 1H), 6,55 (m, 3H), 7,0 (d, 2H), 7,1 (t, 2H), 7,15 (m, 2H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 483.
Eksempel 42
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(metylfenylamino)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 20 mg, 19%.<1>H-NMR (DMSO-d6): 8 1,65-2,0 (m, 6H), 2,9 (s, 3H), 3,1 (m, 1H), 3,2-3,45 (m, 8H), 3,95 (m, 1H), 5,2 (m, 1H), 6,65 (t, 1H), 6,75 (d, 2H), 7,0 (m, 2H), 7, 2 (m, 4H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 497.
Eksempel 43
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-fenylsulfanylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 800 mg, 83%.<1>H-NMR (DMSO-d6): 8 1,6-1,9 (m, 6H), 2,3 (m, 1H), 2,95 (t, 2H), 3,05 (m, 1H), 3,2-3,5 (m, 6H), 3,9 (m, 1H), 5,2 (m, 1H), 7,0 (m, 2H), 7,15 (m, 2H), 7,2 (m, 1H), 7,35 (m, 4H), 7,5 (m, 2H); MS [M-Br]<+>: 500.
Eksempel 44
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-fenoksypropyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 490 mg, 90%.<1>H-NMR (DMSO-d6): 8 1,7 (m, 2H), 1,95 (m, 2H), 2,1 (m, 2H), 2,3 (m, 1H), 3,2 (m, 1H), 3,45 (m, 6H), 4,0 (m, 3H), 5,15 (m, 1H), 6,9 (m, 3H), 7,0 (m, 2H), 7,2 (m,2H), 7,3 (t, 2H), 7,5 (m, 3H); MS [M-Br]<+>: 484; smp. 227°C.
Eksempel 45
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-o-tolyloksypro-
pyl)-l- azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b Utbyttet i siste trinn var 19 mg, 18%.<1>H-NMR (DMSO-d6): 5 1,7-2,0 (m, 4H), 2,1-2,2 (m, 5H), 2,3 (m, 1H), 3,15 - 3,5 (m, 7H), 3,9-4,05 (m, 3H), 5,05 (m, 1H), 6,85 (t, 1H), 6,9 (d, 1H), 7,0 (m, 2H), 7,15 (m, 4H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 498.
Eksempel 46
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(2,4,6-trimetylfenoksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 22 mg, 20%.<1>H-NMR (DMSO-d6): 5 l,7(m, 2H), 1,95 (m, 2H), 2,1 (m, 2H), 2,2 (s, 9H), 2,35 (m,lH), 3,2-3,5 (m, 7H), 3,7 (t,2H), 3,95 (m, 1H), 5,25 (m, 1H), 6,8 (s, 2H), 7,0 (m, 2H), 7,2 (m, 2H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 526.
Eksempel 47 l-[3-(2-tert-Butyl-6-metylfenoksy)propyl]-3(R)-(2-hydroksy-2,2- di-tien-2-ylacetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 18 mg, 16%.<1>H-NMR (DMSO-d6): 5 1,3 (s, 9H), 2,7 (m, 2H), 2,9 (m, 2H), 2.1 (m, 2H), 2,2 (s, 3H), 2,3 (m, 1H), 3,2-3,5 (m, 7H), 3,8 (t, 2H), 3,95 (m, 1H), 5.2 (m, 1H), 6,9-7,15 (m, 7H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 554.
Eksempel 48
l-[3-(Bifenyl-4-yloksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2-yl-acetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 22 mg, 19%.<1>H-NMR (DMSO-d6): 5 1,7 (m, 2H), 1,9 (m, 2H), 2,15 (m, 2H), 2,3(m, 1H), 3,2-3,5(m, 7H), 3,95(m, 1H), 4,1 (t, 2H), 5,25 (m, 1H), 7,0 (m, 4H), 7,2(m, 2H), 7,3(t, 1H), 7,45 (t, 2H), 7,5 (m, 3H), 7,6 (m, 4H); MS [M-CF3COO]<+>: 560.
Eksempel 49
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(5,6,7,8-tetrahydro-naftalen-2-yloksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 23 mg, 21%.<1>H-NMR (DMSO-d6): 5 1,7 (m, 6H), 1,9-2,1 (m, 4H), 2,3 (m, 1H), 2,65 (m, 4H), 3,15-3,5 (m, 7H), 3,95 (m, 2H), 5,25 (m, 1H), 6,65 (m, 2H), 6,95 (d, 1H), 7,0 (m, 2H), 7,2 (m, 2H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 538.
Eksempel 50
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(naftalen-2-yloksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 17 mg, 15%.<1>H-NMR (DMSO-d6): 5 1,7-2,0 (m, 4H), 2,1 (m, 1H), 2,35 (m, 1H), 3,15-3,35 (m, 7H), 3,95 (m, 1H), 4,17 (t, 2H), 5,25 (m, 1H), 7,0 (m, 2H), 7,15 (m, 3H), 7,35 (m, 2H), 7,5 (m, 4H), 7,85 (m, 3H); MS [M-CF3COO]<+>: 534.
Eksempel 51
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(naftalen-l-yloksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen har blitt beskrevet i fremgangsmåte -b-.
Eksempel 52
l-[3-(2-Klorfenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2-ylacetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 20 mg, 18%.<1>H-NMR (DMSO-d6): 5 1,65-2,0 (m, 6H), 2,35 (m, 1H), 3,2 (m, 1H), 3,3-3,55 (m, 6H), 3,95 (m, 1H), 4,15 (t, 2H), 5,25 (m, 2H), 7,0 (m, 3H), 7,2 (m, 3H), 7,35 (t, 1H), 7,45 (d, 1H), 7,55 (m, 3H); MS [M-CF3COO]<+>: 519.
Eksempel 53
l-[3-(4-Fluorfenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2-yla-cetoksy)-l-azoniabicyklo[2.2.2]oktan; klorid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 180 mg, 59%.<1>H-NMR (DMSO-d6): 8 1,65-2,15 (m, 6H), 2,25 (m, 1H), 3,2 (m, 1H), 3,25-3,55 (m, 6H), 3,95 (m, 2H), 4,0 (t, 2H), 5,25 (m, 1H), 7,0 (m, 4H), 7,15 (m, 4H), 7,55 (m, 3H); MS [M-CI]<+>: 502; smp. 160°C.
Eksempel 54
l-[3-(2,4-Difluorfenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2-yl-acetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 14 mg, 13%.<1>H-NMR (DMSO-d6): 5 1,65-2,0 (m, 4H), 2,15 (m, 2H), 2,35 (m, 1H), 3,2 (m, 1H), 3,25-3,35 (m, 6H), 3,95 (m, 1H), 4,1 (t, 2H), 5,15 (m, 1H), 7,05 (m, 3H), 7,2 (d, 2H), 7,25-7,35 (m, 2H), 7,55 (m, 3H); MS [M-CF3COO]<+>: 520.
Eksempel 55
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(3-trifluormetylfenoksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 19 mg, 17%.<1>H-NMR (DMSO-d6): 5 1,65-2,1 (m, 6H), 2,35 (m, 1H), 3,2 (m, 1H), 3,3-3,55 (m, 6H), 3,95 (m, 1H), 4,15 (t, 2H), 5,25 (m, 1H), 7,0 (m, 2H), 7,2 (m, 2H), 7,25-7,35 (m, 3H), 7,5-7,6 (m, 4H); MS [M-CF3COO]<+>: 552.
Eksempel 56
l-[3-(3-Cyanofenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2-yl-acetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 18 mg, 17%.<1>H-NMR (DMSO-d6): 5 1,65-2,1 (m, 6H), 2,35 (m, 1H), 3,2 (m, 1H), 3,3-3,55 (m, 6H), 3,95 (m, 1H), 4,15 (t, 2H), 5,25 (m, 1H), 7,0 (m, 2H), 7, 18 (m, 2H), 7,3 (d, 1H), 7,45 (m, 2H), 7,55 (m, 4H); MS [M-CF3COO]<+>: 509.
Eksempel 57
l-[3-(4-Cyanofenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2-yla-cetoksy)- l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 180 mg, 53%.<1>H-NMR (DMSO-d6): 8 1,65-2,2 (m, 6H), 2,3 (m, 1H), 3,2 (m, 1H), 3,3-3,55 (m, 6H), 3,95 (m, 1H), 4,15 (t, 2H), 5,25 (m, 1H), 7,0 (m, 2H), 7,1 (d, 2H), 7,15 (m, 2H), 7,5 (m, 2H), 7,8 (d, 2H); MS [M-Br]<+>: 509; smp. 158°C.
Eksempel 58
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(3-metoksyfenoksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 19 mg, 18%.<1>H-NMR (DMSO-d6): 5 1,65-2,15 (m, 6H), 2,15 (m, 1H), 3,2
(m, 1H), 3,3-3,5 (m, 6H), 3,75 (s, 3H), 3,95 (m, 1H), 4,0 (t, 2H), 5,25 (m, 1H), 6,55 (m, 3H), 7,0 (m, 2H), 7,2 (m, 3H), 7,55 (m, 3H); MS [M-CF3COO]<+>: 514.
Eksempel 59
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(4-metoksyfenoksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 14 mg, 13%.<1>H-NMR (DMSO-d6): 5 1,65-2,15 (m, 6H), 2,35 (m, 1H), 3,2 (m, 1H), 3,3-3,55 (m, 6H), 3,7 (s, 3H), 3,9 -4,0 (m, 3H), 5,25 (m, 1H), 6,9 (s, 4H), 7,0 (m, 2H), 7,15 (m, 2H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 514.
Eksempel 60 l-[3-(Benzo[l/3]dioksol-5-yloksy)propyl]-3(R)-(2-hydroksy-2/2-ditien-2-y lacetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 19 mg, 17%.<1>H-NMR (DMSO-d6): 5 1,65-2,15 (m, 7H), 2,3 (m, 1H), 3,15 (m, 1H), 3,25-3,5 (m, 6H), 3,9-4,0 (m, 3H), 5,25 (m, 1H), 5,95 (s, 2H), 6,4 (d, 1H), 6,65 (s, 1H), 6,85 (d, 1H), 7,0 (m, 2H), 7,2 (m, 2H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 528.
Eksempel 61
l-[3-(2-Karbamoylfenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2-yl-acetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 18 mg, 16%/H-NMR (DMSO-d6): 8 1,65-2,0 (m, 4H), 2,2 (m, 2H), 2,3 (m, 1H), 3,15 (m, 1H), 3,25-3,55 (m, 6H), 3,95 (m, 1H), 4,15 (t, 2H), 5,25 (m, 1H), 7,0-7,2 (m, 6H), 7,4-7,6 (m, 6H), 7,7 (d, 1H); MS [M-CF3COO]<+>: 527.
Eksempel 62
l-[3-(3-Dimetylaminofenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2-yl-acetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 19 mg, 17%.<1>H-NMR (DMSO-d6): 5 1,65-2,15 (m, 6H), 2,3 (m, 1H), 2,85 (s, 6H), 3,1-3,5 (m, 7H), 3,85-4,0 (m, 3H), 5,25 (m, 1H), 6,2 (m, 1H), 6,25 (d, 1H), 6,35 (d, 1H), 7,0 (m, 2H), 7,1 (t, 1H), 7,2 (m, 2H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 527.
Eksempel 63
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(4-nitro-fenoksy)propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 22 mg, 20%.<1>H-NMR (DMSO-d6): 5 1,65-2,0 (m, 4H), 2,2 (m, 2H), 2,3 (m, 1H), 3,2 (m, 1H), 3,3-3,5 (m, 6H), 3,95 (m, 1H), 4,2 (t, 2H), 5,25 (m, 1H), 7,0 (m, 2H), 7,15 (m, 4H), 7,5 (m, 3H), 8,15 (d, 2H); MS [M-CF3COO]<+>: 529.
Eksempel 64
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(3-nitro-fenoksy)propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 18 mg, 16%.<1>H-NMR (DMSO-d6): 5 1,65-2,2 (m, 6H), 2,3 (m, 1H), 3,15-3,55 (m, 7H), 3,95 (m, 1H), 4,2 (t, 2H), 5,25 (m, 1H), 7,0 (m, 2H), 7,2 (m, 2H), 7,45 (dd, 1H), 7,55 (m, 3H), 7,6 (t, 1H), 7,75 (s, 1H), 7,85 (d, 1H); MS [M-CF3COO]<+>: 529.
Eksempel 65
l-[3-(4-Acetylaminofenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2- yla-cetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 19 mg, 17%.<1>H-NMR (DMSO-d6): 5 1,65-2,15 (m, 6H), 2,0 (s, 3H), 2,3 (m, 1H), 3,2 (m, 1H), 3,3-3,55 (m, 6H), 3,9-4,0 (m, 3H), 5,25 (m, 1H), 6,85 (d, 2H), 7,0 (m, 2H), 7,2 (m, 2H), 7,5 (m, 5H), 9,8 (s, 1H); MS [M-CF3COO]<+>: 541.
Eksempel 66
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(3-metoksykarbonyl-fenoksy)propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 18 mg, 16%.<1>H-NMR (DMSO-d6): 5 1,65-2,2 (m, 6H), 2,3 (m, 1H), 3,2 (m, 1H), 3,3-3,5 (m, 6H), 3,85 (s, 3H), 3,95 (m, 1H), 4,1 (t, 2H), 5,25 (m, 1H), 7,0 (m, 2H), 7,15 (m, 2H), 7,25 (dd, 1H), 7,45-7,6 (m, 6H); MS [M-CF3COO]<+>: 542.
Eksempel 67
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-{3-[4-(3-hydroksypropyl)-fenoksy]propyl}-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste
trinn var 14 mg, 13%.<1>H-NMR (DMS0-d6): 5 1,6-2,15 (m, 8H), 2,3 (m, 1H), 2,55 (t, 2H), 3,2 (m, 1H), 3,25-3,55 (m, 9H), 3,85-4,0 (m, 3H), 4,45 (t, OH), 5,25 (m, 1H), 7,85 (d, 2H), 7,0 (m, 2H), 7,1 (d, 2H), 7,15 (m, 2H), 7,5 (m, 2H); MS [M-CF3COO]<+>: 542.
Eksempel 68
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(2-hydroksymetyl-fenoksy)propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 16 mg, 15%.<1>H-NMR (DMSO-d6): 5 1,7-2,2 (m, 6H), 2,35 (m, 1H), 3,1-3,5 (m, 7H), 3,9-4,05 (m, 3H), 4,5 (m, 2H), 5,0 (t, OH), 5,15 (m, 1H), 6,9-7,05 (m, 4H), 7,2 (m, 2H), 7,4 (d, 1H), 7,5 (m, 3H); MS [M-CF3COO] + : 514.
Eksempel 69
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(3-hydroksymetyl-fenoksy)propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 16 mg, 15%.<1>H-NMR (DMSO-d6): 5 1,7-2,2 (m, 6H), 2,35 (m, 1H), 3,15-3,5 (m, 7H), 3,9 (m, 1H), 4,05 (t, 2H), 4,45 (d, 2H), 5, 25 (m, 2H), 6,8 (d, 1H), 6,9 (m, 2H), 7,2 (m, 2H), 7,25 (t, 1H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 514.
Eksempel 70
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(4-hydroksymetyl-fenoksy)propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 17 mg, 16%.<1>H-NMR (DMSO-d6): 5 1,65-2,2 (m, 6H), 2,3 (m, 1H), 3,15-3,55 (m, 7H), 3,9-4,05 (m, 3H), 4,4 (d, 2H), 5,1 (t, OH), 5,25 (t, 1H), 6,9 (d, 2H), 7,0 (m, 2H), 7,2 (m, 2H), 7,25 (d, 2H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 514.
Eksempel 71
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(2-hydroksyfenoksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 24 mg, 19%.<1>H-NMR (DMSO-d6): 5 1,65-2,15 (m, 6H), 2,35 (m, 1H), 3,2 (m, 1H), 3,25-3,55 (m, 6H), 3,95 (m, 1H), 4,0 (t, 2H), 5,25 (m, 1H), 6,7-6,85 (m, 3H), 6,95 (d, 1H), 7,0 (m, 2H), 7,2 (m, 2H), 7,5 (m, 3H), 8,85 (s, OH); MS [M-CF3COO]<+>: 500.
Eksempel 72
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(4-hydroksyfenoksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 16 mg, 15%.<1>H-NMR (DMSO-d6): 5 1,65-2,1 (m, 6H), 2,3 (m, 1H), 3,2 (m, 1H), 3,25-3,5 (m, 6H), 3,95 (m, 3H), 5,25 (m, 1H), 6,7 (d, 2H), 6,75 (d, 2H), 7,0 (m, 2H), 7,2 (m, 2H), 7,5 (t, 3H), 9,0 (s, OH); MS [M-CF3COO]<+>: 500.
Eksempel 73
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(3-hydroksyfenoksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 16 mg, 15%.<1>H-NMR (DMSO-d6): 5 1,65-2,15 (m, 6H), 2,3 (m, 1H), 3,2 (m, 1H), 3,3-3,55 (m, 6H), 3,9-4,0 (m, 3H), 5,25 (m, 1H), 6,9-6,0 (m, 3H), 7,0-7,1 (m, 3H), 7,2 (m, 2H), 7,5 (m, 3H), 9,45 (s, OH); MS [M-CF3COO] + : 500.
Eksempel 74
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-pyrrol-l-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 21 mg, 22%.<1>H-NMR (DMSO-d6): 5 1,65-1,8 (m, 2H), 1,8-2,0 (m, 2H), 2,0-2,15 (m, 2H), 2,3 (m, 1H), 3,05-3,2 (m, 3H), 3,2-3,5 (m, 4H), 3,8-3,95 (m, 3H), 5,2 (m, 1H), 6,05 (t, 2H), 6,75 (t, 2H), 7,0 (t, 2H), 7,15 (d, 2H), 7,55 (m, 3H);MS [M-CF3COO]<+>: 457.
Eksempel 75
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(4-okso-4-tien-2-yl-butyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 18 mg, 17%.<1>H-NMR (DMSO-d6): 5 1,7-1,85 (m, 2H), 1,9-2,1 (m, 4H), 2,3 (m, 1H), 3,1 (t, 2H), 3,15-3,55 (m, 7H), 3,95 (m, 1H), 5,25 (m, 1H), 7,0 (t, 2H), 7,4 (d, 2H), 7,25 (t, 1H), 7,55 (m, 3H), 7,95 (d, 1H), 8,05 (d, 1H); MS [M-CF3COO]<+>: 502.
Eksempel 76
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(l-metyl-[lH]-imidazol-2
-ylsulfanyl)propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste
trinn var 26 mg, 25%.<1>H-NMR (DMS0-d6): 8 1,7 (m, 2H), 1,85-2,05 (m, 4H), 2,3 (m, 1H), 3,25-3,5 (m, 7H), 3,6 (s, 3H), 3,9 (m, 1H), 4,2 (t, 2H), 5,2 (m, 1H), 7,0 (m, 3H), 7,15 (m, 2H), 7,3 (m, 1H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 504.
Eksempel 77
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(2-tien-2-yletyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 430 mg, 54%.<1>H-NMR (DMSO-d6): 8 1,6-1,8 (m, 2H), 2,3 (m, 1H), 3,15-3,3 (m, 4H), 3,35-3,55(m, 5H), 3,95 (m, 1H), 5,25 (m, 1H), 7,0 (m, 4H), 7,15 (m, 2H), 7,4-7,5 (m, 4H); MS [M-Br]<+>: 460; smp. 206°C.
Eksempel 78
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 600 mg, 77%.<1>H-NMR (DMSO-d6): 8 1,6-1,8 (m, 2H), 1,85-2,1 (m, 4H), 2,3 (m, 1H), 2,8 (t, 2H), 3,1-3,5 (m, 7H), 3,9 (m, 1H), 5,2 (m, 1H), 6,9-7,05 (m, 4H), 7,15 (m, 2H), 7,4 (d, 1H), 7,5 (m, 3H); MS [M-Br]<+>: 474; smp. 138°C.
Eksempel 79
l-[3-(Benzotiazol-2-yloksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2- yla-cetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 23 mg, 21%.<1>H-NMR (DMSO-d6): 8 1,65-2,1 (m, 6H), 2,3 (m, 1H), 3,15 (m, 1H), 3,25-3,5 (m, 6H), 3,85 (m, 1H), 4,0 (t, 2H), 5,2 (m, 1H), 7,0 (t, 2H), 7,15 (m, 2H), 7,25 (m, 1H), 7,45 (m, 5H), 7,7 (d, 1H); MS [M-CF3COO]<+>: 541.
Eksempel 80
l-(3-Benzyloksypropyl)-3(R)-(2-hydroksy-2,2-ditien-2-ylace-
toksy)-l- azoniabicyklo[2.2.2] oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 16 mg, 15%.<1>H-NMR (DMSO-d6): 8 1,65 (m, 2H), 1,9 (m, 4H), 2,3 (m, 1H), 3,1-3,4 (m, 7H), 3,5 (t, 2H), 3,9 (m, 1H), 3,9 (s, 2H), 5,2 (m, 1H), 7,0 (m, 2H), 7,15 (m, 2H), 7,35 (m, 5H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 498.
Eksempel 81
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[6-(4-fenyl-butoksy)heksyl]-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 560 mg, 60%.<1>H-NMR (CDCI3): 8 1,2-1,75 (m, 16H), 1,8-2,1 (m, 4H), 2,4 (m, 1H), 2,6 (t, 2H), 3,3-3,75 (m, 11H), 4,2 (m, 1H), 5,3 (m, 1H), 6,0 (bs, OH), 6,95 (m, 2H), 7,15-7,3 (m, 9H); MS [M-Br]<+>: 582.
Eksempel 82
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(4-fenoksybutyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 240 mg, 30%.<1>H-NMR (DMSO-d6/CDCI3): 8 1,8-1,95 (m, 6H), 2,1 (m, 2H), 2,45 (m, 1H), 3,18 (m, 1H), 3,5-3,8 (m, 6H), 4,0 (t, 2H), 4,15 (m, 1H), 5,15 (m, 1H), 6,7 (s, OH), 6,9 (m, 5H), 7,15 (d, 1H), 7,25 (m, 5H); MS [M-Br]<+>: 498; smp. 161°C.
Eksempel 83
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(2-fenoksyetyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 380 mg, 50%.<1>H-NMR (DMSO-d6): 8 1,85 (m, 2H), 2,05 (m, 2H), 2,4 (m, 1H), 3,6-4,1 (m, 7H), 4,35 (m, 3H), 5,25 (m, 1H), 6,0 (bs, OH), 6,9 (m, 4H), 7,0 (t, 1H), 7,1 (dd, 2H), 7,2 (dd, 2H), 7,3 (t, 2H); MS [M-Br]<+>: 470; smp. 48°C.
Eksempel 84
l-(2-Benzyloksyetyl)-3(R)-(2-hydroksy-2,2-ditien-2-ylacetoksy)-l- azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 17 mg, 17%.<1>H-NMR (DMSO-d6): 8 1,65-2,0 (m, 4H), 2,3 (m, 1H), 3,2-3,55 (m, 7H), 3,85 (m, 2H), 4,5 (s, 2H), 5,25 (m, 1H), 7,0 (t, 2H), 7,15 (t, 2H), 7,3-7,4 (m, 4H), 7,5 (m, 3H); MS [M-CF3COO]<+>: 484.
Eksempel 85
3(S)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-fenoksypropyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 600 mg, 54%.<1>H-NMR (DMSO-d6/CDCI3): 8 1,85-2,3 (m, 6H), 2,5 (m, 1H), 3,3 (m, 1H), 3,4 (d, 1H), 3,5-3,7 (m, 5H), 4,05 (t, 2H), 4,2 (m, 1H), 5,25 (m, 1H), 6,85 (d, 2H), 7,0 (m, 3H), 7,15 (m, 2H), 7,2 (d, 1H), 7,3 (m, 4H); MS [M-Br]<+>: 484; smp. 230°C.
Eksempel 86
4-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte fog a. Utbyttet i siste trinn var 290 mg, 60%.<1>H-NMR (DMSO-d6): 8 2,15 (m, 2H), 2,35 (m, 6H), 3,35 (m, 2H), 3,65 (m, 6H), 4,05 (t, 2H), 6,9-7,05 (m, 5H), 7,1 (m, 2H), 7,3 (m, 3H), 7,55 (m, 2H); MS [M-Br]<+>: 484; smp. 168°C.
Eksempel 87
4-(2-Hydroksy-2,2-ditien-2-yl-acetoksy)-l-fenetyl-l-azoniabicyklo-[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte fog a. Utbyttet i siste trinn var 260 mg, 57%.<1>H-NMR (DMSO-d6): 8 2,35 (m, 6H), 3,0 (m, 2H), 3,4 (m, 2H), 3,75 (m, 6H),7,0 (m, 2H), 7,3-7,5 (m, 6H), 7,55 (m, 2H); MS [M-Br]<+>: 454; smp. 195°C.
Eksempel 88
l-(3-fenoksypropyl)-3(R)-(2,2-ditien-2-ylpropionyloksy)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 390 mg, 92%.<1>H-NMR (DMSO-d6): 8 1,65-2,20 (m, 6H), 2,10 (s, 3H), 2,30 (bs, 1H), 3,10 (m, 1H), 3,30-3,60 (m, 6H), 3,95-4,10 (m, 3H), 5,20 (m, 1H), 6,90-7,05 (m, 5H), 7,05-7,10 (m, 2H), 7,25-7,35 (m, 2H), 7,50 (m, 2H); MS [M-Br]<+>: 482; smp. 170°C.
Eksempel 89
3(R)-(2-Hydroksy-2,2-ditien-3-ylacetoksy)-l-(3-fenoksypropyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 300 mg, 76%.<1>H-NMR (DMSO-d6): 8 1,6 (m, 1H), 1,75 (m, 1H), 1,8-2,0 (m, 2H), 2,0-2,2 (m, 2H), 2,3 (m, 1H), 3,15 (m, 1H), 3,3-3,6 (m, 6H), 3,9 (m, 1H), 4,05 (t, 2H), 5,2 (m, 1H), 6,75 (s, OH), 6,95 (m, 3H), 7,15 (m, 2H), 7,3 (t, 2H), 7,4-7,5 (m, 4H); MS [M-Br]<+>: 484; smp. 219°C.
Eksempel 90
3(R)-(2-Hydroksy-2,2-ditienyl-3-ylacetoksy)-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 300 mg, 77%.<1>H-NMR (DMSO-d6): 8 1,5-1,6 (m, 1H), 1,6-1,75 (m, 1H), 1.8- 2,1 (m, 4H), 2,25 (m, 1H), 2,8 (t, 2H), 3,05-3,5 (m, 7H), 3,8-3,95 (m, 1H), 5,15 (m, 1H), 6,75 (s, OH), 6,9-7,0 (m, 2H), 7,1 (m, 2H), 7,35-7,55 (m, 5H); MS [M-Br]<+>: 474 ; smp. 192°C.
Eksempel 91
3(R)-(2-Hydroksy-2,2-ditien-3-yl-acetoksy)-l-fenetyl-l-azoniabicyklo-[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 63 mg, 48%.<1>H-NMR (DMSO-d6): 8 1,5-1,7 (m, 1H), 1,7-1,85 (m, 1H), 1.9- 2,1 (m, 2H), 2,3 (m, 1H), 2,9-3,1 (m, 2H), 3,15-3,6 (m, 7H), 3,9-4,0 (m, 1H), 5,2 (m, 1H), 6,8 (s, OH), 7,1 (m, 2H), 7,25-7,35 (m, 5H), 7,4 (m, 2H), 7,5 (m, 2H); MS [M-CF3COO] + : 454.
Eksempel 92
3(R)-(2-Hydroksy-2/2-ditien-3-yl-acetoksy)-l-(3-fenylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 75 mg, 55%.<1>H-NMR (DMSO-d6): 8 1,5-2,0 (m, 6H), 2,25 (m, 1H), 2,5-2,6 (m, 2H), 3,05-3,6 (m, 8H), 3,8-3,9 (m, 1H), 5,15(m, 1H), 6,75 (s, OH), 7,1 (d, 2H), 7,2-7,35 (m, 5H), 7,4 (m, 2H), 7,5 (m, 2H); MS [M-CF3COO]<+>: 468.
Eksempel 93
3(R)-(2-Hydroksy-2/2-ditien-3-ylacetoksy)-l-(4-fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 68 mg, 48%.<1>H-NMR (DMSO-d6): 8 1,5-1,8 (m, 6H), 1,8-2,0 (m, 2H), 2,25 (m, 1H), 2,6 (m, 2H), 3,05 (m, 1H), 3,15-3,45 (m, 6H), 3,85 (m, 1H), 5,15(m, 1H), 6,75 (s, OH), 7,1 (d, 2H), 7,2 (m, 2H), 7,3 (m, 3H), 7,4 (m, 2H), 7,5 (m, 2H); MS [M-CF3COO]<+>: 482.
Eksempel 94
3(R)-(2-Hydroksy-2/2-ditien-3-ylacetoksy)-l-(2-tien-2-yletyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 65 mg, 49%.<1>H-NMR (DMSO-d6): 5 1,5-1,65 (m, 1H), 1,65-1,78 (m, 1H), 1,85-2,05 (m, 2H), 2,3 (m, 1H), 3,1-3,6 (m, 9H), 3,95 (m, 1H), 5,2 (m, 1H), 6,75 (s, OH), 7,0 (m, 2H), 7,15 (m, 2H), 7,45 (m, 3H), 7,5 (m, 2H); MS [M-CF3COO] + : 460.
Eksempel 95
3(R)-(2-Hydroksy-2,2-ditien-3-ylacetoksy)-l-(4-fenoksybutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 63 mg, 43%.<1>H-NMR (DMSO-d6): 5 1,5-2,0 (m, 8H), 2,3 (m, 1H), 3,1 (m, 1H), 3,2-3,5 (m, 6H), 3,85 (m, 1H), 4,0 (m, 2H), 5,2(m, 1H), 6,75 (s, OH), 6,95 (m, 3H), 7,1 (d, 2H), 7,2 (m, 2H), 7,3 (t, 2H), 7,45 (m, 2H), 7,5 (m, 2H); MS [M-CF3COO]<+>: 498.
Eksempel 96
3(R)-(2-Hydroksy-2/2-ditien-3-ylacetoksy)-l-(2-fenoksyetyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 72 mg, 52%.<1>H-NMR (DMSO-d6): 5 1,55-1,65 (m, 1H), 1,7-1,8 (m, 1H), 1,85-2,05 (m,2H), 2,3 (m, 1H), 3,2-3,6 (m, 5H), 3,7 (m, 2H), 4,05 (m, 1H), 4,4 (m, 2H), 5,2(m, 1H), 6,75 (s, OH), 6,95-7,05 (m, 3H), 7,1 (d, 2H), 7,3-7,5 (m, 6H); MS [M-CF3COO] + : 470.
Eksempel 97
l-[3-(4-Fluorfenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-3-ylacetoksy)-l
-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 79 mg, 54%.<1>H-NMR (DMSO-d6): 5 1,55-1,65 (m, 1H), 1,7-1,8 (m, 1H), 1,85-2,0 (m, 2H),2,05-2,2 (m, 2H), 2,3 (m, 1H), 3,1-3,2 (m, 1H), 3,25-3,55 (m, 6H), 3,85-3,95 (m, 1H), 4,0 (t, 2H), 5,2(m, 1H), 6,75 (s, OH), 6,95 (m, 2H), 7,15 (m, 4H), 7,4 (m, 2H), 7,5 (m, 2H); MS [M-CF3COO] + : 502.
Eksempel 98
3(R)-(2-Hydroksy-2/2-ditien-3-ylacetoksy)-l-(3-fenylallyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 24 mg, 17%.<1>H-NMR (DMSO-d6): 8 1,8-2,05 (m, 4H), 2,3 (m, 1H), 3,15 (m, 1H), 3,3-3,5 (m, 4H), 3,9 (m, 1H), 4,05 (m 2H), 5,25 (m, 1H), 6,35 (m, 1H), 6,75 (s, OH), 6,85 (t, 1H), 7,1 (m, 2H), 7,3-7,5 (m, 5H), 7,55 (m, 4H); MS [M-CF3COO] + : 502.
Eksempel 99
l-(3-Fenylallyl)-3(R)-(9-hydroksy-9[H]-fluoren-9-karbonyloksy)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 400 mg, 93%.<1>H-NMR (DMSO-d6): 8 1,35-1,50 (m, 1H), 1,60-1,75 (m, 1H), 1,75-1,95 (m, 2H), 2,10 (m, 1H), 2,85 (m, 1H), 3,10 (d, 1H), 3,20-3,50 (m, 3H), 3,85 (m, 1H), 4,0 (dd, 2H), 5,05 (m, 1H), 6,40 (dd, 1H), 6,80-6,90 (d, 1H), 6,85 (s, OH), 7,20-7,50 (m, 7H), 7,60 (m, 4H), 7,80 (m, 2H); MS [M-Br]<+>: 452; smp. 146°C.
Eksempel 100
3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-(3-fenoksy-
propyl)- l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 690 mg, 83%.<1>H-NMR (DMSO-d6): 8 1,47 (m, 1H), 1,68 (m, 1H), 1,87 (m, 2H), 2,1 (m, 3H), 2,89 (m, 1H), 3,15 (d, 1H), 3,4 (m, 5H), 3,9 (m, 1H), 4,0 (m, 2H), 5,04 (m, 1H), 6,85 (s, OH), 6,97 (m, 3H), 7,35 (m, 4H), 7,45 (m, 2H), 7,65 (m, 2H), 7,85 (m, 2H); MS [M-Br]<+>: 470; smp. 108°C.
Eksempel 101
3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-fenetyl-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 170 mg, 74%.<1>H-NMR (DMSO-d6): 8 1,45 (m, 1H), 1,65 (m, 1H), 1,85 (m, 2H), 2,1 (m, 1H), 2,9 (m, 3H), 3,15 (m, 1H), 3,3-3,5 (m, 5H), 3,85 (m, 1H), 5,05 (m, 1H), 6,85 (s, OH), 7,2-7,4 (m, 7H), 7,45 (t, 2H), 7,55 (d, 1H), 7,65 (d, 1H), 7,85 (d, 2H); MS [M-Br]<+>: 440; smp. 118°C.
Eksempel 102
3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-(2-fenoksy-
etyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 460 mg, 96%.<1>H-NMR (DMSO-d6): 8 1,42 (m, 1H), 1,66 (m, 1H), 1,80-1,88 (m, 2H), 2,08 (m, 1H), 2,93 (m, 1H), 3,25-3,60 (m, 4H), 3,65 (m, 2H), 3,95 (m, 1H), 4,35 (m, 2H), 5,02 (m, 1H), 6,85 (s, 1H, OH), 6,97 (d, 2H), 7,04 (t, 1H), 7,20-7,45 (m, 6H), 7,55-7,60 (t, 2H), 7,80 (d, 2H); MS [M-Br] + : 456; smp. 140°C.
Eksempel 103
3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-(4-okso-4-fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 15 mg, 15%.<1>H-NMR (DMSO-d6): 8 1,45 (m, 1H), 1,65 (m, 1H), 1,7-2,0 (m, 4H), 2,1 (m, 1H), 2,75 (m, 1H), 3,0-3,2 (m 4H), 3,25-3,4 (m, 4H), 3,85 (m, 1H), 5,05 (m, 1H), 6,85 (s, OH), 7,35 (t, 2H), 7,45 (t, 2H), 7,55-7,7 (m, 5H), 7,85 (d, 2H), 8,0 (d, 2H); MS [M-CF3COO]<+>: 482.
Eksempel 104
l-[3-(4-Fluorfenoksy)propyl]-3(R)-(9-hydroksy-9[H]-fluoren-9-karbonyl-oksy)-l-azoniabicyklo[2.2.2]oktan; klorid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 440 mg, 94%.<1>H-NMR (DMSO-d6): 8 1,4 (m, 1H), 1,65 (m, 2H), 1,7-1,95 (m, 2H), 2,0-2,1 (m, 3H), 2,8 (m, 1H), 3,1 (d, 1H), 3,2-3,4 (m, 5H), 3,8 (m, 1H), 4,0 (t, 2H), 5,0 (m, 1H), 6,85 (s, OH), 6,95 (m, 2H), 7,15 (t, 2H), 7,35 (t, 2H), 7,45 (t, 2H), 7,55 (d, 1H), 7,65 (d, 1H), 7,85 (d, 2H); MS [M-Br]<+>: 488; smp. 142°C.
Eksempel 105 l-[3-(2,4-Difluorfenoksy)propyl]-3(R)-(9-hydroksy-9[H]-fluoren-9- kar-bonyloksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 14 mg, 13%.<1>H-NMR (DMSO-d6): 8 1,4 (m, 1H), 1,6-1,9 (m, 3H), 2,1 (m, 3H), 2,8 (m, 1H), 3,1 (d, 1H), 3,2-3,4 (m, 5H), 3,85 (m, 1H), 4,05 (t, 2H), 5,0 (m, 1H), 6,85 (s, OH), 7,05 (t, 1H), 7,15-7,4 (m, 4H), 7,45 (t, 2H), 7,55 (d, 1H), 7,65 (d, 1H), 7,85 (d, 2H); MS [M-CF3COO]<+>: 506.
Eksempel 106
3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-(3-fenylaminopropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 14 mg, 15%.<1>H-NMR (DMSO-d6): 8 1,4 (m, 1H), 1,6 (m, 1H), 1,8 (m, 4H), 2,05 (m, 1H), 2,7 (m, 1H), 3, 0 (m, 3H), 3,2-3,4 (m, 6H), 3,8 (m, 1H), 5,0 (m, 1H), 5,6 (t, NH), 6,55 (m, 3H), 6,85 (s, OH), 7,1 (t, 2H), 7,35 (dd, 2H), 7,45 (dd, 2H), 7,55 (dd, 2H), 7,8 (d, 2H); MS [M-CF3COO] + : 469.
Eksempel 107
3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-[3-(4-hydroksy-fenoksy)propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 15 mg, 15%.<1>H-NMR (DMSO-d6): 8 1,4 (m, 1H), 1,6 (m, 1H), 1,7-1,9 (m, 2H), 1,95-2,05 (m, 2H), 2,1 (m, 1H), 2,8 (m, 1H), 3,1 (d, 1H), 3,25-3,4 (m, 5H), 3,8-3,9 (m, 3H), 5,0 (m, 1H), 6,7 (d, 2H), 6,75 (d, 2H), 6,85 (s, OH), 7,35 (t, 2H), 7,45 (t, 2H), 7,55 (d, 1H), 7,65 (d, 1H), 7,85 (d, 2H), 9,0 (s, OH); MS [M-CF3COO]<+>: 486.
Eksempel 108
l-(2-Benzyloksyetyl)-3(R)-(9-hydroksy-9[H]-fluoren-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 470 mg, 96%.<1>H-NMR (DMSO-d6): 8 1,4 (m, 1H), 1,65 (m, 1H), 1,7-1,9 (m, 2H), 2,1 (m, 1H), 2,9 (m, 1H), 3,15-3,5 (m, 6H), 3,75 (m, 2H), 3,85 (m, 1H), 4,5 (s, 2H), 5,0 (m, 1H), 6,85 (s, OH), 7,3-7,5 (m, 9H), 7,55 (m, 2H), 7,8 (d, 2H); MS [M-Br]<+>: 470; smp. 86°C.
Eksempel 109
3(R)-(9-Hydroksy-9H-fluoren-9-karbonyloksy)-l-(3-tienyl-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 180 mg, 70%.<1>H-NMR (DMSO-d6): 8 1,37 (m, 1H), 1,62 (m, 1H), 1,75-1,95 (m, 4H), 2,06 (m, 1H), 2,72 (m, 1H), 2,80 (m, 2H), 3,02-3,06 (m, 1H), 3,15-3,20 (m, 2H), 3,25-3,40 (m, 3H), 3,80 (m, 1H), 5,0 (m, 1H), 6,85 (s, 1H, OH), 6,95-7,0 (m, 2H), 7,25-7,50 (m, 5H), 7,55-7,65 (m, 2H), 7,85 (d, 2H); MS [M-Br]<+>: 460; smp. 140°C.
Eksempel 110
3(R)-(9-Hydroksy-9H-fluoren-9-karbonyloksy)-l-(3-fenylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 80 mg, 40%.<1>H-NMR (DMSO-d6): 5 1,35 (m, 1H), 1,6 (m, 1H), 1,7-1,90 (m, 2H), 2,05 (m, 1H), 2,5 (m, 2H), 2,7 (m, 1H), 3,0 (m, 1H), 3,15 (m, 2H), 3,2-3,4 (m, 3H), 3,75 (m, 1H), 5,0 (m, 1H), 6,85 (s, OH), 7,20-7,50 (m, 9H), 7,55 (dd, 2H), 7,85 (d, 2H); MS [M-CF3COO] + : 454.
Eksempel 111
3(R)-(9-Hydroksy-9H-fluoren-9-karbonyloksy)-l-(4-fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 74 mg, 35%.<1>H-NMR (DMSO-d6): 5 1,35 (m, 1H), 1,45-1,65 (m, 5H), 1,7-1,90 (m, 2H), 2,05 (m, 1H), 2,55-2,75 (m, 3H), 3,0 (m, 1H), 3,15-3,45 (m, 5H), 3,75 (m, 1H), 5,0 (m, 1H), 6,85 (s, OH), 7,20 (m, 3H), 7,25-7,35 (m, 4H), 7,45-7,5 (m, 2H), 7,55-7,6 (dd, 2H), 7,85 (d, 2H); MS [M-CF3COO]<+>: 468.
Eksempel 112
3(R)-(9-Hydroksy-9H-fluoren-9-karbonyloksy-l-(2-tienyl-2-yletyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 79 mg, 39%.<1>H-NMR (DMSO-d6): 5 1,4 (m, 1H), 1,65 (m, 1H), 1,8-1,95 (m, 2H), 2,1 (m, 1H), 2,9 (m, 1H), 3,1-3,25 (m, 4H), 3,15 -3,45 (m, 5H), 3,85 (m, 1H), 5,05 (m, 1H), 6,85 (s, OH), 7,0 (m, 2H), 7,35 (t, 2H), 7,45-7,5 (m, 3H), 7,55 (d, 1H), 7,65 (d, 1H), 7,85 (d, 2H); MS [M-CF3COO] + : 446.
Eksempel 113
3(R)-(9-Hydroksy-9H-fluoren-9-karbonyloksy)-l-(4-fenoksybutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 72 mg, 33%.<1>H-NMR (DMSO-d6): 5 1,4 (m, 1H), 1,55-1,9 (m, 7H), 2,05 (m, 1H), 2,7 (m, 1H), 3,0 (m, 1H), 3,15-3,5 (m, 7H), 3,8 (m, 1H), 4,0 (m, 2H), 5.05 (m, 1H), 6,85 (s, OH), 6,95 (m, 3H), 7,25-7,35 (m, 4H), 7,4-7,45 (m, 2H), 7.6 (dd, 2H), 7,85 (d, 2H); MS [M-CF3COO]<+>: 484.
Eksempel 114
3(R)-(9-Metyl-9[H]-fluoren-9-karbonyloksy)-l-(3-fenylallyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 200 mg, 76%.<1>H-NMR (DMSO-d6): 8 1,54 (m, 1H), 1,70-1,86 (m, 3H), 1,76 (s, 3H), 2,13 (m, 1H), 3,06 (m, 1H), 3,20-3,50 (m, 4H), 3,86 (m, 1H), 4,05 (dd, 2H), 5,02 (m, 1H), 6,43 (dd, 1H), 6,86 (d, 1H), 7,26-7,46 (m, 7H), 7,58-7,65 (m, 3H), 7,70-7,72 (m, 1H), 7,87-7,90 (m, 2H); MS [M-Br]<+>: 450; smp. 234°C.
Eksempel 115
3(R)-(9-Metyl-9[H]-fluoren-9-karbonyloksy)-l-(2-fenoksyetyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 210 mg, 66%.<1>H-NMR (DMSO-d6): 8 1,55 (m, 1H), 1,60-2,0 (m, 3H), 1,76 (s, 3H), 2,12 (m, 1H), 3,10-3,25 (m, 1H), 3,40-3,80 (m, 6H), 4,0 (m, 1H), 4,41 (m, 2H), 4,98 (m, 1H), 6,98-7,05 (m, 3H), 7,27-7,46 (m, 6H), 7,63-7,71 (m, 2H), 7,87-7,90 (m, 2H); MS [M-Br] + : 454; smp. 202°C.
Eksempel 116
3(R)-(9-Metyl-9[H]-fluoren-9-karbonyloksy)-l-(3-fenoksypropyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 210 mg, 61%.<1>H-NMR (DMSO-d6): 8 1,55 (m, 1H), 1,60-2,0 (m, 3H), 1,78 (s, 3H), 2,0-2,20 (m, 3H), 3,0-3,10 (m, 1H), 3,25-3,53 (m, 6H), 3,86 (m, 1H), 4,03 (m, 2H), 4,98 (m, 1H), 6,95-7,0 (m, 3H), 7,30-7,48 (m, 6H), 7,65-7,92 (m, 4H); MS [M-Br]<+>: 468; smp. 204°C.
Eksempel 117
3(R)-(9-Metyl-9[H]-fluoren-9-karbonyloksy)-l-fenetyl-l-azoniabicyklo-[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 18 mg, 19%.<1>H-NMR (DMSO-d6): 8 1,55 (m, 1H), 1,65-1,95 (m, 3H), 1,75 (s, 3H), 2,15 (m, 1H), 2,9-3,1 (m, 4H), 3,25-3,55 (m, 5H), 3,85 (m, 1H), 5,05 (m, 1H), 7,25-7,55 (m, 9H), 7,65 (d, 1H), 7,75 (d, 1H), 7,95 (d, 2H); MS [M-CF3COO]<+>: 438.
Eksempel 118
3(R)-(9-Metyl-9[H]-fluoren-9-karbonyloksy)-l-(4-okso-4-fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 19 mg, 19%.<1>H-NMR (DMSO-d6): 5 1,55 (m, 1H), 1,65-2,05 (m, 5H), 1,75 (s, 3H), 2,1 (m, 1H) 3,0 (m, 1H), 3,1-3,5 (m, 8H), 3,85 (m, 1H), 7,35-7,5 (m, 4H), 7,55 (t, 2H), 7,65 (t, 2H), 7,7 (d, 1H), 7,9 (d, 2H), 8,0 (d, 2H); MS [M-CF3COO]<+>: 480.
Eksempel 119
l-[3-(4-Fluorfenoksy)propyl]-3(R)-(9-metyl-9[H]-fluoren-9-karbonyl-oksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 23 mg, 23%.<1>H-NMR (DMSO-d6): 5 1,55 (m, 1H), 1,65-1,95 (m, 3H), 1,75 (s, 3H), 2,05-2,15 (m, 3H), 3,0 (m, 1H), 3,25-3,5 (m, 6H), 3,85 (m, 1H), 4,0 (t, 2H), 5,0 (m, 1H), 6,95 (m, 2H), 7,15 (t, 2H), 7,35-7,5 (m, 4H), 7,65 (d, 1H), 7,75 (d, 1H), 7,9 (d, 2H); MS [M-CF3COO]<+>: 486.
Eksempel 120
l-[3-(2,4-Difluorfenoksy)propyl]-3(R)-(9-metyl-9H-fluoren-9-karbonyl-oksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 20 mg, 19%.<1>H-NMR (DMSO-d6): 5 1,55 (m, 1H), 1,65-1,95 (m, 3H), 1,75 (s, 3H), 2,05-2,2 (m, 3H), 3,0 (m, 1H), 3,25- 3,55 (m, 6H), 3,85 (m, 1H), 4,1 (t, 2H), 5,0 (m, 1H), 7,05 (t, 1H), 7,2-7,5 (m, 6H), 7,65 (d, 1H), 7,75 (d, 1H), 7,9 (d, 2H); MS [M-CF3COO]<+>: 504.
Eksempel 121
3(R)-(9-Metyl-9[H]-fluoren-9-karbonyloksy)-l-(3-fenylaminopropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 19 mg, 19%.<1>H-NMR (DMSO-d6): 5 1,55 (m, 1H), 1,65-1,95 (m, 5H), 1,75 (s, 3H), 2,1 (m, 1H), 2,95 (m, 1H), 3,05 (m, 2H), 3,15-3,45 (m, 6H), 3,8 (m, 1H), 5,0 (m, 1H), 5,65 (t, NH), 6,6 (m, 3H), 7,1 (t, 2H), 7,35-7,55 (m, 4H), 7,65 (d, 1H), 7,75 (d, 1H), 7,9 (d, 2H); MS [M-CF3COO]<+>: 467.
Eksempel 122
l-[3-(4-Hydroksyfenoksy)propyl]-3(R)-(9-metyl-9[H]-fluoren-9-karbonyl-oksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 22 mg, 22%.<1>H-NMR (DMSO-d6): 8 1,55 (m, 1H), 1,65-1,9 (m, 3H), 1,75 (s, 3H), 2,0-2,15 (m, 3H), 3,0 (m, 1H), 3,25-3,5 (m, 6H), 3,8-3,95 (m, 3H), 5,0 (m, 1H), 6,7 (d, 1H), 6,75 (d, 1H), 7,35-7,45 (m, 4H), 7,65 (d, 1H), 7,75 (d, 1H), 7,9 (d, 2H), 9,0 (s, OH); MS [M-CF3COO]<+>: 484.
Eksempel 123
l-(2-Benzyloksyetyl)-3(R)-(9-metyl-9[H]-fluoren-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 17 mg, 17%.<1>H-NMR (DMSO-d6): 8 1,55 (m, 1H), 1,65-1,95 (m, 4H), 1,75 (s, 3H), 2,15 (m, 1H), 3,1 (m, 1H), 3,3-3,55 (m, 6H), 3,8-3,95 (m, 3H), 4,5 (s, 2H), 5,0 (m, 1H), 7,3-7,5 (m, 9H), 7,6-7,7 (m, 2H), 7,9 (d, 2H); MS [M-CF3COO]<+>: 468.
Eksempel 124
3(R)-(9,10-Dihydroantracen-9-karbonyloksy)-l-fenetyl-l-azoniabicyklo-[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 420 mg, 89%.<1>H-NMR (DMSO-d6): 8 1,55 (m, 1H), 1,65-1,95 (m, 3H), 2,15 (m, 1H), 2,95 (m, 2H), 3,15 (m, H), 3,25-3,60 (m, 6H), 3,85 (m, 1H), 3,95-4,15 (dd, 2H, Jl = l,8 Hz, J2= 4,2 Hz), 5,02 (m, 1H), 5,25 (s, 1H), 7,25-7,43 (m, 11H), 7,48-7,55 (m, 2H); MS [M-Br] + : 438; smp. 216°C.
Eksempel 125
3(R)-(9,10-Dihydroantracen-9-karbonyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 450 mg, 82%.<1>H-NMR (DMSO-d6): 8 1,56 (m, 1H), 1,65-1,95 (m, 3H), 2,05-2,15 (m, 3H), 3,10 (m, 1H), 3,20-3,50 (m, 6H), 3,80 (m, 1H), 3,94-4,14 (m, 4H), 5,0 (m, 1H), 5,22 (s, 1H), 6,94-7,0 (m, 3H), 7,25-7,35 (m, 6H), 7,40 (m, 2H), 7,54-7,47 (m, 2H); MS [M-Br] + : 468; smp. 157°C.
Eksempel 126
l-(4-Fenylbutyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-azoniabicyklo-[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 83 mg, 21%.<1>H-NMR (DMSO-d6): 8 1,50-2,0 (m, 8H), 2,15 (m, 1H), 2,65 (m, 2H), 3,05-3,65 (m, 7H), 3,80 (m, 1H), 5,0 (m, 1H), 5,30 (s, 1H), 7,10-7,45 (m, 11H), 7,45-7,60 (m, 2H); MS [M-Br]<+>: 468; smp. 95°C.
Eksempel 127
l-(2-Fenoksyetyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo-[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 300 mg, 73%.<1>H-NMR (DMSO-d6): 8 1,70-2,0 (m, 4H), 2,2 (m, 1H), 3,20-3,80 (m, 7H), 4,0 (m, 1H), 4,40 (m, 2H), 5,05 (m, 1H), 5,30 (s, 1H), 7,0-7,10 (m, 7H), 7,30-7,45 (m, 4H), 7,45-7,55 (m, 2H); MS [M-Br] + : 456; smp. 200°C.
Eksempel 128
l-(3-Fenoksypropyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo-[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 350 mg, 83%.<1>H-NMR (DMSO-d6): 8 1,70-2,0 (m, 4H), 2,0-2,25 (m,3H), 3,15-3,65 (m, 7H), 3,85-3,95 (m, 1H), 3,95-4,10 (m, 2H), 5,0 (m, 1H), 5,30 (s, 1H), 6,90-7,0 (m, 3H), 7,10-7,25 (m, 4H), 7,25-7,40 (m, 4H), 7,40-7,60 (m, 2H); MS [M-Br]<+>: 470; smp. 184°C.
Eksempel 129
l-Fenetyl-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo[2.2.2]-oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 100 mg, 44%.<1>H-NMR (DMSO-d6): 8 1,65-2,0 (m, 4H), 2,1 (m, 1H), 2,9-3,05 (m, 2H), 3,15-3,6 (m, 7H), 3,85 (m, 1H), 5,05 (m, 1H), 5,3 (s, 1H)), 7,15-7,55 (m, 13H); MS [M-Br]<+>: 440.
Eksempel 130
l-(4-Okso-4-fenylbutyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og b. Utbyttet i siste trinn var 16 mg, 15%.<1>H-NMR (DMS0-d6): 5 1,65-2,05 (m, 6H), 2,1 (m, 1H), 3,1-3,55 (m, 9H), 3,8 (m, 1H), 5,05 (m, 1H), 5,25 (s, 1H), 7,1-7,3 (m, 4H), 7,35 (t, 2H), 7,45-7,6 (m, 4H), 7,7 (d, 1H), 8,0 (d, 1H); MS [M-CF3COO]<+>: 482.
Eksempel 131
l-[3-(4-Fluorfenoksy)propyl]-3(R)-(9[H]-xanten-9-karbonyl-oksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og b. Utbyttet i siste trinn var 18 mg, 18%.<1>H-NMR (DMSO-d6): 5 1,7-2,1 (m, 6H), 2,15 (m, 1H), 3,1-3,5 (m, 7H), 3,8 (m, 1H), 4,0 (t, 2H), 5,0 (m, 1H), 5,3 (s, 1H), 6,95 (m, 2H), 7,1-7,3 (m, 6H), 7,4 (t, 2H), 7,5 (dd, 2H); MS [M-CF3COO] + : 488.
Eksempel 132
l-[3-(2,4-Difluorfenoksy)propyl]-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og b. Utbyttet i siste trinn var 14 mg, 14%.<1>H-NMR (DMSO-d6): 5 1,65-1,95 (m, 4H), 2,05-2,2 (m, 3H), 3,1-3,55 (m, 7H), 3,8 (m, 1H), 4,05 (t, 2H), 5,0 (m, 1H), 5,3 (s, 1H), 7,05 (t, 1H), 7,1-7,55 (m, 10H); MS [M-CF3COO]<+>: 506.
Eksempel 133
l-(3-Fenylaminopropyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l- azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og b. Utbyttet i siste trinn var 17 mg, 17%.<1>H-NMR (DMSO-d6): 5 1,65-2,0 (m, 6H), 2,15 (m, 1H), 3.0- 3,5 (m, 9H), 1,75 (m, 1H), 5,0 (m, 1H), 5,3 (s, 1H), 6,65 (t, NH), 6,55 (m, 3H), 7,05-7,3 (m, 6H), 7,35-7,55 (m, 4H); MS [M-CF3COO]<+>: 469.
Eksempel 134
l-[3-(4-Hydroksyfenoksy)propyl]-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og b. Utbyttet i siste trinn var 21 mg, 20%.<1>H-NMR (DMSO-d6): 5 1,7-2,1 (m, 6H), 2,15 (m, 1H), 3.1- 3,5 (m, 7H), 3,7-3,95 (m, 3H), 5,0 (m, 1H), 5,3 (s, 1H), 6,7 (d, 2H), 6,75 (d, 2H), 7,1-7,3 (m, 4H), 7,35-7,55 (m, 4H), 9,0 (s, OH); MS [M-CF3COO]<+>: 486.
Eksempel 135
l-(2-Benzyloksyetyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l- azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og b. Utbyttet i siste trinn var 16 mg, 16%.<1>H-NMR (DMSO-d6): 8 1,65-1,95 (m, 4H), 2,1 (m, 1H), 3,1-3,9 (m, 10H), 4,5 (s, 2H), 5,0 (m, 1H), 5,3 (s, 1H), 7,15 (m, 4H), 7,3-7,5 (m, 7H), 7,55 (t, 2H); MS [M-CF3COO]<+>: 470.
Eksempel 136
3(R)-(9-Hydroksy-9[H]-xanten-9-karbonyloksy)-l-(3-fenoksy-
propyl)-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 340 mg, 71%.<1>H-NMR (DMSO-d6): 8 1,30 (m, 1H), 1,65 (m, 1H), 1,70-1,95 (m, 2H), 1,95-2,10 (m, 3H), 2,70 (m, 1H), 2,90 (m, 1H), 3,2-3,5 (m, 5H), 3,80 (m, 1H), 4,0 (t, 2H), 5,05 (m, 1H), 6,90-7,0 (m, 3H), 7,20-7,35 (m, 7H), 7,40-7,46 (m, 2H), 7,65-7,70 (m, 2H); MS [M-Br]<+>: 486; smp. 219°C.
Eksempel 137
3(R)-(9-Hydroksy-9[H]-xanten-9-karbonyloksy)-l-fenetyl-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 290 mg, 64%.<1>H-NMR (DMSO-d6): 8 1,32 (m, 1H), 1,65 (m, 1H), 1,70-1,95 (m, 2H), 2,1 (m, 1H), 2,75-2,90 (m, 3H), 3,05 (m, 1H), 3,30-3,50 (m, 5H), 3,82 (m, 1H), 5,05 (m, 1H), 7,20-7,40 (m, 10H), 7,40-7,50 (m, 2H), 7,65-7,70 (m, 2H); MS [M-Br]<+>: 456; smp. 221°C.
Eksempel 138
3(R)-(9-Hydroksy-9H-xanten-9-karbonyloksy)-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 310 mg, 97%.<1>H-NMR (DMSO-d6): 8 1,30 (m, 1H), 1,62 (m, 1H), 1,70-1,90 (m, 4H), 2,05 (m, 1H), 2,60 (m, 1H), 2,75-2,85 (m, 4H), 3,15 (m, 2H), 3,25-3,40 (m, 2H), 3,75 (m, 1H), 5,0 (m, 1H), 6,93 (m, 1H), 7,0 (m, 1H), 7,14-7,26 (m, 5H), 7,36-7,45 (m, 3H), 7,63-7,67 (m, 2H); MS [M-Br]<+>: 476; smp. 111°C.
Eksempel 139
3(R)-(9-Hydroksy-9H-xanten-9-karbonyloksy)-l-(3-fenylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 85 mg, 41%.<1>H-NMR (DMSO-d6): 5 1,30 (m, 1H), 1,65 (m, 1H), 1,70-1,95 (m, 2H), 2,05 (m, 1H), 2,5-2,6 (m, 2H), 2,80 (m, 1H), 3,05-3,75 (m, 7H), 5,05 (m, 1H), 7,1-7,45 (m, 12H), 7,65-7,70 (m, 2H); MS [M-CF3COO] + : 470.
Eksempel 140
3(R)-(9-Hydroksy-9H-xanten-9-karbonyloksy)-l-(4-fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 84 mg, 38%.<1>H-NMR (DMSO-d6): 5 1,30 (m, 1H), 1,4-1,85 (m, 7H), 2,05 (m, 1H), 2,5-2,6 (m, 2H), 2,80 (m, 1H), 3,05-3,4 (m, 6H), 3,7 (m, 1H), 5,05 (m, 1H), 7,15-7,35 (m, 10H), 7,4 (m, 1H), 7,65 (m, 2H); MS [M-CF3COO]<+>: 484.
Eksempel 141
3(R)-(9-Hydroksy-9H-xanten-9-karbonyloksy)-l-(2-tien-2-yletyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 81 mg, 39%.<1>H-NMR (DMSO-d6): 5 1,30 (m, 1H), 1,6 (m, 1H), l,7-l,9(m, 2H), 2,05 (m, 1H), 2,75(m, 1H), 3,0(m, 1H), 3,1-3,2 (m, 2H), 3,3-3,6 (m, 5H), 3,8 (m, 1H), 5,05 (m, 1H), 6,95-7,0 (m, 2H), 7,15-7,3 (m, 5H), 7,45 (m, 3H), 7,65 (m, 2H); MS [M-CF3COO] + : 462.
Eksempel 142
3(R)-(9-Hydroksy-9H-xanten-9-karbonyloksy)-l-(4-fenoksybutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 83 mg, 37%.<1>H-NMR (DMSO-d6): 5 1,3 (m, 1H), 1,5-1,9 (m, 7H), 2,05 (m, 1H), 2,6 (m, 1H), 2,8 (m, 1H), 3,1-3,45 (m, 7H), 3,75 (m, 1H), 4,0 (m, 2H), 5,05 (m, 1H), 6,95-7,0 (m, 3H), 7,15-7,45 (m, 9H), 7,65 (m, 2H); MS [M-CF3COO] + : 500.
Eksempel 143
3(R)-(9-Hydroksy-9H-xanten-9-karbonyloksy)-l-(2-fenoksyetyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 102 mg, 48%.<1>H-NMR (DMSO-d6): 8 1,3 (m, 1H), 1,55-1,95 (m, 3H), 2.05 (m, 1H), 2,8 (m, 1H), 3,1 (m, 1H), 3,35-3,65 (m, 5H), 3,9 (m, 1H), 4,35 (m, 2H), 5,05 (m, 1H), 6,95 (d, 2H), 7,0-7,1 (m, 2H), 7,2 (m, 4H), 7,3-7,45 (m, 4H), 7.6 (t, 2H); MS [M-CF3COO] + : 472.
Exemple 144
l-[3-(4-Fluorfenoksy)propyl]-3(R)-(9-hydroksy-9H-xanten-9-karbonyl-oksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 99 mg, 44%.<1>H-NMR (DMSO-d6): 5 1,3 (m, 1H), 1,6 (m, 1H), 1,7-2,0 (m, 4H), 2,05 (m, 1H), 2,7 (m, 1H), 2,9 (m, 1H), 3,2-3,5 (m, 5H), 3,75-3,85 (m, 1H), 3,95 (m, 2H), 5,0 (m, 1H), 6,95 (m, 2H), 7,1-7,3 (m, 7H), 7,45 (t, 2H), 7,65 (t, 2H); MS [M-CF3COO] + : 504.
Exemple 145
3(R)-(9-Hydroksy-9H-xanten-9-karbonyloksy)-l-(3-fenylallyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 25 mg, 12%.<1>H-NMR (DMSO-d6): 5 1,25-1,30 (m, 1H), 1,55-1,95 (m, 3H), 2,10 (m, 1H), 2,65-2,75 (m, 1H), 2,9 (m, 1H), 3,25-3,50 (m, 2H), 3,75-3,8 (m, 1H), 3,95 (m, 2H), 4,2 (d, 1H), 5,0 (m, 1H), 6,35 (m, 1H), 6,80 (d, 1H), 7,05-7,50 (m, 8H), 7,60 (m, 4H); MS [M-CF3COO]<+>: 468.
Eksempel 146
3(R)-(9-Metyl-9[H]-xanten-9-karbonyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og a. Utbyttet i siste trinn var 110 mg.<1>H-NMR (DMSO-d6): 5 1,4 (m, 1H), 1,65 (m, 1H), 1,75-1,95 (m, 2H), 1,9 (s, 3H), 2,05-2,15 (m, 3H), 1,8 (m, 1H), 3,15 (m, 2H), 3,25-3,5 (m, 5H), 3,85 (m, 1H), 4,0 (t, 2H), 5,05 (m, 1H), 6,95-7,0 (m, 3H), 7,15-7,2 (m, 4H), 7,3-7,4 (m, 4H), 7,45 (d, 1H), 7,55 (d, 1H); MS [M-Br]<+>: 484; smp. 195°C.
Eksempel 147
3(R)-(9-Metyl-9[H]-xanten-9-karbonyloksy)-l-fenetyl-l-azoniabicyklo-[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 19 mg, 20%.<1>H-NMR (DMSO-d6): 5 1,4 (m, 1H), 1,65 (m, 1H), 1,8-1,95 (m, 2H), 1,9 (s, 3H), 2,15 (m, 1H), 2,8-2,95 (m, 3H), 3,15 (d, 1H), 3,3-3,5 (m, 5H), 4,9 (m, 1H), 5,1 (m, 1H), 7,15 (m, 4H), 7,25-7,4 (m, 7H), 7,45 (d, 1H), 7,55 (d, 1H); MS [M-CF3COO]<+>: 454.
Eksempel 148
3(R)-(9-Metyl-9[H]-xanten-9-karbonyloksy)-l-(2-fenoksyetyl)-l- azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 24 mg, 24%.<1>H-NMR (DMSO-d6): 5 1,4 (m, 1H), 1,65 (m, 1H), 1,8-1,95 (m, 2H), 1,9 (s, 3H), 2,15 (m, 1H), 2,95 (m, 1H), 3,25 (m, 1H), 3,4-3,65 (m, 5H), 3,85 (m, 1H), 4,35 (t, 2H), 5,05 (m, 1H), 6,95 (d, 2H), 7,05 (t, 2H), 7,15 (m, 3H), 7,25-7,45 (m, 6H); MS [M-CF3COO]<+>: 470.
Eksempel 149
3(R)-(9-Metyl-9[H]-xanten-9-karbonyloksy)-l-(4-okso-4-fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 19 mg, 19%.<1>H-NMR (DMSO-d6): 5 1,4 (m, 1H), 1,65 (m, 1H), 1,75-1,95 (m, 7H), 2,15 (m, 1H), 2,8 (m, 1H), 3,05-3,25 (m, 4H), 3,3-3,5 (m, 4H), 3,85 (m, 1H), 5,05 (m, 1H), 7,15 (m, 4H), 7,35 (t, 2H), 7,45-7,6 (m, 4H), 7,7 (t, 1H), 8,0 (d, 2H); MS [M-CF3COO]<+>: 496.
Eksempel 150
l-[3-(4-Fluorfenoksy)propyl]-3(R)-(9-metyl-9[H]-xanten-9-karbonyl-oksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 25 mg, 24%.<1>H-NMR (DMSO-d6): 5 1,4 (m, 1H), 1,65 (m, 1H), 1,75-1,95 (m, 2H), 1,9 (s, 3H), 1,95-2,1 (m, 2H), 2,15 (m, 1H), 2,8 (m, 1H), 3,1 (d, 1H), 3,25-3,5 (m, 5H), 3,8 (m, 1H), 4,0 (t, 2H), 5,05 (m, 1H), 6,95 (m, 2H), 7,15 (m, 6H), 7,35 (t, 2H), 7,5 (dd, 2H); MS [M-CF3COO]<+>: 502.
Eksempel 151
l-[3-(2/4-Difluorfenoksy)propyl]-3(R)-(9-metyl-9[H]-xanten-9-karbonyl-oksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 16 mg, 15%.<1>H-NMR (DMSO-d6): 5 1,4 (m, 1H), 1,65 (m, 1H), 1,75-1,95 (m, 2H), 1,9 (s, 3H), 2,0-2,15 (m, 3H), 2,8 (m, 1H), 3,1 (d, 1H), 7,05 (t, 1H), 7,1-7,4 (m, 8H), 7,5 (dd, 2H); MS [M-CF3COO]<+>: 520.
Eksempel 152
3(R)-(9-Metyl-9[H]-xanten-9-karbonyloksy)-l-(3-fenylaminopropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 16 mg, 15%.<1>H-NMR (DMSO-d6): 6 1,35 (m, 1H), 1,6 (m, 1H), 1,7-1,9 (m, 4H), 1,9 (s, 3H), 2,1 (m, 1H), 2,7 (m, 1H), 2,95-3,05 (m, 3H), 3,1-3,4 (m, 6H), 3,75 (m, 1H), 5,0 (m, 1H), 5,6 (m, 1H), 6,55 (m, 3H), 7,05-7,15 (m, 6H), 7,3 (m, 2H), 7,45 (t, 2H); MS [M-CF3COO]<+>: 483.
Eksempel 153
l-[3-(4-Hydroksyfenoksy)propyl]-3(R)-(9-metyl-9[rl]-xanten-9-karbonyl-oksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 19 mg, 18%.<1>H-NMR (DMSO-d6): 5 1,4 (m, 1H), 1,65 (m, 1H), 2,75-2,05 (m, 4H), 1,9 (s, 3H), 2,15 (m, 1H), 2,8 (m, 1H), 3,1 (d, 1H), 3,25-3,5 (m, 5H), 3,8-3,95 (m, 3H), 5,05 (m, 1H), 6,65-6,8 (m, 4H), 7,2 (m, 4H), 7,35 (t, 2H), 7,5 (m, 2H), 9,0 (s, OH); MS [M-CF3COO]<+>: 500.
Eksempel 154
l-(2-Benzyloksyetyl)-3(R)-(9-metyl-9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte c og b. Utbyttet i siste trinn var 14 mg, 14%.<1>H-NMR (DMSO-d6): 5 1,4 (m, 1H), 1,65 (m, 1H), 1,75-1,95 (m, 2H), 1,9 (s, 3H), 2,1 (m, 1H), 2,9 (m, 1H), 3,2-3,5 (m, 6H), 3,75-3,95 (m, 3H), 4,5 (s, 2H), 5,05 (m, 1H), 7,15 (m, 4H), 7,3-7,5 (m, 9H); MS [M-CF3COO]<+>: 484.
Eksempel 155
l-(3-Fenoksypropyl)-3(R)-(9[H]-tioxanten-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 323 mg, 50%.<1>H-NMR (DMSO-d6): 8 1,35 (m, 1H), 1,65 (m, 1H), 1,70-1,95 (m, 2H), 2,0-2,2 (m, 3H), 2,75-2,90 (m, 1H), 3,12 (m, 1H), 3,25-3,50 (m, 5H), 3,80 (m, 1H), 4,0 (t, 2H), 5,0 (m, 1H), 5,6 (s, 1H), 6,94-7,0 (m, 3H), 7,22-7,41 (m, 6H), 7,45-7,64 (m, 4H); MS [M-Br]<+>: 486; smp. 157°C.
Eksempel 156
l-(3-Fenylallyl)-3(R)-(10,ll-dihydro-5H-dibenzo[a,d]cyklohepten-5-ka rbony loksy)- 1-azonia bicy klo [ 2.2.2 ]oktan; brom id
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 250 mg, 94%.<1>H-NMR (CDCI3): 8 1,50-1,60 (m,lH), 1,60-1,80 (m,lH), 1,90 (m, 2H), 2,30 (m, 1H), 2,65-2,80 (m, 2H), 2,90-3,20 (m, 3H), 3,50 (d, 1H), 3,60-3,90 (m, 3H), 4,20 (m, 1H), 4,35-4,60 (dobbel dd, 2H), 5,10 (m, 1H), 5,15 (s, 1H), 6,05 (dd, 1H), 6,90-7,0 (m, 2H), 7,0-7,5 (m, 11H); MS [M-Br]<+>: 464; smp. 132°C.
Eksempel 157
l-(3-Fenoksypropyl)-3(R)-(10,ll-dihydro-5H-dibenzo[a,d]cyklohepten-5-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 290 mg, 94%.<1>H-NMR (CDCI3): 8 1,45-1,60 (m, 1H), 1,65-1,80 (m, 1H), 1,80-2,0 (m, 2H), 2,0-2,20 (m, 3H), 2,80-3,0 (m, 3H), 3,15-3,30 (m, 2H), 3,30-3,45 (d, 1H), 3,45-3,80 (m, 5H), 3,85-4,0 (m, 2H), 4,20 (m, 1H), 5,10 (m, 1H), 5,20 (s, 1H), 6,80-6,90 (d, 2H), 6,90-7,0 (t, 1H), 7,10-7,30 (m, 8H), 7,40 (m, 2H); MS [M-Br]<+>: 482; smp. 182°C.
Eksempel 158
3(R)-(5[H]-Dibenzo[a,d]cyklohepten-5-karbonyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 180 mg, 56%.<1>H-NMR (DMSO-d6): 8 1,2 (m, 1H), 1,6 (m, 1H), 1,7-1,9 (m, 2H), 1,95 (m, 1H), 2,1 (m, 2H), 2,8 (m, 1H), 2,95 (d, 1H), 3,25-3,45 (m, 5H), 3,8 (m, 1H), 4,05 (t, 2H), 4,9 (m, 1H), 5,45 (s, 1H), 6,9-7,1 (m, 5H), 7,3-7,5 (m, 9H), 7,55 (d, 2H); MS [M-Br]<+>: 480; smp. 111°C.
Eksempel 159
3(R)-(5[H]-Dibenzo[a,d]cyklohepten-5-karbonyloksy)-l-fenetyl-l- azoniabicyklo[2.2.2]oktan; bromid
Tittelforbindelsen ble syntetisert i henhold til fremgangsmåte d og a. Utbyttet i siste trinn var 210 mg, 68%.<1>H-NMR (DMSO-d6): 8 1,2 (m, 1H), 1,7-1,9 (m, 2H), 2,0 (m, 1H), 2,85-3,1 (m, 4H), 3,3-3,5 (m, 5H), 3,85 (m, 1H), 4,95 (m, 1H), 5,45 (s, 1H), 7,05 (m, 2H), 7,25-7,5 (m, 11H), 7,55 (m, 2H); MS [M-Br]<+>: 450; smp. 248°C.
Eksempel 160 til 164 illustrerer farmasøytiske sammensetninger i henhold til den foreliggende oppfinnelse og fremgangsmåte ved deres fremstilling.
Eksempel 160
Fremstilling av en farmasøytisk sammensetning: tabletter
Formulering:
Ved å anvende en blandemaskin ble 15 g av forbindelsen av den foreliggende oppfinnelse blandet med 340,8 g laktose og 85,2 g mikrokrystaMinsk cellulose. Blandingen ble underkastet kompresjonsforming ved å anvende en rullekompaktor for å gi et flaklignende sammenpresset materiale. Det flaklignende sammenpressede materiale ble pulverisert ved å anvende en hammermølle, og det pulveriserte materiale ble siktet gjennom en 20 mesh sikt. En 4,5 g porsjon av lys kiselanhydrid og 4,5 g magnesiumstearat ble tilsatt til det siktede materiale og blandet. Blanderpro-duktet ble underkastet en tablettlagingsmaskin utstyrt med et form/stempelsystem av 7,5 mm i diameter, for derved å oppnå 3.000 tabletter hver med 150 mg vekt.
Eksempel 161
Fremstilling av en farmasøytisk sammensetning: belagte tabletter Formulering:
Ved å anvende en fluidisert sjiktgranuleringsmaskin ble 15 g av forbindelsen av den foreliggende oppfinnelse blandet med 285,6 g laktose og 122,4 g maisstivelse. Separat ble 22,5 g polyvinylpyrrolidon løst i 127,5 g vann for å fremstille en bindings-løsning. Ved å anvende en fluidisert sjiktgranuleringsmaskin, ble bindingsløsningen sprayet på blandingen overfor å gi granulater. En 4,5 g porsjon magnesiumstearat ble tilsatt til de erholdte granulater og blandet. Den erholdte blanding ble underkastet en tablettlagingsmaskin utstyrt med et form/stempel bikonkavt system på 6,5 mm i diameter, for derved å oppnå 3.000 tabletter, hver med 150 mg vekt.
Separat ble en beleggingsløsning fremstilt ved å suspendere 6,9 g hydroksypropyl-metylcellulose 2910, 1:2 g polyetylenglykol 6000, 3,3 g titandioksid og 2,1 g renset talk i 72,6 g vann. Ved å anvende en "High Coated", ble de 3.000 tabletter fremstilt over belagt med beleggingsløsningen for å gi filmbelagte tabletter, hver med 154,5 mg vekt.
Eksempel 162
Fremstilling av en farmasøytisk sammensetning: flytende medikament for inhalasjon
Formulering:
En 40 mg porsjon av forbindelsen av den foreliggende oppfinnelse ble løst i 90 ml fysiologisk saltløsning, og løsningen ble justert til et totalvolum på 100 ml med den samme saltløsning, dispensert i 1 ml porsjoner i 1 ml kapasitet ampulle og deretter sterilisert ved 115° i 30 minutter for å gi flytende medikament for inhalasjon.
Eksempel 163
Fremstilling av en farmasøytisk sammensetning: pulver for inhalasjon Formulering:
En 20 g porsjon med forbindelsen av den foreliggende oppfinnelse ble uniformt blandet med 400 g laktose, og en 200 mg porsjon av blandingen ble pakket i en pulverinhalator for eksklusiv anvendelse for å frembringe et pulver for inhalasjon.
Eksempel 164
Fremstilling av en farmasøytisk sammensetning: inhalasjonsaerosol. Formulering:
Det aktive ingredienskonsentrat fremstilles ved å løse opp 0,0480 g av forbindelsen av den foreliggende oppfinnelse i 2,0160 g etylalkohol. Konsentratet tilsettes til et passende fyllapparat. Det aktive ingredienskonsentrat dispenseres i aerosol-beholder, beholderens luftrom luftes ut med nitrogen eller HFC-134A damp (utblås-ningsingredienser bør ikke inneholde mer enn 1 ppm oksygen) og forsegles med ventil. 11,2344 g HFC-134A drivmiddel trykkfylles deretter på den forseglede be-holder.
Claims (36)
1. Forbindelse i henhold til formel (I)
hvori: © er en fenyl-, pyrrolyl-, tienyl-, furyl-, bifenyl-, naftalenyl-, 5,6,7,8-tetrahydronaftalenyl-, benzo[l,3]dioksolyl-, imidazolyl- eller benzotiazolylgruppe
R<1>, R2 ogR<3>hver uavhengig representerer et hydrogenatom eller halogenatom, eller en -OR<4>, -NHCOR<4>, -CN, -N02eller -COOR<4>-gruppe, eller en rett eller forgrenet Ci-C8alkylgruppe som eventuelt kan være substituert med en hydroksygruppe, hvori R<4>representerer et hydrogenatom eller en rett eller forgrenet Ci-C8alkylgruppe;
n er et heltall fra 0 til 4;
A representerer en -CH=CH-, -CH2-, -0-, -S- eller -S(0)-gruppe,
m er et heltall fra 0 til 8; forutsatt at når m = 0, er A ikke -CH2-;
p er et heltall fra 1 til 2 og substitusjonen i den azoniabicyklisk ring kan være i 2-, 3- eller 4-stillingen inklusive alle mulige konfigurasjoner av de asymmetriske karboner;
B representerer en gruppe med formel i) eller ii):
hvori R<10>representerer et hydrogenatom, en hydroksy- eller metylgruppe; og R8 og R<9>representerer hver uavhengig
hvori R<11>representerer et hydrogen- eller halogenatom eller en rett eller forgrenet Ci-C8alkylgruppe og Q representerer en enkeltbinding eller -0-; og
X representerer et farmasøytisk akseptabelt anion av en mono- eller po I yva I ent syre.
2. Forbindelse i henhold til krav 1, hvori enhver alkylgruppe til stede som R<1>til R<4>eller R<11>inneholder fra 1 til 4 karbonatomer.
3. Forbindelse i henhold til kravene 1 eller 2, hvori p = 2.
4. Forbindelse ifølge ethvert av de foregående krav, hvori © representerer en fenyl-, pyrrolyl- eller tienylgruppe.
5. Forbindelse ifølge et hvilket som helst av de foregående krav, hvori R<1>, R<2>og R3 hver uavhengig representerer et hydrogen- eller halogenatom eller en hydroksy, metyl, tert-butyl, -CH2OH, 3-hydroksypropyl, -OMe, -NHCOMe, -CN, -N02eller -COOMe-gruppe.
6. Forbindelse ifølge krav 5, hvori R<1>, R<2>og R<3>hver uavhengig representerer et hydrogen- eller halogenatom eller en hydroksygruppe.
7. Forbindelse ifølge krav 6, hvori halogenatomet er fluor.
8. Forbindelse ifølge et hvilket som helst av de foregående krav, hvori A representerer en -CH2-, -CH=CH-, -O- eller -S-gruppe; n er 0 eller 1; og m er et heltall fra 1 til 6.
9. Forbindelse ifølge krav 8, hvori A representerer en -CH2-, -CH=CH- eller -O-gruppe og m er 1, 2 eller 3.
10. Forbindelse ifølge et hvilket som helst av de foregående krav, hvori azoniabicyklogruppen er substituert på nitrogenatomet med en 3-fenoksypropyl-, 2-fenoksyetyl-, 3-fenylallyl-, fenetyl-, 3-fenylpropyl-, 4-fenylbutyl-, 3-(2-hydroksy-fenoksy)propyl-, 3-(4-fluorfenoksy)propyl-, 2-benzyloksyetyl-, 3-pyrrol-l-ylpropyl-, 2-tien-2-yletyl- eller 3-tien-2-ylpropylgruppe.
11. Forbindelse ifølge et hvilket som helst av de foregående krav, hvori B representerer en gruppe med formel (i) og R<8>og R<9>hver uavhengig representerer en fenyl-, 2-tienyl-, 3-tienyl-, 2-furyl- eller 3-furylgruppe og R<11>representerer et hydrogenatom.
12. Forbindelse ifølge et hvilket som helst av kravene 1 til 10, hvori B representerer en gruppe med formel (ii) og Q representerer en enkeltbinding eller et oksygenatom.
13. Forbindelse ifølge et hvilket som helst av de foregående krav, hvori X representerer et bromid-, klorid- eller trifluoracetatanion.
14. Forbindelse ifølge et hvilket som helst av de foregående krav, hvori azoniabicyklogruppen er substituert i 3-stillingen.
15. Forbindelse ifølge krav 14, hvori substituenten i 3-stillingen har (R)-konfigurasjon.
16. Forbindelse ifølge krav 15, hvori R<8>er forskjellig fra R<9>i gruppe i), og det asymmetriske karbon til hvilket R<8>og R<9>er bundet har (R)-konfigurasjon.
17. Forbindelse ifølge krav 15, hvori R<8>er forskjellig fra R<9>i gruppe i), og det asymmetriske karbon til hvilket R<8>og R<9>er bundet har (S)-konfigurasjon.
18. Forbindelse ifølge et hvilket som helst av de foregående krav, hvilken er en enkelt isomer.
19. Forbindelse ifølge krav 1, hvilken er 3(R)-Difenylacetoksy-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(2-Hydroksy-2,2-difenylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(2,2-Difenylpropionyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2-Hydroksy-2-fenyl-2-tien-2-yl-acetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)-l-(3-fenylallyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)-l-(2-fenoksyetyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(2-Furan-2-yl-2-hydroksy-2-fenylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(2,2-Ditien-2-ylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-fenetyl-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(4-fenylbutyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid l-[3-(4-Fluorfenoksy)propyl]-3(R)-(2-hydroksy-2,2-ditien-2-yla-cetoksy)-l-azoniabicyklo[2.2.2]oktan; klorid
3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-[3-(2-hydroksyfenoksy)-propyl]-l-azoniabicyklo[2.2.2]oktan; trifluoracetat 3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-pyrrol-l-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat 3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(2-tien-2-yletyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(2-Hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid l-(2-Benzyloksyetyl)-3(R)-(2-hydroksy-2,2-ditien-2-ylacetoksy)-l-azoniabicyklo[2.2.2]oktan; trifluoracetat
3(R)-(2-Hydroksy-2,2-ditien-3-ylacetoksy)-l-(3-fenoksypropyl)-l- azoniabicyklo[2.2.2]oktan; bromid l-(3-Fenylallyl)-3(R)-(9-hydroksy-9[H]-fluoren-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(9-Hydroksy-9[H]-fluoren-9-karbonyloksy)-l-fenetyl-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(9-Hydroksy-9H-fluoren-9-karbonyloksy)-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(9-Metyl-9[H]-fluoren-9-karbonyloksy)-l-(3-fenylallyl)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(9-Metyl-9[H]-fluoren-9-karbonyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid l-(4-Fenylbutyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan;
bromid l-(2-Fenoksyetyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo-[2.2.2]oktan; bromid l-(3-Fenoksypropyl)-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo-[2.2.2]oktan; bromid l-Fenetyl-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo[2.2.2]oktan; bromid 3(R)-(9-Hydroksy-9[H]-xanten-9-karbonyloksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2.2.2]oktan; bromid
3(R)-(9-Hydroksy-9[H]-xanten-9-karbonyloksy)-l-fenetyl-l-azoniabicyklo-[2.2.2]oktan; bromid 3(R)-(9-Hydroksy-9H-xanten-9-karbonyloksy)-l-(3-tien-2-ylpropyl)-l-azoniabicyklo[2.2.2]oktan; bromid eller 3(R)-(9-Metyl-9[H]-xanten-9-karbonyloksy)-l-(3-fenoksy-propyl)-l-azoniabicyklo[2.2.2]oktan; bromid.
20. Forbindelse i henhold til krav 1 som er 3(R)-(2-hydroksy-2,2-ditien,2-ylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo[2,2,2]oktan; X", hvori X" representerer et farmasøytisk akseptabelt anion av en mono- eller polyvalent syre.
21. Forbindelse i henhold til krav 1, som er 3(R)-(2-hydroksy-2,2-ditien-2-ylacetoksy)-l-(3-fenoksypropyl)-l-azoniabicyklo(2,2,2]oktan; bromid.
22. Forbindelse i henhold til krav 1, som er l-fenetyl-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azoniabicyklo(2,2,2]oktan; X" hvori X" representerer et farmasøy-tisk akseptabelt anion av en mono- eller polyvalent syre.
23. Forbindelse ifølge krav 1, som er l-fenetyl-3(R)-(9[H]-xanten-9-karbonyloksy)-l-azanoiabicyklo[2,2,2]oktan; bromid.
24. Fremgangsmåte ved fremstillingen av en forbindelse med formel (I) som definert i et hvilket som helst av kravene 1 til 23
karakterisert vedat den omfatter å reagere et alkyleringsmiddel med formel (II)
med en forbindelse med formel (III)
hvori, i hver av formlene I, II og III,R<1>,R2,R3,©, A, X, B, n, m og p er som definert i et hvilket som helst av kravene 1 til 23.
25. Fremgangsmåte ifølge krav 24,
karakterisert vedat den resulterende reaksjonsblanding renses ved fast fase ekstraksjon.
26. Forbindelse med formel (III)
hvori B og p er som definert i et hvilket som helst av kravene 1, 2, 3, 11, 12 eller 14 til 19 og hvori substituenten på azabicyklogruppen har (R)-konfigurasjon.
27. Forbindelse ifølge krav 26, som er 9-metyl-9[H]-fluoren-9-karboksylsyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester; 9-metyl-9[H]-xanten-9-karboksylsyre-l-azabicyklo[2.2.2]okt-3(R)-ylester; 2-hydroksy-2,2-difuran-2-yl-eddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
28. Forbindelse med formel (VII)
hvori p er som definert i krav 1 eller 3, R<8>er en 2-tienyl- eller 2-furylgruppe og hvori substituenten på azabicyklogruppen har (R) konfigurasjon.
29. Forbindelse ifølge krav 28, som er oksotien-2-yl-eddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester; eller oksofuran-2-yl-eddiksyre-l-azabicyklo[2.2.2]okt-3(R)-yl-ester.
30. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1 til 19 i blanding med en farmasøytisk akseptabel bærer eller fortynningsmiddel.
31. Farmasøytisk sammensetning ifølge krav 30, som videre omfatter en2-agonist.
32. Farmasøytisk sammensetning ifølge krav 30, som videre omfatter et kortikosteroid.
33. Farmasøytisk sammensetning ifølge krav 30 som videre omfatter en fosfod i estera se-1 V- i n h i bito r.
34. Forbindelse ifølge et hvilket som helst av kravene 1 til 23 for anvendelse i en fremgangsmåte ved behandling av det humane eller animalske legeme ved terapi.
35. Anvendelse av en forbindelse ifølge et hvilket som helst av kravene 1 til 23 ved fremstillingen av et medikament for anvendelse i behandlingen av respiratorisk, urinveis- eller gastrointestinal sykdom.
36. Anvendelse av en forbindelse ifølge et hvilket som helst av kravene 1 til 23 ved fremstillingen av et medikament for anvendelse i behandlingen av COPD, kronisk bronkitt, astma og rhinitt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES009901580A ES2165768B1 (es) | 1999-07-14 | 1999-07-14 | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
PCT/EP2000/006469 WO2001004118A2 (en) | 1999-07-14 | 2000-07-07 | Quinuclidine derivatives and their use as muscarinic m3 receptor ligands |
Publications (4)
Publication Number | Publication Date |
---|---|
NO20020180D0 NO20020180D0 (no) | 2002-01-14 |
NO20020180L NO20020180L (no) | 2002-03-13 |
NO329484B1 NO329484B1 (no) | 2010-10-25 |
NO329484B3 true NO329484B3 (no) | 2013-04-29 |
Family
ID=8309225
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20020180A NO329484B3 (no) | 1999-07-14 | 2002-01-14 | Nye kinuklidinderivater og medisinske sammensetninger inneholdende det samme, samt anvendelse derav for fremstilling av medikamenter |
NO2013002C NO2013002I2 (no) | 1999-07-14 | 2013-01-18 | Aklidiniumsalt med et farmaøytisk akseptabelt anion av en mono-eller polyvalent syre, spesielt aklidiniumbromid |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2013002C NO2013002I2 (no) | 1999-07-14 | 2013-01-18 | Aklidiniumsalt med et farmaøytisk akseptabelt anion av en mono-eller polyvalent syre, spesielt aklidiniumbromid |
Country Status (39)
Country | Link |
---|---|
US (16) | US6750226B2 (no) |
EP (1) | EP1200431B3 (no) |
JP (2) | JP4030040B2 (no) |
KR (3) | KR100854321B1 (no) |
CN (2) | CN100451018C (no) |
AR (1) | AR029760A1 (no) |
AT (1) | ATE235492T1 (no) |
AU (1) | AU2005202144B2 (no) |
BE (1) | BE2013C001I2 (no) |
BG (1) | BG65565B1 (no) |
BR (1) | BRPI0012434B8 (no) |
CA (1) | CA2381165C (no) |
CO (1) | CO5200759A1 (no) |
CY (1) | CY2013001I2 (no) |
CZ (1) | CZ304292B6 (no) |
DE (2) | DE60001840T4 (no) |
DK (1) | DK1200431T6 (no) |
EE (1) | EE04915B3 (no) |
EG (1) | EG24066A (no) |
ES (2) | ES2165768B1 (no) |
FR (1) | FR13C0001I2 (no) |
HK (1) | HK1042487B (no) |
HU (1) | HU228594B1 (no) |
IL (1) | IL147533A0 (no) |
LU (1) | LU92132I2 (no) |
MY (1) | MY126959A (no) |
NO (2) | NO329484B3 (no) |
PE (1) | PE20010397A1 (no) |
PL (1) | PL204024B1 (no) |
PT (1) | PT1200431E (no) |
RU (2) | RU2264401C3 (no) |
SI (1) | SI1200431T1 (no) |
SK (1) | SK287480B6 (no) |
TR (1) | TR200200768T2 (no) |
TW (1) | TWI284644B (no) |
UA (1) | UA73509C2 (no) |
UY (2) | UY26244A1 (no) |
WO (1) | WO2001004118A2 (no) |
ZA (1) | ZA200200232B (no) |
Families Citing this family (219)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7214687B2 (en) | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
AR028948A1 (es) * | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
US20040077605A1 (en) * | 2001-06-20 | 2004-04-22 | Salvati Mark E. | Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function |
US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
US6787532B2 (en) | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
CZ301323B6 (cs) * | 2000-12-22 | 2010-01-13 | Laboratorios Almirall, S.A. | Chinuklidinkarbamátové deriváty a lécivé kompozice je obsahující |
BR0116624A (pt) * | 2000-12-28 | 2003-12-23 | Almirall Prodesfarma Ag | Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto ou da composição farmacêutica, e, produto de combinação |
UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
PT1425001E (pt) | 2001-09-14 | 2009-02-18 | Glaxo Group Ltd | Derivados de fenetanolamina para o tratamento de doenças respiratórias |
CN1832948B (zh) | 2001-12-20 | 2011-06-15 | 基耶西药品股份公司 | 1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途 |
US7405224B2 (en) | 2002-01-31 | 2008-07-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Xanthenecarboxylates, processes for preparing them, and their use as pharmaceutical compositions |
DE10203753A1 (de) * | 2002-01-31 | 2003-08-14 | Boehringer Ingelheim Pharma | Neue Xanthencarbonsäureester, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
GB0202635D0 (en) * | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
ES2206021B1 (es) * | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
ES2203327B1 (es) * | 2002-06-21 | 2005-06-16 | Almirall Prodesfarma, S.A. | Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen. |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
TW200410951A (en) * | 2002-08-06 | 2004-07-01 | Glaxo Group Ltd | M3 muscarinic acetylcholine receptor antagonists |
TW200800953A (en) | 2002-10-30 | 2008-01-01 | Theravance Inc | Intermediates for preparing substituted 4-amino-1-(pyridylmethyl) piperidine |
WO2004056810A1 (en) * | 2002-12-23 | 2004-07-08 | Ranbaxy Laboratories Limited | Xanthine derivatives as muscarinic receptor antagonists |
GB0303396D0 (en) | 2003-02-14 | 2003-03-19 | Glaxo Group Ltd | Medicinal compounds |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
AR044134A1 (es) * | 2003-05-02 | 2005-08-24 | Novartis Ag | Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas. |
CN100445281C (zh) * | 2003-05-02 | 2008-12-24 | 诺瓦提斯公司 | 与毒蕈碱性m3受体结合的奎宁环衍生物 |
WO2004106333A1 (en) | 2003-05-28 | 2004-12-09 | Theravance, Inc. | Azabicycloalkane compounds as muscarinic receptor antagonists |
EP1644356A1 (en) | 2003-07-11 | 2006-04-12 | Theravance, Inc. | Substituted 4-amino-1-benzylpiperidine compounds |
GB0316290D0 (en) | 2003-07-11 | 2003-08-13 | Glaxo Group Ltd | Novel compounds |
AR045913A1 (es) * | 2003-07-17 | 2005-11-16 | Glaxo Group Ltd | Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina |
AR045914A1 (es) * | 2003-07-17 | 2005-11-16 | Glaxo Group Ltd | Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima |
AR048573A1 (es) * | 2003-07-17 | 2006-05-10 | Glaxo Group Ltd | Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima |
GB0317374D0 (en) | 2003-07-24 | 2003-08-27 | Glaxo Group Ltd | Medicament dispenser |
JP2007500150A (ja) * | 2003-07-29 | 2007-01-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗コリン作用薬とステロイドとの併用剤及び吸入により呼吸障害を治療するためのその使用 |
EP1803469A3 (en) * | 2003-07-29 | 2011-10-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Medicaments for inhalation comprising betamimetics and an anticholinergic |
US20050026887A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a steroid |
US20050026948A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
US20050026886A1 (en) * | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
CA2534125A1 (en) * | 2003-07-29 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
ATE526967T1 (de) * | 2003-07-31 | 2011-10-15 | Boehringer Ingelheim Int | Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum |
US20050025718A1 (en) * | 2003-07-31 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
KR20080067023A (ko) | 2003-10-14 | 2008-07-17 | 글락소 그룹 리미티드 | 무스카린성 아세틸콜린 수용체 길항제 |
EA200600787A1 (ru) * | 2003-10-17 | 2006-08-25 | Глэксо Груп Лимитед | Антагонисты мускариновых ацетилхолиновых рецепторов |
PE20050489A1 (es) * | 2003-11-04 | 2005-09-02 | Glaxo Group Ltd | Antagonistas de receptores de acetilcolina muscarinicos |
GB0329182D0 (en) | 2003-12-17 | 2004-01-21 | Glaxo Group Ltd | Chemical compounds |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
EP1725236A4 (en) * | 2004-03-11 | 2009-05-13 | Glaxo Group Ltd | NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS |
ES2239546B1 (es) * | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
JP2007529513A (ja) | 2004-03-17 | 2007-10-25 | グラクソ グループ リミテッド | M3ムスカリン性アセチルコリン受容体アンタゴニスト |
TWI363759B (en) | 2004-04-27 | 2012-05-11 | Glaxo Group Ltd | Muscarinic acetylcholine receptor antagonists |
JP2007537261A (ja) * | 2004-05-13 | 2007-12-20 | グラクソ グループ リミテッド | ムスカリン性アセチルコリン受容体アンタゴニスト |
PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
PL1905451T3 (pl) * | 2004-05-31 | 2010-05-31 | Almirall Sa | Kombinacje obejmujące środki przeciwmuskarynowe i kortykosteroidy |
ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
WO2006005980A1 (en) * | 2004-06-16 | 2006-01-19 | Ranbaxy Laboratories Limited | Xanthine derivatives useful as muscarinic receptor antagonists |
TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
GB0418045D0 (en) | 2004-08-12 | 2004-09-15 | Glaxo Group Ltd | Compounds |
GB0418278D0 (en) | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Medicament dispenser |
GT200500281A (es) | 2004-10-22 | 2006-04-24 | Novartis Ag | Compuestos organicos. |
GB0424284D0 (en) * | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
ATE517908T1 (de) | 2005-01-10 | 2011-08-15 | Glaxo Group Ltd | Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände |
JP2008532973A (ja) * | 2005-03-09 | 2008-08-21 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗コリン作用薬とpde5−阻害剤に基づく新規な医薬組成物 |
PE20100737A1 (es) | 2005-03-25 | 2010-11-27 | Glaxo Group Ltd | Nuevos compuestos |
EP2484382A1 (en) | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
GB0507577D0 (en) | 2005-04-14 | 2005-05-18 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
WO2007016639A2 (en) * | 2005-08-02 | 2007-02-08 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
TW200738634A (en) * | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
WO2007016650A2 (en) * | 2005-08-02 | 2007-02-08 | Glaxo Group Limited | M3 muscarinic acetylcholine receptor antagonists |
EP2281813A1 (en) | 2005-08-08 | 2011-02-09 | Pulmagen Therapeutics (Synergy) Limited | Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses |
EP1937068A4 (en) * | 2005-08-18 | 2010-08-04 | Glaxo Group Ltd | ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS |
TW200744612A (en) * | 2005-08-26 | 2007-12-16 | Astrazeneca Ab | New combination |
NZ567124A (en) | 2005-10-21 | 2011-08-26 | Novartis Ag | Human antibodies against Interleukin-13 and therapeutic uses to treat asthma |
AR058109A1 (es) | 2005-12-20 | 2008-01-23 | Glaxo Group Ltd | Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie |
US20100015061A1 (en) * | 2006-01-06 | 2010-01-21 | Boehringer Ingeheim International GmnH | Pharmaceutical Compositions Based on Anticholinergics and Andolast |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
EA200801997A1 (ru) | 2006-04-20 | 2009-04-28 | Глаксо Груп Лимитед | Новые соединения |
EP2322525B1 (en) | 2006-04-21 | 2013-09-18 | Novartis AG | Purine derivatives for use as adenosin A2A receptor agonists |
GB0611587D0 (en) | 2006-06-12 | 2006-07-19 | Glaxo Group Ltd | Novel compounds |
EP2043717A1 (en) * | 2006-07-14 | 2009-04-08 | Astra Zeneca AB | Inhalation system and delivery device for the administration of a drug in the form of dry powder |
JP2009543860A (ja) | 2006-07-19 | 2009-12-10 | アストラゼネカ・アクチエボラーグ | 新規三環系スピロピペリジン化合物、それらの合成およびケモカイン受容体活性モジュレーターとしてのそれらの使用 |
ES2298049B1 (es) * | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
CA2664378A1 (en) | 2006-09-29 | 2008-04-03 | Novartis Ag | Pyrazolopyrimidines as pi3k lipid kinase inhibitors |
TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
GB0622827D0 (en) | 2006-11-15 | 2006-12-27 | Glaxo Group Ltd | Sheet driver for use in a drug dispenser |
JP2010513277A (ja) * | 2006-12-13 | 2010-04-30 | ギリード・サイエンシズ・インコーポレーテッド | COPDおよび慢性気管支炎の治療のためのムスカリン受容体アンタゴニストおよびβ−アゴニストの共通プロドラッグとしてのモノホスフェート |
ATE493174T1 (de) | 2007-01-10 | 2011-01-15 | Irm Llc | Verbindungen und zusammensetzungen als kanal- aktivierende proteasehemmer |
GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
US20110243924A1 (en) * | 2007-02-21 | 2011-10-06 | Jorge Beleta Supervia | Novel methods |
AR065804A1 (es) | 2007-03-23 | 2009-07-01 | Smithkline Beecham Corp | Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento |
CN101687851B (zh) | 2007-05-07 | 2013-02-27 | 诺瓦提斯公司 | 有机化合物 |
RU2480458C2 (ru) | 2007-09-07 | 2013-04-27 | Тереванс, Инк. | Гуанидинсодержащие соединения, применимые в качестве антагонистов мускариновых рецепторов |
CA2608561A1 (en) * | 2007-10-29 | 2009-04-29 | Carl Paluszkiewicz | Motorcycle wind deflector accessory support |
AU2008334629B2 (en) | 2007-12-10 | 2012-04-12 | Novartis Ag | Organic compounds |
EP2222637A1 (en) | 2007-12-14 | 2010-09-01 | Theravance, Inc. | Amidine-containing compounds useful as muscarinic receptor antagonists |
CN101910153B (zh) | 2008-01-11 | 2014-01-22 | 诺华股份有限公司 | 作为激酶抑制剂的嘧啶类 |
EP2080508A1 (en) * | 2008-01-15 | 2009-07-22 | CHIESI FARMACEUTICI S.p.A. | Dry powder formulation comprising an anticholinergic drug |
WO2009134524A2 (en) * | 2008-02-26 | 2009-11-05 | Elevation Pharmaceuticals, Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
EP2100599A1 (en) * | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
US8268834B2 (en) | 2008-03-19 | 2012-09-18 | Novartis Ag | Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme |
WO2009138707A1 (en) | 2008-05-13 | 2009-11-19 | Astrazeneca Ab | Quinuclidine derivatives as muscarinic m3 receptor antagonists |
GB0808707D0 (en) * | 2008-05-13 | 2008-06-18 | Argenta Discovery Ltd | New compounds 275 |
KR20160129109A (ko) | 2008-05-23 | 2016-11-08 | 아미라 파마슈티칼스 인코포레이티드 | 5-리폭시게나아제 활성화 단백질 억제제 |
MX2010012492A (es) | 2008-05-27 | 2010-12-21 | Astrazeneca Ab | Derivados de fenoxipiridinilamida y su uso en el tratamiento de estados de enfermedad mediados por fosfodiesterasa 4. |
US20090326004A1 (en) | 2008-06-03 | 2009-12-31 | Ranbaxy Laboratories Limited | Muscarinic receptor antagonists |
US8163743B2 (en) | 2008-06-05 | 2012-04-24 | GlaxoGroupLimited | 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases |
US8236808B2 (en) | 2008-06-10 | 2012-08-07 | Novartis Ag | Pyrazine derivatives as ENAC blockers |
US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
EP2154136A1 (en) * | 2008-08-08 | 2010-02-17 | CHIESI FARMACEUTICI S.p.A. | Quinuclidine carbonate derivatives and medicinal compositions thereof |
TW201031406A (en) | 2009-01-29 | 2010-09-01 | Novartis Ag | Substituted benzimidazoles for the treatment of astrocytomas |
WO2010094643A1 (en) | 2009-02-17 | 2010-08-26 | Glaxo Group Limited | Quinoline derivatives and their uses for rhinitis and urticaria |
ES2542551T3 (es) | 2009-03-09 | 2015-08-06 | Glaxo Group Limited | 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas |
WO2010102968A1 (en) | 2009-03-10 | 2010-09-16 | Glaxo Group Limited | Indole derivatives as ikk2 inhibitors |
JP2012520845A (ja) | 2009-03-17 | 2012-09-10 | グラクソ グループ リミテッド | Itk阻害剤として使用されるピリミジン誘導体 |
EP2408915A2 (en) | 2009-03-19 | 2012-01-25 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CN102439151A (zh) | 2009-03-19 | 2012-05-02 | 默沙东公司 | 使用短干扰核酸(siNA)的RNA干扰介导的BTB和CNC同系物1,碱性亮氨酸拉链转录因子1(Bach1)基因表达的抑制 |
US20120004282A1 (en) | 2009-03-27 | 2012-01-05 | Merck Sharp & Dohme Corp, | RNA Interference Mediated Inhibition of the Intercellular Adhesion Molecule 1 (ICAM-1) Gene Expression Using Short Interfering Nucleic Acid (siNA) |
JP2012521762A (ja) | 2009-03-27 | 2012-09-20 | メルク・シャープ・エンド・ドーム・コーポレイション | 低分子干渉核酸(siNA)を用いた神経成長因子β鎖(NGFβ)遺伝子発現のRNA干渉媒介性阻害 |
WO2010111464A1 (en) | 2009-03-27 | 2010-09-30 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
CA2758100C (en) | 2009-04-09 | 2017-08-29 | Novartis Ag | Process for preparing pyrrolidinium salts |
US20100273744A1 (en) | 2009-04-24 | 2010-10-28 | Paul Martin Gore | Compounds |
JP2012524754A (ja) | 2009-04-24 | 2012-10-18 | グラクソ グループ リミテッド | Cracチャネル阻害剤としてのピラゾールおよびトリアゾ−ルカルボキサミド |
EA021056B1 (ru) | 2009-04-30 | 2015-03-31 | Глаксо Груп Лимитед | Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ, содержащая их фармацевтическая композиция и их применение в лечении расстройств, опосредованных ненадлежащей активностью pi3-киназ |
AR076621A1 (es) | 2009-05-29 | 2011-06-22 | Pearl Therapeutics Inc | Composiciones para el suministro de antagonistas muscarinicos de accion prolongada y agonista del receptor adrenergico b2 de accion prolongada. metodo de tratamiento. sistemas asociados. inhalador dosificador |
US8815258B2 (en) | 2009-05-29 | 2014-08-26 | Pearl Therapeutics, Inc. | Compositions, methods and systems for respiratory delivery of two or more active agents |
GB0910537D0 (en) | 2009-06-18 | 2009-07-29 | Ivax Pharmaceuticals Ireland | Inhaler |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
AU2010283806A1 (en) | 2009-08-12 | 2012-03-01 | Novartis Ag | Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation |
MX2012002066A (es) | 2009-08-17 | 2012-03-29 | Intellikine Inc | Compuestos heterociclicos y usos de los mismos. |
JP5775871B2 (ja) | 2009-08-20 | 2015-09-09 | ノバルティス アーゲー | ヘテロ環式オキシム化合物 |
JP2013508414A (ja) | 2009-10-22 | 2013-03-07 | バーテックス ファーマシューティカルズ インコーポレイテッド | 嚢胞性線維症および他の慢性疾患の治療のための組成物 |
GB0919465D0 (en) | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
EP2507231A1 (en) | 2009-12-03 | 2012-10-10 | Glaxo Group Limited | Indazole derivatives as pi 3 - kinase inhibitors |
JP2013512879A (ja) | 2009-12-03 | 2013-04-18 | グラクソ グループ リミテッド | Pi3キナーゼの阻害剤としてのベンズピラゾール誘導体 |
US20120238559A1 (en) | 2009-12-03 | 2012-09-20 | Glaxo Group Limited | Novel compounds |
WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
WO2011110575A1 (en) | 2010-03-11 | 2011-09-15 | Glaxo Group Limited | Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases |
US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
GB201007203D0 (en) | 2010-04-29 | 2010-06-16 | Glaxo Group Ltd | Novel compounds |
DK2614058T3 (en) | 2010-09-08 | 2015-09-28 | Glaxosmithkline Ip Dev Ltd | Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide. |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8372845B2 (en) | 2010-09-17 | 2013-02-12 | Novartis Ag | Pyrazine derivatives as enac blockers |
WO2012035055A1 (en) | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
GB201016912D0 (en) | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
WO2012052459A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
WO2012052458A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
GB201018124D0 (en) | 2010-10-27 | 2010-12-08 | Glaxo Group Ltd | Polymorphs and salts |
US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン, エルエルシー | 複素環化合物およびその使用 |
GEP20156285B (en) | 2011-02-25 | 2015-05-11 | Aierem Elelsi | Compounds and compositions as trk inhibitors |
GB201104153D0 (en) | 2011-03-11 | 2011-04-27 | Glaxo Group Ltd | Novel compounds |
JP2014507458A (ja) | 2011-03-11 | 2014-03-27 | グラクソ グループ リミテッド | Sykインヒビターとしてのピリド[3,4−B]ピラジン誘導体 |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
US8883819B2 (en) | 2011-09-01 | 2014-11-11 | Irm Llc | Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension |
WO2013038362A1 (en) | 2011-09-15 | 2013-03-21 | Novartis Ag | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase |
JP6165733B2 (ja) | 2011-09-16 | 2017-07-19 | ノバルティス アーゲー | N−置換ヘテロシクリルカルボキサミド類 |
WO2013038381A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine/pyrazine amide derivatives |
WO2013038378A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
US9034879B2 (en) | 2011-09-16 | 2015-05-19 | Novartis Ag | Heterocyclic compounds for the treatment of CF |
WO2013038373A1 (en) | 2011-09-16 | 2013-03-21 | Novartis Ag | Pyridine amide derivatives |
CN104363914A (zh) | 2011-11-23 | 2015-02-18 | 因特利凯有限责任公司 | 使用mTOR抑制剂的增强的治疗方案 |
WO2013090620A1 (en) | 2011-12-13 | 2013-06-20 | Genomedx Biosciences, Inc. | Cancer diagnostics using non-coding transcripts |
US8809340B2 (en) | 2012-03-19 | 2014-08-19 | Novartis Ag | Crystalline form |
CN104245701A (zh) | 2012-04-03 | 2014-12-24 | 诺华有限公司 | 有酪氨酸激酶抑制剂的组合产品和其应用 |
EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
CN104837828B (zh) * | 2012-12-05 | 2017-07-18 | 奇斯药制品公司 | 作为pde4‑抑制剂的苯基乙基吡啶衍生物 |
AU2013363837A1 (en) | 2012-12-17 | 2015-06-11 | Almirall, S.A. | New use of aclidinium |
US9073921B2 (en) | 2013-03-01 | 2015-07-07 | Novartis Ag | Salt forms of bicyclic heterocyclic derivatives |
CN105246482A (zh) | 2013-03-15 | 2016-01-13 | 因特利凯有限责任公司 | 激酶抑制剂的组合及其用途 |
CN105188679B (zh) | 2013-03-15 | 2018-10-16 | 珍珠治疗公司 | 用于微粒晶体材料的状态调节的方法和系统 |
AU2014292722B2 (en) * | 2013-07-13 | 2017-03-09 | Beijing Showby Pharmaceutical Co., Ltd. | Quinine compounds, and optical isomers, preparation method and medical use thereof |
RU2675105C9 (ru) | 2013-09-22 | 2019-01-09 | Саншайн Лейк Фарма Ко., Лтд. | Замещенные аминопиримидиновые соединения и способы их использования |
CA2925064A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
CA2923995A1 (en) | 2013-10-17 | 2015-04-23 | Glaxosmithkline Intellectual Property Development Limited | Pi3k inhibitor for treatment of respiratory disease |
CZ306791B6 (cs) | 2013-10-29 | 2017-07-12 | Zentiva, K.S. | Průmyslově využitelný způsob přípravy aklidinium bromidu o vysoké čistotě |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
CN103755699A (zh) * | 2014-01-06 | 2014-04-30 | 万特制药(海南)有限公司 | 一种2-羟基-2,2-二噻吩-2-基乙酸-1-氮杂二环[2,2,2]辛-3(r)-基酯制备方法 |
CN103755698A (zh) * | 2014-01-06 | 2014-04-30 | 万特制药(海南)有限公司 | 一锅法制备阿地溴铵的工艺 |
CZ2014188A3 (cs) | 2014-03-26 | 2015-10-07 | Zentiva, K.S. | Nové formy aclidinium chloridu a způsob jejich přípravy |
US9394281B2 (en) | 2014-03-28 | 2016-07-19 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
PT3134396T (pt) | 2014-04-24 | 2019-12-16 | Novartis Ag | Derivados de amino piridina como inibidores da fosfatidilinositol 3-quinase |
WO2015162459A1 (en) | 2014-04-24 | 2015-10-29 | Novartis Ag | Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors |
JP6404944B2 (ja) | 2014-04-24 | 2018-10-17 | ノバルティス アーゲー | ホスファチジルイノシトール3−キナーゼ阻害薬としてのピラジン誘導体 |
CN107072976A (zh) | 2014-05-12 | 2017-08-18 | 葛兰素史克知识产权第二有限公司 | 用于治疗传染性疾病的包含Danirixin的药物组合物 |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
JP6526789B2 (ja) | 2014-07-31 | 2019-06-05 | ノバルティス アーゲー | 組み合わせ療法 |
EP3266777B1 (en) * | 2015-03-02 | 2021-05-05 | LTT Bio-Pharma Co., Ltd. | Quinuclidine derivative |
PT108370B (pt) | 2015-03-30 | 2018-10-25 | Hovione Farm S A | Processo de preparação de brometo de aclidínio |
WO2016162878A1 (en) * | 2015-04-04 | 2016-10-13 | Harman Finochem Limited | An advantageous process for preparing 1-azoniabicyclo[2.2.2]octane,3-[(hydroxydi-2-thienylacetyl)oxy]-1-(3¬phenoxypropyl)-, bromide, (3r)- and its novel crystalline form-i |
CZ2015257A3 (cs) | 2015-04-16 | 2016-10-26 | Zentiva, K.S. | Způsob pro zmenšování velikosti částic bromidu [(3R)-1-(3-fenoxypropyl)chinuklidin-1-ium-3-yl] 2-hydroxy-2,2-bis(2-thienyl)acetátu |
CN105085355B (zh) * | 2015-06-25 | 2017-11-14 | 御盛隆堂药业有限责任公司 | 一种取代的吡咯烷羧酸酯类化合物及其制备方法和应用 |
WO2017044434A1 (en) | 2015-09-11 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Substituted heteroaryl compounds and methods of use |
GB201602527D0 (en) | 2016-02-12 | 2016-03-30 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
JP2019524792A (ja) | 2016-08-08 | 2019-09-05 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 化合物 |
WO2018094392A1 (en) | 2016-11-21 | 2018-05-24 | Lupin Inc. | Medicament dispenser |
GB201700727D0 (en) | 2017-01-16 | 2017-03-01 | Teva Pharma | Inhalers and airflow adaptors therefor |
GB201706102D0 (en) | 2017-04-18 | 2017-05-31 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201712081D0 (en) | 2017-07-27 | 2017-09-13 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
US20190076607A1 (en) | 2017-09-13 | 2019-03-14 | Lupin Atlantis Holdings Sa | Inhaler and mesh for an inhaler |
JP7254076B2 (ja) | 2017-11-19 | 2023-04-07 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | 置換ヘテロアリール化合物及び使用方法 |
WO2019129801A1 (en) | 2017-12-28 | 2019-07-04 | Linnea S.A. | Process for the purification of methyl-2,2-dithienylglycolate |
AU2019209960B2 (en) | 2018-01-20 | 2023-11-23 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine compounds and methods of use |
WO2020058823A1 (en) | 2018-09-17 | 2020-03-26 | Lupin, Inc. | Dose indicator assembly for a medicament dispenser |
AU2020290094B2 (en) | 2019-06-10 | 2024-01-18 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF, COPD, and bronchiectasis |
JOP20220044A1 (ar) | 2019-08-28 | 2023-01-30 | Novartis Ag | مشتقات 1، 3- فينيل أريل غير متجانسة بها استبدال واستخدامها في معالجة مرض |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
US20230120431A1 (en) | 2020-03-25 | 2023-04-20 | Lupin Inc. | Multi-Carrier Medicament Dispensers |
US20240066037A1 (en) | 2020-03-26 | 2024-02-29 | Glaxosmithkline Intellectual Property Development Limited | Cathepsin inhibitors for preventing or treating viral infections |
CA3186551A1 (en) | 2020-07-23 | 2022-01-27 | Lupin Inc. | Dose counter assemblies for medicament dispensers |
Family Cites Families (182)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3091570A (en) | 1960-08-08 | 1963-05-28 | Lakeside Lab Inc | Antidepressant: 3-pyrrolidyl glycolates |
GB1219606A (en) * | 1968-07-15 | 1971-01-20 | Rech S Et D Applic Scient Soge | Quinuclidinol derivatives and preparation thereof |
FR2414044A1 (fr) | 1978-01-10 | 1979-08-03 | Pharmindustrie | Nouveaux derives d'aza-1 bicyclo(2,2,2) octane, utilisables comme medicaments |
IT7920688V0 (it) | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore. |
IT1116047B (it) | 1979-04-27 | 1986-02-10 | Sigma Tau Ind Farmaceuti | Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma |
DE3274065D1 (de) | 1981-07-08 | 1986-12-11 | Draco Ab | Powder inhalator |
FR2539135B1 (fr) | 1983-01-11 | 1986-02-28 | Essilor Int | Hydrogels de polyurethane et procede de fabrication |
US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
GB8334494D0 (en) | 1983-12-24 | 1984-02-01 | Tanabe Seiyaku Co | Carbostyril derivatives |
GB8613811D0 (en) | 1986-06-06 | 1986-07-09 | Phares Pharm Res Nv | Composition & method |
FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
US4675326A (en) * | 1985-05-08 | 1987-06-23 | Gabriel Amitai | Bisquaternary antidotes |
US4855290A (en) | 1985-05-10 | 1989-08-08 | State Of Israel, Represented By Prime Minister's Office, Israel Institute For Biological Research | Derivatives of quinuclidine |
GB8718345D0 (en) * | 1987-08-03 | 1987-09-09 | Fordonal Sa | N-substituted benzamides |
US4843074A (en) | 1988-05-17 | 1989-06-27 | Marion Laboratories, Inc. | 1-azabicyclo[2.2.2]octan-3-yl 2-aryl-3-azacyclo-2-hydroxypropionates and their quaternary salts |
DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
US5290815A (en) | 1989-09-07 | 1994-03-01 | Glaxo Group Limited | Treatment of inflammation and allergy |
DE3931041C2 (de) * | 1989-09-16 | 2000-04-06 | Boehringer Ingelheim Kg | Ester von Thienylcarbonsäuren mit Aminoalkoholen, ihre Quaternierungsprodukte, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
US5610163A (en) | 1989-09-16 | 1997-03-11 | Boehringer Ingelheim Gmbh | Esters of thienyl carboxylic acids and amino alcohols and their quaternization products |
GB8923590D0 (en) * | 1989-10-19 | 1989-12-06 | Pfizer Ltd | Antimuscarinic bronchodilators |
IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
GB9001635D0 (en) | 1990-01-24 | 1990-03-21 | Ganderton David | Aerosol carriers |
US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
US5507281A (en) | 1990-08-30 | 1996-04-16 | Boehringer Ingelheim Kg | Device for initiating a mechanical switching operation in synchronism with the breathing |
DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
ES2161211T3 (es) | 1990-09-06 | 2001-12-01 | Pfizer | Broncodilatadores antimuscarinicos. |
US5091528A (en) | 1990-09-12 | 1992-02-25 | Allergan, Inc. | 6- or 7- (2-imino-2-imidazolidine)-1,4-benzoxazines as α adrenergic agents |
WO1992004928A2 (en) | 1990-09-26 | 1992-04-02 | Pharbita B.V. | Inhaler devices provided with a reservoir for several doses of medium for inhaling, transporting device, whirl chamber |
GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
US5290539A (en) | 1990-12-21 | 1994-03-01 | Minnesota Mining And Manufacturing Company | Device for delivering an aerosol |
US5263480A (en) | 1991-02-01 | 1993-11-23 | Cyberonics, Inc. | Treatment of eating disorders by nerve stimulation |
EP0504112A3 (en) | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
DE4108393A1 (de) | 1991-03-15 | 1992-09-17 | Boehringer Ingelheim Kg | Neue ester bi- und tricyclischer aminoalkohole, ihre herstellung und ihre verwendung in arzneimitteln |
AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
US6299863B1 (en) | 1992-04-03 | 2001-10-09 | Sepracor Inc. | Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy |
GB9119705D0 (en) | 1991-09-14 | 1991-10-30 | Pfizer Ltd | Therapeutic compounds |
DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
SK280911B6 (sk) | 1992-12-09 | 2000-09-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Farmaceutický prostriedok |
ES2128550T3 (es) | 1992-12-18 | 1999-05-16 | Schering Corp | Inhalador para medicamentos en polvo. |
KR970701174A (ko) | 1994-02-10 | 1997-03-17 | 오노다 마사요시 | 신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same) |
GB9404945D0 (en) | 1994-03-15 | 1994-04-27 | Glaxo Group Ltd | Pharmaceutical composition |
US5569447A (en) * | 1994-04-19 | 1996-10-29 | The United States Of America Represented By The Secretary Department Of Health And Human Services | Stannylated 3-quinuclidinyl benzilates and methods of preparing radiohalogenated derivatives |
WO1996004346A1 (en) | 1994-07-29 | 1996-02-15 | Minnesota Mining And Manufacturing Company | Acrylic syrup curable to a crosslinked viscoelastomeric material |
GB9426252D0 (en) | 1994-12-24 | 1995-02-22 | Glaxo Group Ltd | Pharmaceutical composition |
NO2005012I1 (no) | 1994-12-28 | 2005-06-06 | Debio Rech Pharma Sa | Triptorelin og farmasoytisk akseptable salter derav |
US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
GB9501841D0 (en) | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
CZ296209B6 (cs) | 1995-04-14 | 2006-02-15 | Glaxo Wellcome Inc. | Inhalátor a inhalacní systém |
TR199701665T1 (xx) | 1995-06-21 | 1998-06-22 | Asta Med�Ca Aktingesellschaft | B�t�nle�ik �l�me cihaz�na sahip farmas�tik toz kartu�u ve toz halinde t�bbi maddeler i�in soluma cihaz�. |
WO1997001337A1 (en) | 1995-06-29 | 1997-01-16 | Mcneil-Ppc, Inc. | The combination of topical nasal antihistamines and topical nasal steroids |
DE19528145A1 (de) | 1995-08-01 | 1997-02-06 | Boehringer Ingelheim Kg | Neue Arzneimittel und ihre Verwendung |
DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
US5846983A (en) | 1996-02-09 | 1998-12-08 | Mayo Foundation For Medical Education And Research | Colonic delivery of nicotine to treat inflammatory bowel disease |
US5824669A (en) | 1996-03-22 | 1998-10-20 | Nitromed, Inc. | Nitrosated and nitrosylated compounds and compositions and their use for treating respiratory disorders |
US6150415A (en) | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
US5885834A (en) | 1996-09-30 | 1999-03-23 | Epstein; Paul M. | Antisense oligodeoxynucleotide against phosphodiesterase |
SE9603669D0 (sv) | 1996-10-08 | 1996-10-08 | Astra Ab | New combination |
FR2756739B1 (fr) | 1996-12-05 | 2000-04-28 | Astra Ab | Nouvelle formulation de budesonide |
US6495167B2 (en) | 1997-03-20 | 2002-12-17 | Schering Corporation | Preparation of powder agglomerates |
GB9807232D0 (en) | 1998-04-03 | 1998-06-03 | Univ Cardiff | Aerosol composition |
US6423298B2 (en) | 1998-06-18 | 2002-07-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical formulations for aerosols with two or more active substances |
PT1087750E (pt) | 1998-06-18 | 2004-02-27 | Boehringer Ingelheim Pharma | Formulacoes farmaceuticas para aerossois com duas ou mais substancias activas |
ITMI981671A1 (it) | 1998-07-21 | 2000-01-21 | Zambon Spa | Derivati ftalazinici inibitori della fosfodisterasi 4 |
EP1102579B1 (de) | 1998-08-04 | 2003-03-19 | Jago Research Ag | Medizinische aerosolformulierungen |
US5962505A (en) | 1998-08-31 | 1999-10-05 | Bobrove; Arthur M. | Method for treating hot flashes in humans |
DE19847968A1 (de) | 1998-10-17 | 2000-04-20 | Boehringer Ingelheim Pharma | Verschlußkappe und Behälter als Zweikammer-Kartusche für Vernebler zur Erzeugung von Aerosolen |
GB9902689D0 (en) | 1999-02-08 | 1999-03-31 | Novartis Ag | Organic compounds |
DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
US20040002548A1 (en) | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
ES2165768B1 (es) * | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
US7214687B2 (en) * | 1999-07-14 | 2007-05-08 | Almirall Ag | Quinuclidine derivatives and medicinal compositions containing the same |
SE9902935D0 (sv) | 1999-08-18 | 1999-08-18 | Astra Pharma Prod | Pharmaceutical compositions |
GB9928311D0 (en) | 1999-11-30 | 2000-01-26 | Novartis Ag | Organic compounds |
US6410563B1 (en) | 1999-12-22 | 2002-06-25 | Merck Frosst Canada & Co. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
FR2803378B1 (fr) | 1999-12-29 | 2004-03-19 | Valeo Climatisation | Echangeur de chaleur a tubes a plusieurs canaux, en particulier pour vehicule automobile |
WO2001054728A1 (en) | 2000-01-28 | 2001-08-02 | Asahi Kasei Kabushiki Kaisha | NOVEL REMEDIES WITH THE USE OF β3 AGONIST |
JP2003522165A (ja) | 2000-01-31 | 2003-07-22 | ファイザー・プロダクツ・インク | Pde4アイソザイムの阻害剤として有用なピリミジンカルボキサミド |
EP1270577B1 (en) | 2000-03-23 | 2006-12-06 | Takeda Pharmaceutical Company Limited | Furoisoquinoline derivatives, process for producing the same and use thereof |
GB0008485D0 (en) | 2000-04-07 | 2000-05-24 | Glaxo Group Ltd | Pharmaceutical compositions |
GB0009592D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory combinations |
GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
GB0009605D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Medicaments |
GB0009606D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Therapeutic combinations |
US6777132B2 (en) | 2000-04-27 | 2004-08-17 | Valence Technology, Inc. | Alkali/transition metal halo—and hydroxy-phosphates and related electrode active materials |
GB0012261D0 (en) | 2000-05-19 | 2000-07-12 | Astrazeneca Ab | Novel process |
AU2000250701B2 (en) | 2000-05-22 | 2004-07-01 | Chiesi Farmaceutici S.P.A. | Stable pharmaceutical solution formulations for pressurised metered dose inhalers |
US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
AR029984A1 (es) | 2000-07-27 | 2003-07-23 | Smithkline Beecham Corp | Metodo para reducir las exacerbaciones asociadas copd ambito |
US6852728B2 (en) | 2000-10-14 | 2005-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics, processes for preparing them, and pharmaceutical compositions containing them |
US6706726B2 (en) | 2000-10-14 | 2004-03-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Anticholinergics which may be used as medicaments as well as processes for preparing them |
US6620438B2 (en) | 2001-03-08 | 2003-09-16 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and NK1-receptor antagonists |
US20020122773A1 (en) | 2000-12-20 | 2002-09-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and dopamine agonists |
US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
US20030158196A1 (en) | 2002-02-16 | 2003-08-21 | Boehringer Ingelheim Pharma Gmbh Co. Kg | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors |
US20020193393A1 (en) | 2001-03-07 | 2002-12-19 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
DE10062712A1 (de) | 2000-12-15 | 2002-06-20 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Corticosteroiden |
US20020183292A1 (en) | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
DE10110772A1 (de) | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
JP2004512359A (ja) | 2000-10-31 | 2004-04-22 | ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト | 抗コリン作用薬及びコルチコステロイドをベースとする新規医薬組成物 |
US20020137764A1 (en) | 2000-10-31 | 2002-09-26 | Karin Drechsel | Inhalable formulation of a solution containing a tiotropium salt |
US20020151541A1 (en) | 2000-10-31 | 2002-10-17 | Michel Pairet | Pharmaceutical compositions containing tiotropium salts and antihistamines and their use |
US6608054B2 (en) | 2001-03-20 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics and endothelin antagonists |
US20020193392A1 (en) | 2000-11-13 | 2002-12-19 | Christel Schmelzer | Pharmaceutical compositions based on tiotropium salts of salts of salmeterol |
DE10056104A1 (de) | 2000-11-13 | 2002-05-23 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Tiotropiumsalzen und Salzen des Salmeterols |
US20100310477A1 (en) | 2000-11-28 | 2010-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg. | Pharmaceutical compositions based on anticholingerics and additional active ingredients |
CZ301323B6 (cs) | 2000-12-22 | 2010-01-13 | Laboratorios Almirall, S.A. | Chinuklidinkarbamátové deriváty a lécivé kompozice je obsahující |
BR0116624A (pt) | 2000-12-28 | 2003-12-23 | Almirall Prodesfarma Ag | Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto ou da composição farmacêutica, e, produto de combinação |
DE10104370A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Arzneimittelkompositionen mit geringeren Nebenwirkungen |
DE10104367A1 (de) | 2001-02-01 | 2002-08-08 | Boehringer Ingelheim Pharma | Betamimetika enthaltende Arzneimittelkompositionen mit geringeren Nebenwirkungen |
US20020179087A1 (en) | 2001-02-01 | 2002-12-05 | Karl-Heinz Bozung | Pharmaceutical compositions containing an oxitropium salt and a betamimetic |
US20020189610A1 (en) | 2001-02-01 | 2002-12-19 | Karl-Heinz Bozung | Pharmaceutical compositions containing an ipratropium salt and a betamimetic |
GB0103630D0 (en) | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
US20030216329A1 (en) | 2001-04-24 | 2003-11-20 | Robinson Cynthia B. | Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s) |
CA2448363A1 (en) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
NZ529335A (en) | 2001-05-25 | 2005-09-30 | Pfizer | A PDE 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
GB0115181D0 (en) | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Novel use |
DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
US20030018019A1 (en) | 2001-06-23 | 2003-01-23 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics |
DE10130371A1 (de) | 2001-06-23 | 2003-01-02 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika |
GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
US6680345B2 (en) | 2001-09-14 | 2004-01-20 | Boehringer Ingelheim Pharma Kg | Salicylic acid salts of salmeterol |
US6919325B2 (en) | 2001-09-14 | 2005-07-19 | Boehringer Ingelheim Pharma Kg | Pharmaceutical compositions containing tiotropium salts and low-solubility salmeterol salts |
EP1429768B1 (de) | 2001-09-14 | 2016-11-16 | Boehringer Ingelheim Pharma GmbH & Co.KG | Neue arzneimittel zur inhalation |
US6653323B2 (en) | 2001-11-13 | 2003-11-25 | Theravance, Inc. | Aryl aniline β2 adrenergic receptor agonists |
US6974803B2 (en) | 2001-12-06 | 2005-12-13 | Pfizer Inc | Pharmaceutical combination |
DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
US6790856B2 (en) | 2002-01-31 | 2004-09-14 | Boehringer Ingelheim Pharma Kg | Fluorenecarboxylic acid esters, process for the manufacture thereof, and use thereof as medicaments |
GB0202635D0 (en) | 2002-02-05 | 2002-03-20 | Glaxo Wellcome Mfg Pte Ltd | Formulation containing novel anti-inflammatory androstane derivative |
SI1480615T1 (sl) | 2002-03-01 | 2010-07-30 | Chiesi Farma Spa | Superfina formulacija formoterola |
US6756508B2 (en) | 2002-03-04 | 2004-06-29 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Cinnamic acid salts, processes for their preparation, and their use as medicaments |
DE10216429A1 (de) | 2002-04-12 | 2003-10-23 | Boehringer Ingelheim Pharma | Arzneimittel enthaltend Steroide und ein neues Anticholinergikum |
DE10216333A1 (de) | 2002-04-13 | 2003-10-30 | Boehringer Ingelheim Pharma | Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel |
US7094788B2 (en) | 2002-04-13 | 2006-08-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Esters of hydroxyl-substituted nitrogen heterocycles, processes for the preparation thereof as well as the use thereof as pharmaceutical compositions |
ES2206021B1 (es) | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
CN1655819A (zh) | 2002-05-17 | 2005-08-17 | 诺瓦提斯公司 | 包含肾素抑制剂、钙通道阻断剂和利尿药的药物组合物 |
ES2204295B1 (es) | 2002-07-02 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de quinuclidina-amida. |
US20040058950A1 (en) | 2002-07-09 | 2004-03-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and PDE-IV inhibitors |
GB0230045D0 (en) | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
ES2211315B1 (es) | 2002-11-12 | 2005-10-16 | Almirall Prodesfarma, S.A. | Nuevos compuestos triciclicos. |
WO2004047817A1 (en) | 2002-11-27 | 2004-06-10 | Altana Pharma Ag | Pde4 and pde3/4 inhibitors for use in the treatment of cachexia |
ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
DE10307759B3 (de) | 2003-02-19 | 2004-11-18 | Schering Ag | Trimere makrocyclisch substituierte Benzolderivate, deren Herstellung und Verwendung als Kontrastmittel sowie diese enthaltende pharmazeutische Mittel |
EP1452179A1 (en) | 2003-02-27 | 2004-09-01 | CHIESI FARMACEUTICI S.p.A. | Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid |
US20040184995A1 (en) | 2003-03-17 | 2004-09-23 | Yamanouchi Pharmaceutical Co., Ltd. | Novel dry powder inhalation for lung-delivery and manufacturing method thereof |
US20060189642A1 (en) | 2003-03-28 | 2006-08-24 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
DK1610787T3 (da) | 2003-03-28 | 2008-06-02 | Nycomed Gmbh | Synergistisk kombination der omfatter roflumilast og et antikolinergt middel der er valgt blandt tiotropiumsalte til behandling af respiratoriske sygdomme |
JP2007500150A (ja) | 2003-07-29 | 2007-01-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 抗コリン作用薬とステロイドとの併用剤及び吸入により呼吸障害を治療するためのその使用 |
US20050026887A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a steroid |
CA2534125A1 (en) | 2003-07-29 | 2005-02-17 | Boehringer Ingelheim International Gmbh | Medicaments comprising pde iv inhibitors and an anticholinergic for treating respiratory disorders |
EP1803469A3 (en) | 2003-07-29 | 2011-10-26 | Boehringer Ingelheim Pharma GmbH & Co. KG | Medicaments for inhalation comprising betamimetics and an anticholinergic |
US20050026886A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor |
US20050026948A1 (en) | 2003-07-29 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
ATE526967T1 (de) | 2003-07-31 | 2011-10-15 | Boehringer Ingelheim Int | Medikamente für inhalationen enthaltend ein anticholinergikum und ein betamimetikum |
US20050025718A1 (en) | 2003-07-31 | 2005-02-03 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising an anticholinergic and a betamimetic |
DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
NZ548302A (en) | 2004-02-06 | 2010-04-30 | Meda Pharma Gmbh & Co Kg | Novel combination of anticholinergic and beta mimetics for the treatment of respiratory diseases |
WO2005074982A2 (en) | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
JP4819699B2 (ja) | 2004-02-06 | 2011-11-24 | メダ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディト ゲゼルシャフト | 喘息及びcopdの長期間の治療のための抗コリン作用薬及びグルココルチコイドの組合せ剤 |
US7712077B2 (en) * | 2004-02-27 | 2010-05-04 | International Business Machines Corporation | Method and system for instantiating components conforming to the “COM” specification in custom contexts |
ES2239546B1 (es) | 2004-03-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos esteres de quinuclidina cuaternizados. |
DE102004016179A1 (de) | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
ES2257152B1 (es) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
PL1905451T3 (pl) | 2004-05-31 | 2010-05-31 | Almirall Sa | Kombinacje obejmujące środki przeciwmuskarynowe i kortykosteroidy |
EP2484382A1 (en) | 2005-03-30 | 2012-08-08 | Schering Corporation | Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form |
ES2298049B1 (es) | 2006-07-21 | 2009-10-20 | Laboratorios Almirall S.A. | Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano. |
GB0702457D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination 666 |
EP2327403A3 (en) | 2007-02-19 | 2011-08-31 | Cipla Limited | Pharmaceutical combinations of at least two bronchodilators |
US20110243924A1 (en) | 2007-02-21 | 2011-10-06 | Jorge Beleta Supervia | Novel methods |
EP2165159B1 (en) | 2007-07-03 | 2013-07-17 | Nxp B.V. | Calibration of an amr sensor |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
EP2666465A1 (en) * | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
AU2013363837A1 (en) | 2012-12-17 | 2015-06-11 | Almirall, S.A. | New use of aclidinium |
-
1999
- 1999-07-14 ES ES009901580A patent/ES2165768B1/es not_active Expired - Fee Related
-
2000
- 2000-07-07 RU RU2002103605A patent/RU2264401C3/ru active Protection Beyond IP Right Term
- 2000-07-07 CA CA2381165A patent/CA2381165C/en not_active Expired - Lifetime
- 2000-07-07 DK DK00951361.5T patent/DK1200431T6/en active
- 2000-07-07 CZ CZ2002-121A patent/CZ304292B6/cs unknown
- 2000-07-07 EP EP00951361.5A patent/EP1200431B3/en not_active Expired - Lifetime
- 2000-07-07 KR KR1020067027733A patent/KR100854321B1/ko not_active IP Right Cessation
- 2000-07-07 BR BRPI0012434A patent/BRPI0012434B8/pt not_active IP Right Cessation
- 2000-07-07 SI SI200030108T patent/SI1200431T1/xx unknown
- 2000-07-07 KR KR1020067027730A patent/KR100854315B1/ko active Protection Beyond IP Right Term
- 2000-07-07 AT AT00951361T patent/ATE235492T1/de active
- 2000-07-07 KR KR1020027000479A patent/KR100773844B1/ko not_active IP Right Cessation
- 2000-07-07 TR TR2002/00768T patent/TR200200768T2/xx unknown
- 2000-07-07 PL PL357160A patent/PL204024B1/pl not_active IP Right Cessation
- 2000-07-07 PT PT00951361T patent/PT1200431E/pt unknown
- 2000-07-07 DE DE60001840.7T patent/DE60001840T4/de not_active Expired - Lifetime
- 2000-07-07 JP JP2001509727A patent/JP4030040B2/ja not_active Expired - Lifetime
- 2000-07-07 DE DE60001840A patent/DE60001840D1/de not_active Expired - Lifetime
- 2000-07-07 UA UA2002010323A patent/UA73509C2/uk unknown
- 2000-07-07 WO PCT/EP2000/006469 patent/WO2001004118A2/en active IP Right Grant
- 2000-07-07 IL IL14753300A patent/IL147533A0/xx active Protection Beyond IP Right Term
- 2000-07-07 CN CNB2006100068921A patent/CN100451018C/zh not_active Expired - Lifetime
- 2000-07-07 SK SK43-2002A patent/SK287480B6/sk not_active IP Right Cessation
- 2000-07-07 CN CNB008127549A patent/CN1272334C/zh not_active Expired - Lifetime
- 2000-07-07 EE EEP200200017A patent/EE04915B3/et active Protection Beyond IP Right Term
- 2000-07-07 ES ES951361T patent/ES2193098T7/es active Active
- 2000-07-07 HU HU0202100A patent/HU228594B1/hu active Protection Beyond IP Right Term
- 2000-07-11 PE PE2000000691A patent/PE20010397A1/es not_active IP Right Cessation
- 2000-07-12 EG EG20000907A patent/EG24066A/xx active
- 2000-07-12 TW TW089113865A patent/TWI284644B/zh active
- 2000-07-12 MY MYPI20003178 patent/MY126959A/en unknown
- 2000-07-13 CO CO00052873A patent/CO5200759A1/es active IP Right Grant
- 2000-07-13 AR ARP000103613A patent/AR029760A1/es active IP Right Grant
- 2000-07-14 UY UY26244A patent/UY26244A1/es unknown
-
2002
- 2002-01-10 ZA ZA200200232A patent/ZA200200232B/xx unknown
- 2002-01-14 US US10/047,464 patent/US6750226B2/en not_active Expired - Lifetime
- 2002-01-14 BG BG106301A patent/BG65565B1/bg unknown
- 2002-01-14 NO NO20020180A patent/NO329484B3/no not_active IP Right Cessation
- 2002-05-29 HK HK02103992A patent/HK1042487B/xx not_active IP Right Cessation
-
2003
- 2003-12-17 US US10/740,264 patent/US7109210B2/en not_active Expired - Fee Related
-
2005
- 2005-04-28 US US11/116,777 patent/US7078412B2/en not_active Expired - Lifetime
- 2005-05-18 AU AU2005202144A patent/AU2005202144B2/en active Active
- 2005-07-06 RU RU2005121162/04A patent/RU2306312C2/ru active
- 2005-07-12 JP JP2005203365A patent/JP4951217B2/ja not_active Expired - Fee Related
-
2006
- 2006-01-03 US US11/325,059 patent/US7196098B2/en not_active Expired - Lifetime
- 2006-12-08 US US11/636,181 patent/US7358260B2/en not_active Expired - Fee Related
-
2008
- 2008-03-07 US US12/074,929 patent/US7750023B2/en not_active Expired - Fee Related
-
2010
- 2010-05-26 US US12/787,772 patent/US7897617B2/en not_active Expired - Fee Related
-
2011
- 2011-01-21 US US13/011,131 patent/US8129405B2/en not_active Expired - Fee Related
- 2011-07-08 UY UY0001033494A patent/UY33494A/es not_active Application Discontinuation
-
2012
- 2012-01-20 US US13/354,873 patent/US8513279B2/en not_active Expired - Fee Related
-
2013
- 2013-01-03 BE BE2013C001C patent/BE2013C001I2/fr unknown
- 2013-01-07 CY CY2013001C patent/CY2013001I2/el unknown
- 2013-01-08 FR FR13C0001C patent/FR13C0001I2/fr active Active
- 2013-01-16 LU LU92132C patent/LU92132I2/fr unknown
- 2013-01-18 NO NO2013002C patent/NO2013002I2/no unknown
- 2013-07-11 US US13/939,742 patent/US8802699B2/en not_active Expired - Fee Related
-
2014
- 2014-06-20 US US14/311,102 patent/US9056100B2/en not_active Expired - Fee Related
-
2015
- 2015-05-14 US US14/712,866 patent/US9333195B2/en not_active Expired - Lifetime
-
2016
- 2016-02-09 US US15/019,009 patent/USRE46417E1/en active Active
- 2016-04-09 US US15/095,036 patent/US9687478B2/en not_active Expired - Fee Related
-
2017
- 2017-05-19 US US15/599,646 patent/US10034867B2/en not_active Expired - Fee Related
-
2018
- 2018-07-25 US US16/045,333 patent/US10588895B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10588895B2 (en) | Quinuclidine derivatives and medicinal compositions containing the same | |
US20060106055A1 (en) | Novel quinuclidine derivatives and medicinal compositions containing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Spc suppl protection certif: 2013002 Filing date: 20130118 |
|
LC4 | Limitation of patent rights - b3 (par. 39b patent act) |
Effective date: 20130429 |
|
SPCG | Granted supplementary protection certificate |
Spc suppl protection certif: 2013002 Filing date: 20130118 Extension date: 20250707 |
|
LC4 | Limitation of patent rights - b3 (par. 39b patent act) |
Effective date: 20130429 |
|
MK1K | Patent expired |